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Allison Aldridge: Characterisation of novel F.hepatica activated immune cells 
 
Abstract 
The helminth parasite Fasciola hepatica causes fasciolosis in mammals infecting cattle and 
sheep, causing significant economic loss to the agricultural community annually. It is also a 
zoonotic disease, affecting approximately 2.4 million people worldwide. Infection is 
associated with Th2/Treg immune responses with a direct suppression of Th1/Th17 
responses. With a view to understanding how F. hepatica interacts with its host’s immune 
system we have isolated the tegumental coat antigens (FhTeg) which is a rich source of 
glycoproteins. Previous studies have examined its interaction with macrophages, mast cells 
and dendritic cells demonstrating the induction of novel cell populations that fail to drive Th1 
immune responses. This thesis advances our understanding of FhTeg by examining its 
interaction with dendritic cells and CD4
+
 T-cells and a number of novel findings were 
identified. The interaction of FhTeg with C-type lectin receptors on dendritic cells is 
important for its immunomodulatory effect, while mannose glycans are involved, studies in 
MR knockout mice did not reverse the immune-suppression of FhTeg. We have confirmed 
that the novel dendritic cells population (CD11c
low
, MR
high
, CD40
low
 and SOCS3
high
) induced 
by FhTeg drives anergic CD4
+
 T-cells. We also demonstrated for the first time that anergy is 
associated with F. hepatica infection. More importantly, FhTeg drives these responses and 
MR is critical for cell to cell communication. We have also demonstrated that FhTeg can 
directly interact with CD4
+
 T-cells, enhancing markers of anergy directly and it can suppress 
cytokine secretion from CD4
+
 T-cells. Finally, studies on human PBMCs also show a role for 
FhTegs inhibition, TNF-α was inhibited when PBMCs and CD4+ cells were co-stimulated 
with both LPS and PMA/Ionomycin but not CD14
+
 cells. This thesis presents a number of 
key findings that have never been reported previously in the literature and advance our 
understanding of helminth immune modulation.  
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1. Introduction 
 
Parasitic worms (helminths) can infect both humans and animals causing a wide range of 
diseases (Maizels, Hewitson and Smith 2012). In general, infection leads to a polarised T-
helper cell 2 (Th2) immune response followed by the induction of regulatory networks that 
induce tolerance to control immune mediated pathology. This is beneficial to the survival of 
the parasite within the host as reducing host pathology can prolong the survival of both the 
host and the helminth (Anthony et al. 2007). Helminth infections are characterised by an 
increase in immunoglobulin E (IgE) and the recruitment of cells such as alternatively 
activated macrophages (M2) macrophages, mast cells, eosinophils and basophils (Maizels et 
al. 2004). Helminths also induce T-regulatory (T-reg) cells which are important for 
maintaining tolerance (Belkaid et al. 2002) and can also induce another regulatory network of 
T-cells called T-cell anergy, this is a cellular hypo-responsive state which helps in the 
maintenance of tolerance, but few studies have examined this cell type in the context of 
helminth infection (Taylor, van der Werf and Maizels 2012b, Smith et al. 2004).  
 
We are interested in the helminth parasite Fasciola hepatica which causes fasciolosis in 
mammals infecting cattle, sheep and is a zoonotic disease in humans, affecting approximately 
2.4 million people worldwide (Mas-Coma, Bargues and Valero 2005). Infection with F. 
hepatica generally leads to a Th2/T-reg immune response with a decrease in Th1 responses 
observed (O'Neill et al. 2000). Our studies are focused upon the modulatory properties of F. 
hepatica tegumental antigens as these are a rich source of glycol-conjugates that induce novel 
dendritic cell, mast cell and M2-like populations, which suppress Th1 immune responses. 
While we have made great strides in understanding the immune-modulatory properties of this 
antigen source, no studies to date have fully characterised FhTeg driven T-cell responses 
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during infection (Hamilton et al. 2009b, Adams et al. 2014, Vukman et al. 2013b, Vukman et 
al. 2013a, Vukman, Adams and O'Neill 2013). Further studies are also required to fully 
characterise the interaction of FhTeg with dendritic cells and their subsequent effect on the 
adaptive immune response. These unanswered questions form the central premise of this 
doctoral project where we shed new light on the immune modulatory properties of helminth 
parasites.  
 
1.1. Characteristics of helminth infections 
 
Helminths, derived from the Greek word, hɛlmɪnθ, meaning worm, cause a plethora of 
neglected tropical diseases, infecting up to one third of the world’s population with a high 
prevalence in the developing world. The term helminth encompasses a number of different 
family members including roundworms such as Ascaris lumbricoides, filarial worms which 
cause filariasis, cestodes and trematodes which contain the parasites amongst others, Fasciola 
hepatica and Schistosoma mansoni (Hotez et al. 2008). Helminths can infect both domestic 
and wild animals, causing a significant economic burden to the agricultural community. 
Infection in cattle can lead to weight loss, a poor growth rate and a lower milk yield (Bamaiyi 
2012).   
 
In humans, helminths infection is rarely fatal but can lead to morbidity and chronic 
inflammation; other characteristics are anaemia, weight loss and similar to cattle and sheep an 
increased susceptibility to secondary bystander infections is observed. It is difficult to 
estimate the incidence and burden of infection in human populations but there are a number 
of methods used such as disability-adjusted life year (DALY; to measure the extent of the 
 16 
 
burden,)  or more recently QALY (quality-adjusted life year).  DALY is a time based unit 
which compares two disease related parameters, persons-years lost to disability (YLD) and 
persons-years life lost (YLL) to determine the disability burden for the health condition or 
infection. QALY is based not on what infection or health condition the person may have but 
it is based on quality of life based on the patient status (King, 2010.). Both of these methods 
give a clear picture of the burden of infection on the economy and on the impact on the 
quality of life. In 2010 a global burden of disease study found a total of nearly 15 million 
DALYs due to helminth infection (WHO, 2002). An increase in susceptibility to bystander 
infections is also common during helminth infections. Studies have shown co-infection with 
helminths can inhibit the clearance of TB in patients and it can also have an effect on the 
treatment of the disease itself (Resende Co et al. 2007). Some studies are also on-going on the 
effect of helminth infection with concurrent HIV infection and have showed that infection 
with both helminths and HIV impairs the patients Th1 immune response and this alters the 
clearance of the virus (Bentwich et al. 1999, Mulu, Maier and Liebert 2013). 
 
Infection with helminths can have some evolutionary advantages as proposed by the hygiene 
hypothesis that demonstrates a link between the increase in immune mediated disease such as 
autoimmunity and allergy and the decrease in the numbers of helminth infections in the 
developed world (Yazdanbakhsh, Kremsner and van Ree 2002). Studies in the developed 
world demonstrate a correlation between helminth infections and the low occurrence of auto-
immune diseases (Jackson et al. 2009). This points to the potential therapeutic benefit of 
helminth infection and clinical trials using “worm therapy” are underway in a variety of 
inflammatory disorders. Studies in mouse models of multiple sclerosis, experimental 
autoimmune encephalitis (EAE), have shown that early intervention with helminth therapy 
can reduce Th1 immune responses and bias towards a Th2 immune response, limiting tissue 
 17 
 
damage and migration of lymphocytes to the CNS (Gruden-movsesijan et al. 2010, Reyes et 
al. 2011) but these therapies were only successful upon early treatment, as starting treatment 
once symptoms had progressed had no impact on disease progression.  
 
Investigations into colitis have also shown promising results. Treatment with helminths 
showed a decrease in Th1 cytokines and in most cases, symptoms were attenuated or 
diminished completely (Heylen et al. 2014). Studies have also looked at the treatment of 
celiac disease with hookworms, a study using Necator americanus larvae and challenges of 
increasing gluten consumption showed an increase in T-reg cells and a decrease in disease 
severity (Croese et al. 2015, Croese, Gaze and Loukas 2013).  Some studies have also looked 
at graft versus host disease (GVHD) and infection with Heligmosomoides polygyrus reduces 
the effect of GVHD by reducing inflammatory cytokines and priming the donor T-cells to 
become T-regs (Kuijk et al. 2012b, Li et al. 2015). 
 
Human clinical trials have also been conducted, on the efficiency of helminths as 
therapeutics. The majority of these trials have focused on the use of T. suis, a study using five 
patients with relapsing MS showed an improvement and decrease in neurological and CNS 
lesions while therapy was on-going using T. suis but following the end of the study and the 
expulsion of the parasite, the lesion number increased again but no adverse events were noted 
during the trial (Fleming et al. 2011). Another number of studies also investigated the use of 
T. suis for the treatment of inflammatory bowel disease with an improvement in clinical 
symptoms and remission in some cases. As was seen with MS, continuing treatment with 
follow up doses of parasite is needed or relapses are possible (Summers et al. 2003, Summers 
et al. 2004, Summers et al. 2005, Fleming 2013). While there have been promising results, 
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whole worm therapy cannot always be used as there can be unpredictable side effects such as 
invasion into other tissues and pathology, also certain people would not be able to receive 
worm therapy such as children, pregnant women and individuals who may be immuno-
compromised.  
 
Research into helminth products as an alternative to whole worm therapy is crucial for new 
therapeutic approaches to these diseases and helminth products have shown potential for the 
treatment of MS, with a shift in cytokine responses towards a Th2 immune response (Zheng 
et al. 2008, Kuijk et al. 2012a). Studies using S. mansoni SEA in the treatment of colitis have 
shown that the administration of SEA significantly improved inflammatory factors studied 
but this was time dependent as after 6 weeks of administering the SEA, no effects of these 
were seen whereas at an earlier time point of four weeks, Th2 responses were increased in the 
colon of mice (Heylen et al. 2015). Using ES from the hookworm, Ancylostoma caninum, and 
investigators found intestinal pathology could be suppressed in a mouse model of colitis; this 
was due to a potent Th2 immune response and the recruitment of alternatively activated 
macrophages to the site of ES injection (Ferreira et al. 2013). Investigations into 
inflammatory bowel disease (IBD) have also shown promising results, with studies using T. 
suis ova showing an improvement in ulcerative colitis compared to placebo controls, with 
43% of patients recording an improvement in disease score compared to 16% of controls 
(Heylen et al. 2014, Heylen et al. 2015). Studies on psoriasis and rheumatoid arthritis have 
also shown positive results. Investigations using flaky skin mice which develop lesions 
similar to psoriasis and a glycan isolated from S. mansoni, LNFPIII, reduced lesion 
development with a decrease in IFN-γ production (Atochina and Harn, 2006). ES-62 isolated 
from Acanthocheilonema viteae, has been shown to reduce the initiation of collagen induced 
inflammatory arthritis and also inhibited the progression and severity of the disease (McInnes 
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et al. 2003).To develop these therapies it is important that we understand the immune 
properties of helminths and the products that release.  
 
1.2. Immunology of helminths 
 
The immune response to helminths is well characterised with a Th2/T-regulatory immune 
response observed. This response leads to the production of IL-4, IL-5, IL-10 and IL-13, an 
increase in immunoglobulin E (IgE) and the recruitment and expansion of cells such as mast 
cells, eosinophils, basophils and M2 macrophages (Maizels et al. 2004). This environment in 
the host is beneficial to the parasite as these responses suppress Th1 immune responses that 
can either lead to worm expulsion or immune pathology. The role of eosinophils is not 
entirely clear, however very early in vitro studies have shown them to be involved in parasite 
killing in combination with antibodies and complement and their granular products can also 
mimic this (David, Butterworth and Vadas 1980). In vivo their role is less understood and are 
linked to the production of IL-4 and IL-13 in conjunction with basophils (Anthony et al. 
2007). Infection with helminths has also been shown to increase the numbers of M2 
macrophages (Kreider et al. 2007) which differ from  M1 macrophages in that they produce 
Arginase1 (Arg1) and show an up-regulation of Ym1 and Relm-α genes but not iNOS 
(Gordon 2003).  During helminth infection M2 macrophages are important for controlling 
inflammation, tissue repair and for the killing and expulsion of parasites (Maizels et al. 
2009). While these cells are important in driving the immune response associated with 
helminth infection the communication between dendritic cells with CD4
+
 T-cells is important 
to the development of these responses and is therefore a focus in this thesis.  
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1.3. Helminth infections and Dendritic Cells 
 
Dendritic cells are hematopoietic stem cells in origin and are potent antigen presenting cells 
which are an important bridge between adaptive and innate immunity (Ardavín et al. 2001). 
While in an immature state, dendritic cells are constantly patrolling the body in search of 
foreign antigens. Following internalisation of antigen, dendritic cells generally become 
mature and enhance their expression of co-stimulatory markers like CD80, CD86 and MHC 
Class II which they then use to bind to receptors on other cell types like T-cells or mast cells 
and initiate an effective immune response (Banchereau, Briere and Caux 2000, Bonasio and 
von Andrian 2006). Dendritic cells decide whether an immune outcome will be pro-
inflammatory or anti-inflammatory depending on the antigen it has encountered and can 
produce cytokines like IL-12p70, TNF-α or IL-10 depending on the immune response that is 
to be initiated (Macatonia et al. 1995, Cella, Sallusto and Lanzavecchia 1997, Guermonprez, 
Valladeau and Zitvogel 2002).   
 
Unlike when stimulated with microbial antigens, dendritic cells stimulated with helminth 
products undergo semi-maturation with low levels of major histocompatibility complex 
classes I and II (MHC I/II), CD80 and CD86 being expressed and little or no cytokines like 
IL-12p70, TNF-α or IL-10 being produced. Studies using S. mansoni derived SEA have 
shown that dendritic cells become semi-mature and fail to up-regulate co-stimulatory 
markers, these cells when injected inter-peritoneal  into naïve mice induced strong Th2 
immune responses from splenocytes (MacDonald et al. 2001). Similarly, dendritic cells 
stimulated with products from Nippostrongylus brasiliensis and injected into naive mice 
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primed a Th2 immune response in recipients but in this case there was an up-regulation of co-
stimulatory markers CD86, CD40 and OX40L (Balic et al. 2004). We have also shown that 
F. hepatica tegumental antigen can inhibit the maturation of bacterial ligand stimulated 
dendritic cells also, inhibiting the expression of maturation markers and the production of 
cytokines (Hamilton et al. June 2009). FhTeg also enhances the expression of suppressor of 
cytokine signalling 3 (SOCS3), a negative regulator of cytokine signalling and inhibits 
mitogen-activated protein kinase (MAPK) signalling (Vukman, Adams and O'Neill 2013). 
 
1.4. Signalling Pathways 
 
During helminth infections a number of different signalling molecules and pathways have 
been identified as playing important roles in the induction of the suppressive phenotypes 
seen.  These include toll like receptors (TLRs) and C-type lectin receptors (CLRs) which are 
both pathogen recognition receptors (PRRs). Both TLRs and CLRs recognise pathogen 
associated molecular patterns (PAMPs) which are highly conserved across species. Signalling 
through both TLRs and CLRs contribute to activation of the immune response but can also 
switch off the response. TLRs have been implicated in helminth infections with both TLR2 
and 3 being used for dendritic cell activation following exposure to S. mansoni eggs and leads 
to an inflammatory response being seen but is not required to control infection and pathology 
as studies using TLR2 and TLR3 knockout mice showed no difference in worm burden or the 
numbers of eggs in tissues compared to wild type mice (Vanhoutte et al. 2007). In filariasis 
TLR expression is down-regulated following infection leading to immune tolerance and 
diminished immune responses (Babu et al. 2005). 
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CLRs also play an important role in the immune response to helminths. Several helminth 
products have been shown to signal through CLRs (Tundup, Srivastava and Harn 2012b) and 
it is thought they signal through CLRs as an escape mechanism from the hosts’ immune 
response (van Die and Cummings 2010b).  S. mansoni soluble egg antigens (SEA) have been 
shown to signal through several CLRs; DC-SIGN, MGL and MR and inhibit DC maturation 
and induce a Th2 immune response (van Liempt et al. 2007). The nematode Trichuris suis 
has also been shown to be involved in CLR signalling. Glycans isolated from the parasite, 
signal through MR and DC-SIGN and induce, as was seen with S. mansoni, a DC phenotype 
which inhibits bacterial TLR activation and the activation of an inflammatory immune 
response. It has been shown that F. hepatica is rich in glycans on its structure and in the ES 
products. This may lead to signalling through CLRs rather than traditional routes like TLRs. 
In studies using mannan to block the interaction between the mannose receptor and FhES, the 
alternative activation of macrophages can be prevented and also using blocking antibodies for 
MR and Dectin 1 this can also be achieved (Guasconi et al. 2011). However it has also been 
shown that TLR2 plays a role in the FhES inhibition of macrophages during Mycobacterium 
bovis activation (Flynn et al. 2009). As some of the major components of FhTeg are 
carbohydrates, CLRs may play a role in the immunomodulatory effect seen on cells in the 
immune system.  
 
1.5. The Mannose Receptor 
 
The macrophage mannose receptor (MR) is a carbohydrate binding receptor which plays 
a role in a number of actions in the cell. It is involved in the clearance of endogenous 
molecules, the activation of cells and also the enhancement of antigen presentation from 
APCs. The receptor is found on a number of cell types including dendritic cells, 
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macrophages, mast cells and non-vascular endothelium (Martinez-Pomares 2012). MR is a 
type-I membrane protein with a cytoplasmic domain involved in antigen processing and 
receptor internalisation and three different types of binding domains at its extracellular 
region. It features multiple C-type lectin-like carbohydrate-recognition domains (CRDs) 
responsible for calcium dependent binding to terminal mannose, fucose or N-acetyl 
glucosamine (Gazi and Martinez-Pomares 2009) a fibronectin type II (FNII) domain involved 
in collagen binding (Martinez-Pomares et al. 2006) and an N-terminal cysteine-rich (Cys-
MR) domain that mediates calcium-independent binding to sulfated sugars (Figure 1.1).  
 
Figure 1.1 The structure of the mannose receptor. The mannose receptor has three binding domains. The 
cysteine rich domain controls calcium independent binding to sulphated N-linked sugars. The fibronectin type II 
binding domain is involved in binding to fibronectin or collagen. The carbohydrate recognition domains or 
CRDs are involved in calcium dependent binding of sugars.  
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The mannose receptor has been implicated as a receptor involved both in vivo and in vitro 
after stimulation with helminth products (Vázquez-Mendoza, César Carrero and Rodriguez-
Sosa 2013). During S. mansoni infection, IFN-γ production was seen to be modulated by MR 
(Paveley et al. 2011) and antigens isolated from the soluble egg antigens also from S. 
mansoni which are highly glycosylated signal through MR and induce a Th2 priming DC 
population  (Everts et al. 2012). During T. muris infection the MR receptor is also involved 
and the excretory/secretory products bind through MR but it is not essential for the generation 
of the immune response seen and knockout of the gene does not lead to the expulsion of the 
parasite in a quicker manner than wild-type mice (DeSchoolmeester et al. 2009a). 
 
1.6. Helminth infections and CD4+ cells 
 
CD4
+ 
T-cells are a crucial link, mediating adaptive and innate immune responses. They are 
involved in antibody production from B-cells (MacLennan et al. 1997), regulate macrophage 
function (Chan et al. 2011), mediate CD8
+
 T-cell responses including memory effector cells 
following re-infection (Sun and Bevan 2003) and are important in allergic responses and 
auto-immunity (Wambre, James and Kwok 2012, Burkett et al. 2014). Following recognition 
of antigens presented by APCs like dendritic cells or macrophages they can differentiate into 
various subsets including Th1, Th2, Th17, T-reg or anergic T-cells (Yamane and Paul 2013). 
Following differentiation CD4
+
 cells produce cytokines according to their subset, Th1 cells 
tend to produce pro-inflammatory cytokines like TNF-α and IFN-γ whereas Th2 subsets 
produce IL-5, IL-4 and IL-13. T-reg cells produce TGF-β and IL-10 but anergic T-cells are 
hypo responsive and do not mount an effective immune response or produce cytokines 
following antigen re-challenge (Schwartz 2005, Schwartz 2003, Knoechel et al. 2006, Zhu, 
Yamane and Paul 2010). 
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Helminth parasites typically establish themselves for extended periods of time within their 
host by regulating the immune response using a number of different mechanisms, these 
include the pushing of the immune response towards a Th2 response and a decrease in a Th1 
responses, the production of regulatory T-cells (T-reg) and also anergic T-cells (Maizels et al. 
2004). Helminth infections are characterised by an increase in mast cell numbers, 
eosinophilia and increased production of immunoglobulin E (IgE) (MacDonald, Araujo and 
Pearce 2002). Th2 responses are predominant during helminth infection and are associated 
with the production of IL-4, IL-5, IL-9 and IL-13 which are produced by CD4
+
 T cells 
(Maizels, Hewitson and Smith 2012). The priming of a Th2 immune response can lead to 
gross pathology and to prevent this the helminth can induce FoxP3
+
 T-regulatory (T-reg) 
cells that secrete IL-10 and TGFβ that can dampen Th2  immunity (Maizels et al. 2004). Treg 
cells are important cells used to control inflammatory responses and help maintain tolerance 
to self-antigens. During infection FoxP3
+
 CD4
+
 cells can be observed as early as 3-7 days 
post infection pushing the response towards a regulatory phenotype. Brugia malayi infection 
induces a regulatory response with enhanced FoxP3 expression and increased cell surface 
expression of CTLA4, a negative regulator of T-cell function (McSorley et al. 2008). 
Schistosoma haematobium infection in humans has also been associated with FoxP3
+
 T-reg 
cells with the highest percentage of this cell population observed in younger patients (Nausch 
et al. 2011). 
 
Helminth infections are also associated with anergic T-cells, a second type of inhibitory T-
cell phenotype that maintains tolerance to self-antigen. In this case there is no FoxP3 
expression or production of IL-10 and TGF-β. T-cell anergy is defined as a hypo responsive 
state with the failure of T-cells to proliferate or produce cytokines when re-stimulated with 
parasite antigens in vitro (Schwartz 2003). Anergic cells do not secrete IL-2, a factor 
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important for T-cell proliferation and effector responses. The addition of IL-2 can overcome 
this anergic response restoring the proliferative and cytokine producing ability of the T-cell 
(Carter et al. 2002). Gene analysis studies have shown a number of genes including RNF128 
(GRAIL), ITCH, early growth response genes 2 and 3, (Egr2 and 3) and casitas B-lineage 
Lymphoma Proto-oncogene b (CblB) are involved in the induction and maintenance of T-cell 
anergy (Lechner et al., Mueller 2004b) . The expression of PD1 and CTLA4 by T-cells are 
also a defining mark of anergy (Greenwald et al. 2001, Okazaki and Honjo 2006). T-cell 
anergy rather than FoxP3 T-reg cells are associated with chronic infection which may be due 
to the persistence of parasite antigen and the constant contact of the cells with the antigens.  
T-cell anergy has been shown to one of the main causes of T-cell unresponsiveness in S. 
mansoni  infection mediated by the up-regulation of PD-L1 on the surface of macrophages 
(Smith et al. 2004) and also with the up-regulation of RNF128 (GRAIL) in T-cells isolated 
from chronic infection (Taylor et al. 2009). 
 
1.7. Dendritic cell/T-cell Crosstalk  
 
To mount an effective immune response to antigens, effective crosstalk must occur between 
different cell types. As dendritic cells are the most potent antigen presenting cells in the 
immune system we are interested in how they drive T-cell responses to different helminth 
antigens. Following processing by dendritic cells, they present antigens to T-cells on markers 
like MHC class I and II. They then bind to their respective receptors on T-cells like the T-cell 
Receptor complex (TCR) (Signal 1) and also bind through co-stimulatory markers like CD80 
and 86 to CD28 (Signal 2) to initiate immune responses. If insufficient signals are received 
by T-cells from dendritic cells like Signal 1 alone this may induce anergy (Sadegh-Nasseri et 
al. 2010). 
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There are a number of co-stimulatory ligands and receptors involved in dendritic cell/T-cell 
communication which can drive or inhibit T-cell activation (Guermonprez et al. 2002, Jung 
and Choi 2013). Presentation through CD80 (B7.1) and CD86 (B7.2) to CD28 and the TCR 
on T-cells results in stimulation of T-cells by lowering the threshold needed for activation 
and the subsequent production of IL-2 (Lenschow, Walunas and Bluestone 1996) but 
signalling through CTLA4 on T-cells terminate T-cell responses and maintains tolerance to 
self-antigens by inhibiting IL-2 production and subsequent proliferation (Slavik, Hutchcroft 
and Bierer 1999). Other ligands such as PDL1 and PDL2 are also inhibitory; they bind 
through the receptor PD1 on T-cells and terminate T-cell responses (Carter et al. 2002, 
Okazaki and Honjo 2006, Okazaki and Honjo 2007). C-type lectin receptors also have 
ligands on T-cells for communication and crosstalk. CD45 has been implicated as a co-
receptor for the mannose receptor (Marti´nez-Pomares et al. 1999). CD45 regulates Src 
family kinases and can be both a positive and a negative regulator of T-cell function affecting 
cytokine secretion, migration and TCR signalling (Saunders and Johnson 2010).  
 
1.8. Fasciola hepatica 
 
The helminth parasite Fasciola hepatica causes fasciolosis in mammals infecting cattle, 
sheep and is a zoonotic disease in humans, affecting approximately 2.4 million people 
worldwide. Although generally not fatal, infection causes weight loss and anaemia (Mas-
Coma, Bargues and Valero 2005). In sheep and cattle, infection causes a huge economic 
burden, estimated at more than 100 million dollars a year in the US and more than 80 million 
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pounds in the UK and Ireland. Infection can cause a lower rate of milk production and a 
susceptibility to tuberculosis in cattle (Brady et al. 1999b).   
 
The parasite has a complex life cycle with an intermediate snail host and definitive 
mammalian host. Eggs are released from the definitive host which hatch and produce 
miracidium, these infect the intermediate snail host. The snail host sheds cercariae which then 
encyst as metacercariae (infective larvae) on water plants. The metacercariae are ingested by 
the definitive host and excyst in the duodenum to form newly excysted juvenile flukes that 
penetrate the intestinal wall and migrate through the peritoneal cavity and liver. Finally the 
adult worm resides in the bile ducts, releasing eggs for many years (Robinson and Dalton 
2009) (Figure 1.2).  Generally the process of migration and penetration through the small 
intestine does not outwardly show signs of clinical disease but movement to the liver can 
cause haemorrhaging and fibrosis. 
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Figure 1.2 Life cycle of F. hepatica. The parasite has a complex life cycle with an intermediate snail host and 
definitive mammalian host. The intermediate snail hosts sheds cercariae which then encyst as metacercariae and 
the mammalian host ingests them. These metacercariae excyst in the duodenum to form newly excysted juvenile 
flukes that penetrate the intestinal wall and migrate through the peritoneal cavity towards the liver. Finally the 
adult worm resides in the bile ducts, releasing eggs for many years. 
 
Infection typically exhibits a strong Th2/ T-reg immune response in the host with the 
production of   IL-5, IL-4 and IL-10 with the inhibition of protective Th1 cytokines (O'Neill 
et al. 2000). Figure 1.3 outlines the hosts’ immune response to F. hepatica infection. The 
juvenile fluke migrate through the gut and into the peritoneal cavity and reside in the liver, 
where they release antigens and eggs. The parasite secretes excretory/secretory molecules and 
sheds its tegumental coat, this causes the alternative activation of macrophages with the 
expression of Arg1, YM1, Fizz1 (Relmα) and IL-10. These molecules also suppress the 
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activation of dendritic cells with the down-regulation of MHC I and II, CD80 and 86 but the 
expression of CD40 is enhanced. The secretion of MIP1α and MIP2 attracts mast cells to the 
site and the FhES and FhTeg cause the expression of SOCS3 to be enhanced and ICAM1 to 
be down-regulated. This affects downstream molecules, including MAPK and the mast cells 
fail to produce cytokines. The combined effect on macrophages, dendritic cells and mast cells 
when co-stimulated with bacterial ligands is that they do not respond, produce cytokines or 
mount an immune response to them. This fails to drive Th1 or Th17 immune responses and 
the immune response is pushed towards a Th2 or T-reg immune response. 
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Figure 1.2 The hosts immune response to F. hepatica. 1. Parasite secretes excretory/secretory molecules and 
sheds its tegumental coat. This causes the alternative activation of macrophages with the expression of Arg1, 
YM1, Fizz1 (Relmα) and IL-10. These molecules also suppress the activation of dendritic cells with the down-
regulation of MHC I and II, CD80 and 86 but the expression of CD40 is enhanced. 2. The secretion of MIP1α 
and MIP2 attracts mast cells the site and the FhES and FhTeg cause the expression of SOCS3 to be enhanced 
and ICAm1 to be down-regulated. This affects downstream molecules MAPK and the mast cell fails to produce 
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cytokines. 3. The combined effect on macrophages, dendritic cells and mast cells when stimulated with bacterial 
ligands is that they do not respond, produce cytokines or mount an immune response to them. 4. This fails to 
drive Th1 or Th17 immune responses. 5. The immune response is pushed towards a Th2 or T-reg immune 
response (O’Neill, 2014). 
 
1.9. Fasciola hepatica Antigens 
 
F. hepatica has two main sources of antigen which includes its excretory/secretary products 
which are constantly produced in the host and the tegumental coat which is shed every two to 
three hours. The excretory/secretory products (FhES) have been most widely studied and 
table 1 summarises the different antigen sources and our current understanding of their 
immune modulatory properties.  FhES is composed mainly of cathepsin L, peroxredoxin, 
helminth defence molecules and sigma class gluthathione transferase. FhES modulates the 
immune response by producing a Th2 response. Studies have shown FhES molecules to have 
both in-vitro and in vivo effects. Thioredoxin peroxidise from FhES is involved in reducing 
oxidative stress in flukes (Selzer and Caffrey 2012), it also induces alternative activation of 
macrophages with the expression of YM1, Fizz (Relmα) and Arg1 (Donnelly et al. 2005).  
 
 Another major component of FhES, Cathepsin L cysteine peptidases, play a role in 
degrading host proteins into peptides (Robinson et al. 2013). Cathepsin L induces a 
suppressive dendritic cell phenotype which did not induce a Th2 immune response but 
attenuated a Th17 response (Dowling et al. February 2010) and in another study it was found 
that FhES induced a tolerogenic dendritic cell phenotype with the down-regulation of 
maturation markers and the priming of a Th2/T-reg response from CD4
+
 cells (Falcón et al. 
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2010). Cathepsin L also inhibited IFN-γ production when injected into a model of whole cell 
vaccination of B. pertussis, mimicking what was seen during F. hepatica co-infection 
(O'Neill, Mills and Dalton 2001, Brady et al. 1999a). 
 
Another product from F. hepatica that is used to regulate the immune response is the 
tegumental antigen (FhTeg). FhTeg consists of a surface syncytial cytoplasmic layer bounded 
externally by a plasma membrane and covered by a glycocalyx which is rich in glycoproteins 
(Wilson et al. 2011). The surface layer contains many mitochondria and also two types of 
secretory bodies, T1 and T2. T1 secretory bodies are round and appear in a gradient within 
the syncytial cytoplasmic layer and are also more numerous in numbers. The T2 bodies are a 
biconcave shape and appear in a gradient opposite to that of the T1 bodies.  The syncytial 
cytoplasmic layer is connected by cytoplasmic strands to cell bodies in the parenchyma 
below the muscle layers. The glycocalyx comprises of two layers, a continuous inner layer 
and an outer fibrillary layer. It consists largely of glycoproteins and has a net negative charge 
(Threadgold 1963). The tegument is shed from the fluke every 2-3 hours, so is in constant 
contact with the host and contributes to the evasion of the parasite by the hosts’ immune 
response which is summarised in Table 1.  
 
The tegument is involved in a number of different functions, like absorption of exogenous 
nutrients, synthesis of various substances and protection against bile and hosts enzymes 
(Dalton 1999). The removal of FhTeg from the fluke involves the use of detergents like 
Nonidet P40 and the subsequent removal of this detergent using detergent removal beads. 
This has some difficulties as the glycocalyx is insoluble and FhTeg contains a number of 
different proteins. The components of FhTeg and the glycocalyx have been mostly identified 
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and include a mixture of excretory-secretory proteins, membrane associated proteins, 
cytoskeleton and energy metabolism components (Morphew et al. 2013). Proteomic studies 
have identified some of the components of FhTeg, proteins such as acetylcholinesterase and 
alkaline phosphatase, annexins a,b and c and cathepsins B and L. FhTeg differs from FhES in 
that it is mostly composed of carbohydrates while FhES has high enzymatic activity and 
consists mostly of proteins but the biologically active component(s) of FhTeg are yet to be 
identified and further proteomic analysis are ongoing into the components of FhTeg with 
particular focus on the glyco-proteins (Wilson et al. 2011, Wuhrer and Geyer 2006). 
Table 1. The effect of FhES and FhTeg on DCs, macrophages and mast cells.  
 
 
 
 
 
 
 
 
 
 
 
 Excretory-secretory 
products 
Tegumental antigens 
Dendritic Cells Immature phenotype 
↑ (increase) IL-10 
Induces  Th2/Treg 
immune responses 
Inhibits TLR activation 
of dendritic cells 
Immature phenotype 
Inhibits Th1 immune 
responses 
Inhibits phagocytosis 
Inhibits TLR and non-
TLR activation of 
dendritic cells 
Inhibits NFkB and 
MAPKinases 
Induces SOCS3 
Macrophages Induces regulatory /M2 
macrophages 
↑ Fizz, Arginase and 
Relm1 
↑ IL-10, PGE2, TGFβ 
Promotes Th2 immune 
responses 
Inhibits Th1 immune 
responses 
Induces Relmα 
 
Mast Cells Unknown Immature phenotype 
Inhibits Th1 immune 
responses 
Induces Mast cell 
migration 
Inhibits TLR activation 
of mast cells 
Inhibits NFkB and MAP 
Kinases 
Induces SOCS3 
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The effect of FhTeg on a number of different immune cells has been studied. Dendritic cells 
stimulated with FhTeg fail to produce cytokines like IL-10 and they fail to induce Th2 or T-
reg immune responses in CD4
+
 T-cells which differs from the effect of FhES. Stimulation 
with FhTeg and LPS, a TLR ligand, fail to enhance the expression of co-stimulatory 
molecules like CD80, CD86 and MHC class II and it also inhibits the production of 
inflammatory cytokines like IL-12p70 and TNF-α (Hamilton et al. June 2009). This may 
inhibit DC’s ability to prime T-cells as enhanced co-stimulatory markers on DC’s help in 
communication with T-cells. Further studies have shown that FhTeg induces suppressor of 
cytokines signalling-3 (SOCS3), a negative regulator of the TLR pathway, in dendritic cells 
and this may have an effect on the DC’s ability to produce cytokines. FhTeg also inhibits NF-
κB and the MAPKs p38, JNK and ERK which are very important in inflammatory processes 
(Vukman, Adams and O'Neill 2013).  
 
FhTeg also has an inhibitory role in mast cells. In vivo, the injection of FhTeg mimics 
infection with an increase in mast cell numbers in the peritoneal cavity due to the migration 
of cells to the area (Vukman et al. 2013a). In vitro, cells treated with FhTeg fail to mature and 
it inhibits Th1 responses. Like with dendritic cells, it inhibits TLR activation of cells with no 
production of IL-6, IFN-γ or TNF-α. FhTeg also enhances the expression of SOCS3 and 
affects the NF-κB and MAPKs pathways. FhTeg treated mast cells also fail to drive Th2 
immune responses from CD4
+ 
cells and this may be due to the decrease in expression of 
ICAM1 on mast cells (Vukman et al. 2013b). As mast cells are critical in the clearance of 
microbial infections the suppression of Th1 responses by FhTeg may affect this. Mice 
injected with heat inactivated Bordetella pertussis antigen induce a strong Th1 immune 
response with the production of high levels of TNF-α from mast cells in the peritoneal cavity. 
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Co-injection with FhTeg markedly decreases the levels of TNF-α produced and the resulting 
Th1 immune responses (Vukman et al. 2013b). 
 
Studies have also been recently done on the effect of FhTeg on macrophages. In vivo, the 
injection of FhTeg indirectly induces the alternative activation of macrophages in the 
peritoneal cavity and also increases the number of these cells to the area. These alternatively 
activated macrophages inhibit cytokine production from naïve CD4
+
 T-cells. Studies on Raw 
macrophage cell line have shown that FhTeg induces Relm-α from cells but not other 
markers of alternative activation like Arginase 1 (Adams et al. 2014). 
 
1.11. Summary 
 
Helminths and their antigens exert strong Th2/T-reg immune responses (Anthony et al. 2007) 
and can suppress Th1 immune responses but helminths can also have positive effects on 
autoimmune diseases and clinical trials are underway on a number of inflammatory diseases 
like multiple sclerosis and irritable bowel syndrome (Kuijk et al. 2012a, Heylen et al. 2015, 
Whary et al. 2001). We are interested in studying F. hepatica and its tegumental coat. 
Infection with F. hepatica down-regulated Th1 immune responses in mouse models (O'Neill 
et al. 2000) and also co-infection with Bordetella pertussis inhibits a Th1 immune response 
and the clearance of the bacteria (Brady et al. 1999a). The tegumental coat has also been 
shown to alter dendritic cell maturation, function and inhibits the production of Th1 and Th2 
cytokines to TLR ligands (Hamilton et al. 2009a). The purpose of this study was to 
characterise the T-cell responses during F. hepatica infection and to investigate the role of 
FhTeg and CLRs on dendritic cells and T-cells from both murine and human origin. 
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1.12. Aims 
 
The aims of the project are: 
 To characterise further FhTeg treated dendritic cells and to show the role played by 
CLRs in FhTeg-dendritic cell interactions (Chapter 3)  
 To characterise the T-cell responses during F. hepatica infection and to investigate if 
FhTeg stimulated DCs could mimic this response (Chapter 4) 
 To investigate if FhTeg can interact directly with CD4+ cells and if CLRs play a role 
in this interaction (Chapter 5) 
 To characterise the responses seen in human immune cells following treatment with 
FhTeg (Chapter 6) 
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2. Chapter 2. 
3. Materials and Methods  
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2.1 Materials 
2.1.1 Animals  
PRODUCT COMPANY 
BALB/c mice (female) Charles River (Kent, UK) 
C57BL/6 mice (female) Charles River (Kent, UK) 
MR
-/- 
mice  
Adult Fasciola hepatica Abattoir (Navan, Ireland) 
F. hepatica metacercariae Baldwin Aquatics Ltd (USA) 
 
 
2.1.2 Cell Culture 
PRODUCT CATALOGUE # COMPANY 
Fetal Calf Serum (FCS) 10270-106 Gibco, Invitrogen (Paisley, UK) 
L-Glutamine G7513 Sigma-Aldrich (Wicklow, Ireland) 
Phosphate Buffer Saline 
(PBS) 
14190 Gibco, Invitrogen (Paisley, UK) 
Penicillin/Streptomycin 1570-063 Gibco, Invitrogen (Paisley, UK) 
RPMI 1640 31870-074 Invitrogen (Paisley, UK) 
Trypan blue T8154 Sigma-Aldrich (Wicklow, Ireland) 
X VIVO-15 BE04-48Q Lonza (Walkersville, USA) 
 
2.1.3 Antigens 
PRODUCT CATALOGUE # COMPANY 
anti-CD3 MAB4851 RnD (UK) 
Ionomycin I9657 Sigma-Aldrich (Wicklow, Ireland) 
IL-2 MAB702 RnD (UK) 
Lipopolysaccharide 
(LPS) (E. coli) 
ALX-581-007 Alexis Biochemicals (Lausanne, 
Switzerland) 
Phorbalmyristate acetate 
(PMA) 
P8139 Sigma-Aldrich (Wicklow, Ireland) 
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2.1.4 Commercial Kits 
PRODUCT CATALOGUE 
# 
COMPANY 
Annexin V-FITC apoptosis detection kit 556547 BD Biosciences (Oxford, UK) 
BCA protein kit 23288, 23224 Promega (Madison, USA) 
CD4
+
 Isolation kit Mouse 19852RF Stemcell (France) 
CD4
+ 
Isolation kit Human 19662 Miltenyi Biotec, UK 
Human IFN-γ ELISA kit 430103 Biolegend, (UK) 
Human IL-2 ELISA kit 88-7025 eBiosciences, (UK) 
Human IL-1β 88-7261 eBiosciences, (UK) 
Human TNF-α 430203 Biolegend, (UK) 
Mouse IFN-γ ELISA kit 555138 Biolegend (UK) 
Mouse IL-10 ELISA kit 555252 Biolegend (UK) 
Mouse IL-4 ELISA kit 555232 Biolegend (UK) 
Mouse IL-5 ELISA kit 555236 Biolegend (UK) 
Mouse IL-13 ELISA kit 88-7137-86 eBioscience (Hatfield, UK) 
Mouse IL-2 ELISA kit 88-7024-77 eBioscience (Hatfield, UK) 
Mouse TNF-α ELISA kit 88-7324-77 eBioscience (Hatfield, UK) 
Mouse IL-12p70 ELISA kit 555256 BD Biosciences (UK) 
PGD2 prostaglandin EIA kit 512031 CaymanChemical 
Company, (US) 
PGE2 prostaglandin EIA kit 514531 CaymanChemical 
Company, (US) 
Promofluor Protein Labelling kit PKPFLK488P10 Promokine (Heidelberg, 
Germany) 
Pyrogene Recombinant Factor C Endotoxin 
Detection System 
50-658U Lonza (Walkersville, USA) 
MycoSensor PCR Assay Kit 302109 Agilent Technologies (Cork, 
Ireland) 
RNA extraction kit 11828665001 Roche Diagnostics, (UK) 
rt-PCR kit 04379012001 Roche Diagnostics, (UK) 
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2.1.5 Reagents 
 
PRODUCT CATALOGUE # COMPANY 
2-Mercaptoethanol  63689 Sigma-Aldrich 
(Wicklow, Ireland) 
2-Propanol  24137 Sigma-Aldrich 
(Wicklow, Ireland) 
3,3′,5,5′-Tetramethylbenzidine 
dihydrochloride hydrate  
T8768  Sigma-Aldrich 
(Wicklow, Ireland) 
Agarose BIO-4125 Bioline (London, UK) 
Buffer Solution pH 10.0 (20 °C) 33668 Sigma-Aldrich 
(Wicklow, Ireland) 
Buffer Solution pH 4.0 (20 °C) 33665 Sigma-Aldrich 
(Wicklow, Ireland) 
Buffer Solution pH 7.0 (20 °C) 33666 Sigma-Aldrich 
(Wicklow, Ireland) 
Calcium Chloride 383147 Sigma-Aldrich 
(Wicklow, Ireland) 
Chloroform 3505 Fisher Scientific 
(Dublin, Ireland) 
Dimethyl Sulfoxide D2650  Sigma-Aldrich 
(Wicklow, Ireland) 
Ethanol E7023  Sigma-Aldrich 
(Wicklow, Ireland) 
Ethylenediamine-tetraacetic acid (EDTA) E9884 Sigma-Aldrich 
(Wicklow, Ireland) 
FACS Tubes 352054 Unitech/BD (Dublin 24, 
Ireland) 
FACS Clean 340345  BD Biosciences 
(Oxford, UK) 
FACS Flow Sheath  342003  BD Biosciences 
(Oxford, UK) 
FACS Rinse  340346  BD Biosciences 
(Oxford, UK) 
Formaldehyde Solution  F8775  Sigma-Aldrich 
(Wicklow, Ireland) 
Glycine G/0800 Fisher Scientific 
(Dublin, Ireland) 
Histopaque-1083 1083-1 Sigma-Aldrich 
(Wicklow, Ireland) 
Hydrochloric acid H1758 Sigma-Aldrich 
(Wicklow, Ireland) 
HyperLadder IV BIO33029 Bioline (London, UK) 
HEPES H3375  Sigma-Aldrich 
(Wicklow, Ireland) 
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Immobilon Western Chemiluminescent 
HRP Substrate 
WBKLS0100 Millipore (MA, USA) 
Lymphoprep  Stem Cell, France 
Mannan M7504 Sigma-Aldrich 
(Wicklow, Ireland 
Methanol 65543 Sigma-Aldrich 
(Wicklow, Ireland) 
N-Acetyl-D-Galactosamine 4-sulphate 
(GalNAc-4-Sulphate) 
A5926 Sigma-Aldrich 
(Wicklow, Ireland) 
N,N,N′,N′-Tetramethylethylenediamine T9281  Sigma-Aldrich 
(Wicklow, Ireland) 
Nonidet™ P 40 Substitute  74385 Sigma-Aldrich 
(Wicklow, Ireland) 
Phosphate-Citrate Buffer with Sodium 
Perborate 
P4922  Sigma-Aldrich 
(Wicklow, Ireland) 
Protease Inhibitor Cocktail P8340 Sigma-Aldrich 
(Wicklow, Ireland) 
Sodium Azide 13412 Sigma-Aldrich 
(Wicklow, Ireland) 
Sodium Carbonate S7795 Sigma-Aldrich 
(Wicklow, Ireland) 
Sodium Chloride S/3160 Fisher Scientific 
(Dublin, Ireland) 
Sodium Hydroxide S5881 Sigma-Aldrich 
(Wicklow, Ireland) 
Sodium Phosphate S8282 Sigma-Aldrich 
(Wicklow, Ireland) 
Sulfuric Acid  435589 Sigma-Aldrich 
(Wicklow, Ireland) 
SYBRSafe DNA gel Stain S33102 Invitrogen (Paisley, UK) 
TEMED T9281 Sigma-Aldrich 
(Wicklow, Ireland) 
TMB Substrate Reagent Set 421101 Biolegend (San Diego, 
USA) 
Trizma Base 93352 Sigma-Aldrich 
(Wicklow, Ireland) 
Triton X-100 BDH306324 VWR (East Grinstead, 
UK) 
Tween 20 P1379 Sigma-Aldrich 
(Wicklow, Ireland) 
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2.1.6 Equipment 
 
PRODUCT CATALOGUE # COMPANY 
Analogue Stirred Water bath      NE4-22T VWR (East Grinstead, 
UK) 
Benchtop Microcentrifuge 4214 MSC Co. Ltd. (Dublin, 
Ireland) 
BIOQUEL Microflow Class II ABS Cabinet   ABS1200F   VWR (East Grinstead, 
UK) 
Block Heater    BBA series    MSC Co. Ltd. (Dublin, 
Ireland) 
Consort nv electrophoresis power supply  AE-6450 Belgium 
Compressed carbon dioxide (CO2) industrial 40-VK  BOC Gases Ireland 
(Dublin, Ireland) 
FacsAria 1 flow cytometer           BD Biosciences (Oxford, 
UK) 
Hemocytometer, Neubauer, Double cell   MSC Co. Ltd. (Dublin, 
Ireland) 
 Hotplate Stirrer         AGB1000  Jenway (Stone, UK) 
Leica Inverted microscope        DMIL Leica Microsystems 
(Wetzlar, Germany) 
Mini horizontal electrophoresis unit 658         Z338796  Sigma-Aldrich (Wicklow, 
Ireland) 
Olympus transmitted-reflected light 
microscope wit BF/DF/DIC/Polarised light 
BX60 Olympus (Hamburg, 
Germany) 
Sigma 4K15 Benchtop Refrigerated 
Centrifuge      
10740  Sigma Centrifuges 
(Merringtn, UK) 
Stuart Scientific combined incubator and 
orbital shaker  
S150 MSC Co. Ltd. (Dublin, 
Ireland) 
TECAN GeniosMicroplate Reader            Tecan (Mannedorf, 
Switzerland) 
TECAN Safire2 UV/VIS/IR and fluorescence 
plate reader            
 MSC Co. Ltd. (Dublin, 
Ireland) 
Thermo Scientific CO2 Water Jacketed 
Incubator   
Model 3111 MSC Co. Ltd. (Dublin, 
Ireland) 
Vortex mixer    SA8   Stuart (Stone, UK) 
West balance    BL120S  Sartons (Goettingen, 
Germany) 
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2.1.7 Disposables 
 
PRODUCT 
 
CATALOGUE # COMPANY 
24 Well Plates 83.1836 Sarstedt. (Wexford,Ireland) 
Coverslips  MLS17-20  Lennox Ltd (Dublin 12, Ireland) 
15ml Tubes 62.554.502 Sarstedt. (Wexford,Ireland) 
50ml Tubes 62.559.001 Sarstedt. (Wexford,Ireland) 
25ml Pipettes 86.1685.001 Sarstedt. (Wexford,Ireland) 
1.5ml Tubes 72.706.200 Sarstedt. (Wexford,Ireland) 
96 Well Plates 82.1581 Sarstedt. (Wexford,Ireland) 
Petri Dishes 82.1473.001 Sarstedt. (Wexford,Ireland) 
6 Well Plates  Sarstedt. (Wexford,Ireland) 
 
2.1.8 Software 
PRODUCT COMPANY 
GraphPad Prism GraphPad(USA) 
FlowJo Tree Star (Ashland, USA) 
Origin           Origin Lab Corp. (Northampton, USA) 
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2.2 Methods 
2.2.1 Animals 
BALB/c and C57BL/6 mice 6-8 weeks old were purchased from Charles River (UK). 
Mannose receptor knockout mice on a C57BL/6 background were provided as a kind gift 
from Professor Padraic Fallon (Lee et al. 2002). An enhanced green fluorescent protein 
reporter gene was inserted at the start codon in Exon 1 of the MR gene. It contains a stop 
codon, which abolishes the expression of MR. The successful knocking out of the gene was 
detected by PCR genotyping and immunoblot. Mice were kept under specific pathogen free 
conditions at the Bio-resources unit, DCU. All mice were housed following guidelines from 
The Health Products Regulatory Authority and ethical approval was granted from the DCU 
ethics committee and The Health Products Regulatory Authority (HPRA.ie) before starting 
experiments, licence numbers B100/2833 and DCUREC/2010/033.   
2.2.2 FhTeg Preparation 
Fasciola hepatica tegumental antigen was prepared by adapting a previously published 
method (Hamilton et al. June 2009). Live worms were obtained from infected sheep or cattle 
from Irish Country Meats Abattoir, Navan. The presence of fluke in bile ducts was used to 
differentiate infected from non-infected livers. The flukes were transported back to the lab in 
warm RPMI media supplemented with 10% fetal calf serum (Biosciences, Dun Laoghaire) 
and 100u/ml penicillin/streptomycin (Sigma-Aldrich, Arklow). Back in the lab the flukes 
were washed three times in warm sterile PBS and 10 flukes were placed in 10ml of 1% 
Nonidet P40 for 30 minutes at 37 degrees. Nonidet P40 is a detergent which facilitates in the 
removal of FhTeg from the fluke, the supernatant was collected and the NP-40 was removed 
using detergent removal beads because detergent would interfere in cell assays (Bio-rad,US). 
Protein concentrations were measured using the bicinchoninicacid (BCA) protein assay kit 
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(see section 2.2.3) (Thermo Scientific, Leicestershire, UK), and endotoxin levels were 
assessed using the Pyrogene endotoxin detection system (see section 2.2.4). Negative values 
ensure that there is no contaminating endotoxin interfering in cell assays. 
2.2.3 Bicinchoninic acid (BCA) assay 
Determination of protein concentration on all samples used was performed using the 
bicinchoninic acid (BCA) assay in clear 96 well plates. The BCA Protein Assay combines the 
well-known reduction of Cu
2+
 to Cu
1+
 by protein in an alkaline medium with the highly 
sensitive and selective colorimetric detection of the cuprous cation (Cu
1+
) by bicinchoninic 
acid. In the first reaction, peptides containing three or more amino acid residues form a 
colored chelate complex with cupric ions in an alkaline environment containing sodium 
potassium tartrate. In the second step, bicinchoninic acid reacts with the reduced cation that 
was formed in step one. 10μl of each protein sample was placed in triplicate in a 96 well plate 
along with protein standards ranging from 2000ug to 125ug. The BCA reagents were mixed 
in a 1:50 dilution and 200μl was added to each sample. The plate was incubated at 37 degrees 
for thirty minutes and the plate was then read in a micro-titre plate reader at 562nm. The 
averages of the triplicate values were used and standard curves were generated to determine 
the protein concentrations. 
2.2.4 Endotoxin Testing 
FhTeg was tested for endotoxin contamination using Pyrogene Recombinant Factor C 
Endotoxin Detection System (Lonza, USA). Endotoxin activates a serine protease catalytic 
coagulation cascade that results in the gelation of Limulus blood. Factor C which is isolated 
from Limulus polyphemus is activated by endotoxin binding, recombinant Factor C acts upon 
the fluorogenic substrate in the assay mixture to produce a fluorescent signal in proportion to 
the endotoxin concentration in the sample. FhTeg gave similar or lower levels than 
background levels (0.01EU/ml). 
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2.2.5 Fasciola hepatica infection  
Metacercariae were obtained from Norman Baldwin (Baldwin Aquatics Ltd, USA). Using a 
96 well plate, 20 F. hepatica metacercariae were aliquoted in 20 µl of the metacercariae 
storage water. The mice were infected by pipetting 20μl of the water containing the 
metacercariae orally. Following a two week infection, mice were sacrificed by cervical 
dislocation. To ensure an infection had taken place, pathology was investigated as monitored 
by tissue damage, migrating tracts in liver and enlarged spleens. Spleens were removed and 
processed (see section 2.2.13) 
 
2.2.6 Fasciola hepatica injection 
We have previously shown that by injecting FhTeg into the peritoneal cavity three times a 
week for three weeks, it will mimic infection by recruiting mast cells and alternatively 
activated macrophages (Adams et al. 2014, Vukman et al. 2013a). To investigate if FhTeg 
would mimic T-cell responses seen during infection, PBS (100μl) or FhTeg (10μg in 100μl) 
was injected intraperitoneally (i.p.) into mice and after 6, 24, 72 hours or 1 week, mice were 
sacrificed and mesenteric lymph nodes were removed and analysed for cell surface marker 
expression by flow cytometry. PBS or FhTeg (10μg in 100μl) was also injected over the 
sternum and 1 week later spleens were removed, analysed by flow cytometry for cell surface 
marker expression and re-stimulated with FhTeg (10μg/ml) with or without IL-2 (20ng/ml) or 
PMA (20ng/ml) and anti-CD3 (10μg/ml) to measure cytokine secretion. After 72 hours 
supernatants were removed and analysed for cytokine secretion (see section 2.2.10) 
2.2.7 Generation of bone marrow derived dendritic cells 
Bone marrow dendritic cells (BMDCs) were differentiated using a previously described 
method (Lutz, Manfred B 1999). Bone marrow was harvested from the tibia and fibia of a 
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female BALB/c, MR
-/-
 or C57BL/6 mouse by flushing with ice cold PBS. The cells were 
washed and seeded at 2x10
5 
cells per ml in 10ml of RPMI supplemented with 10% fetal calf 
serum (Biosciences, Dun Laoghaire), 1% L-glutamine, 100u/ml penicillin/streptomycin 
(Sigma-Aldrich, Arklow) and 20ng/ml granulocyte macrophage-colony stimulating factor 
(GM-CSF),  GM-CSF obtained from a GM-CSF producing cell line X63 (a gift from Prof. 
Ton Rolink; University of Basel, Switzerland) is a growth factor which causes the 
differentiation of bone marrow cells into dendritic cells. Cells were fed on days 3, 6 and 8 
and harvested on day 10. On day three, 10ml of fresh media was added with 20ng/ml of 
GMCSF, on day 6, 9ml of media was removed and discarded and 10ml of fresh media with 
20ng/ml of GMCSF added. On day 8, 9ml of media was removed and spun down at 300g, the 
pellet was re-suspended in 10ml of fresh media containing 20ng/ml of GM-CSF and added 
back to the plate. On day 10, the loosely adherent cells were removed and dendritic cell 
purity was analysed by CD11c expression by flow cytometry, giving greater than 95% purity 
(93-99%) (Figure 2.2.7)  
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Figure 2.2.7. Purity of dendritic cells isolated from bone marrow. Dendritic cells were cultured for 10 days, 
on day 10, cells were analysed for CD11c expression as an indicator of purity using flow cytometry. 
 
2.2.8 BMDC activation  
On day 10 of culture dendritic cells were removed and spun down at 300g to pellet the cells 
and re-suspend in fresh media containing growth factors. The pellet was re-suspended in 1ml 
of PBS and cell number and viability was determined using trypan blue staining. The cells 
were spun down again and re-suspended in RPMI to a final concentration of 1x10
6
 cells/ml. 
They were seeded at 1x10
6
 cells/ml and stimulated with FhTeg (10μg/ml) for 2.5 hours 
before LPS (100ng/ml) was added.  
To determine if the mannose receptor was playing a role in signalling following FhTeg 
stimulation, blocking experiments were performed using antibodies and sugars to block the 
interaction of FhTeg and MR. In blocking experiments, anti-MR (10μg/ml) (Abcam, Uk), 
Mannan (50μg/ml) and GalNAc-4-Sulphate (1mM) (Sigma-Aldrich, Ire) were added 30 
minutes before the addition of FhTeg (10μg/ml).  After a further 2.5 hours LPS (100ng/ml) 
was added to appropriate wells. After 18 hours supernatants were removed and analysed for 
cytokine secretion using ELISAs (see section 2.2.11) 
 
2.2.9 Generation and stimulation of Splenocytes and CD4+ cells 
In order to measure antigen specific immune responses following infection with F. hepatica 
metacercariae, spleens were isolated from control and infected mice and splenocytes obtained 
by passing the spleens through a 40μm and 70μm filter before counting and plating at 5x106 
cells per ml in X-Vivo media (Lonza,USA) supplemented with 10% fetal calf serum 
(Biosciences, Dun Laoghaire) and 100u/ml penicillin/streptomycin (Sigma-Aldrich, Arklow).
 
Splencoytes were stimulated with FhTeg (10μg/ml) in the presence or absence of 
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recombinant IL-2 (20ng/ml), phorbol 12-myristate 13-acetate, (PMA), (20ng/ml) and anti-
CD3 (10μg/ml). PMA and anti-CD3 were used as positive controls as they will cause 
proliferation and cytokine production from splenocytes and CD4
+
 T-cells. 
CD4
+
 T-cells were isolated using a negative selection CD4
+
 isolation kit (Stemcell, France) 
and cells with greater than 95 per cent purity were used as analysed by flow cytometry 
(Figure 2.2.9). CD4
+
 T-cells were plated at 2x10
6 
in X-Vivo media (Lonza, USA) and 
stimulated with PMA (20ng/ml) (Sigma-Aldrich,IRE) and anti-CD3 (10μg/ml) (RnD)  in the 
presence or absence of FhTeg (10μg/ml). After 72 hours supernatants were removed and 
analysed for the production of IL-2, IL-4, IL-5, IFN-γ and IL-10 using commercial ELISA 
(see section 2.2.11), following manufacturer’s instructions (Biolegend,UK). 
 
Figure 2.2.9 Analysis of purity of CD4
+
 T-cells used after isolation with negative selection kit. CD4
+ 
cells 
isolated from spleens were labelled with a FITC CD4
+
 antibody and purity was found to be over 95% in each 
case, one representative experiment shown, purity at 98%.  
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2.2.10 Isolation and stimulation of human PBMCs 
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats which were 
sourced from The Irish Blood Transfusion Service, St James’ Hospital, Dublin. PBMCS were 
isolated by density gradient centrifugation using Histopaque-1083 (Sigma Aldrich, Ire). 
Histopaque was layered at the bottom of a 50ml tube, isolated blood which was diluted 1:1 in 
sterile PBS was layered onto the histopaque. Tubes were centrifuged at 800g for 40 mins with 
no brake applied as sudden braking can disrupt the separating of blood into its different 
layers. During centrifugation, erythrocytes are aggregated and rapidly sediment as a pellet at 
the bottom of the tube. Lymphocytes and other mononuclear cells remain at the 
plasma/Histopaque interface. The layer of mononuclear cells are removed and washed three 
times with PBS before being counted. 
PBMCs were plated at 1x10
6 
cells/ml in complete RPMI and stimulated with FhTeg 
(10μg/ml) for 2.5 hours before the addition of PBS, LPS (100ng/ml) or PMA (20ng/ml) and 
Ionomycin (1μM). Supernatants were removed following a 24 hour stimulation and analysed 
by ELISA (see section 2.2.11). CD14
+ 
cells were isolated by positive selection using CD14
+
 
microbeads (Miltenyi Biotec, UK).  Cells were stimulated with FhTeg (10μg/ml) for 2.5 
hours before the addition of LPS (100ng/ml). Supernatants were removed and analysed for 
the production for TNF-α and IL-1β by commercial ELISA. CD4+ cells were isolated by 
negative selection (Miltenyi Biotec, UK), isolated cells were stimulated with FhTeg 
(10μg/ml) for 2.5 hours before the addition of PMA (20ng/ml) and Ionomycin (1μM). PMA 
and Ionomycin were used to activate PBMCs to proliferate and produce cytokines. Following 
a 72 hour stimulation supernatants were removed and analysed by ELISA. 
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2.2.11 Cytokine Analysis  
Cytokine secretion was measured using commercially available sandwich ELISA kits and 
following the manufacturer’s guidelines (Biolegend UK, eBioscience UK, BD Biosciences 
UK). Briefly a monoclonal capture antibody for the cytokine of interest was coated onto the 
bottom of wells of a 96-well plate and left over night at four degrees. The plate was then 
washed three times with wash buffer (1X PBS with 0.05% Tween-20) to remove any 
unbound antibody. The wells were blocked to inhibit non-specific binding using 200μl of 
PBS containing 10% FCS for one hour at room temperature. The plate was then washed three 
times with wash buffer to remove unbound FCS and samples and standard dilutions (100μl to 
each well) were added in triplicate to the plate and left for two hours at room temperature. 
Following five washes to remove unbound sample, a detection antibody was then added to 
the plate and left for an hour at room temperature. The plate was then washed five times to 
remove unbound detection antibody, and a horse radish peroxidise- streptavidin labelled 
antibody was added to the plate for thirty minutes at room temperature. The plate was then 
washed seven times, to remove any unbound horse radish peroxidise and 100μl of TMB 
substrate reagent was added to each well, the plate was left in the dark for up to thirty 
minutes or until the colour change has become strong enough. 50μl of stop solution (0.16M 
Sulphuric Acid) was added to each well and the plate is read at 450nm on a plate reader. 
2.2.12 Flow Cytometry 
Cells were harvested after stimulation or isolation, washed twice in FACS buffer (100μl PBS 
with 2% FCS, 1mM EDTA) and then incubated with the following antibodies listed in Table 
2.2.1, or the relative isotype control for thirty minutes at four degrees in the dark to stop any 
unwanted reactions taking place. The cells were then washed twice with FACS buffer to 
remove any unbound antibody and analysed on a BD FACS Aria.  
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For intracellular staining the cells were fixed with 4% formaldehyde for 10 minutes at 4 
degrees after antibody incubation and then lysed with 0.5% Tween20 for fifteen minutes. The 
relevant antibody or isotype control was then added for thirty minutes at four degrees in the 
dark. The cells were then washed twice and analysed on a BD FACS Aria. The data was 
analysed using Flow Jo software (Treestar, USA). In all experiments unstained and single 
stained controls were used for gating and compensation.  
Gating Strategy 
For gating, splenocytes isolated from spleens from control and infected mice were gated on 
by excluding dead cells using forward and side scatter, (Figure 2.2.12 B). For gating on CD4
+
 
cells, splencoytes were gated on by excluding dead cells and then by using CD4
+
 antibody to 
gate on CD4
+
 cells (Figure 2.2.12C). For BMDCs, cells were gated using CD11c antibody 
(Figure 2.2.7)  
 
Figure 2.2.12.  Gating strategy. A. Forward and side scatter of splenocytes before gating. B. Alive cells gated 
according to their cell size and granularity. C. CD4
+
 T-cells gated on. 
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Table 2.2.1. Antibodies used for flow cytometry  
Antibody Fluorochrome Clone 
CD4 FITC GK1.5 
CD4 APC GK4.5 
CTLA4 APC UC10-4B9 
CD206 FITC C068C2 
CD206 APC C068C2 
MGL FITC ERMP23 
SIGNR1 Alexa 
Fluor647 
eBio22D1 
PD1  APC J43 
CD11c APC N418 
F4/80 FITC BM8 
F4/80 APC BM8 
CD86 FITC GL1 
CD80 PE 16-10A1 
CD40 PE IC10 
γδ-TCR PE-Cy7 eBioGL3 
CD49 PE-Cy7 DX5 
CD62L PerCP/CY5.5 MEL-14 
CD44 PE-CY7 IM7 
 
2.2.13 Proliferation Assay 
Proliferation of cells was measured using the incorporation of the CFSE dye into cells and the 
halving of the fluorescence seen after each cell division (eBioscience, UK). Cells were 
labelled with 5μM CFSE dye for 10mins at room temperature in the dark before the 
remaining CFSE that had not been taken up by cells was quenched using ice cold PBS. The 
cells were washed three times with PBS before being re-suspended at 5x10
6 
cells per ml in X-
vivo media (Lonza, USA) and stimulated with FhTeg (10μg/ml), with and without rIL-2 
(20ng/ml) (RnD, UK),  PMA (20ng/ml) (Sigma-Aldrich, Ire) and anti-CD3 (10μg/ml) (RnD, 
UK). After 24, 48 and 72 hours cells were removed and labelled with CD4
+
 APC, a second 
set of cells were also labelled with PI to check for viability. Cells were then analysed by flow 
cytometry (see section 2.2.12). 
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2.2.14 Cell Binding Assay 
FhTeg and bovine serum albumin (BSA) were fluorescently labelled with a FITC-488 label 
using the Promofluor labelling kit according to the manufacturer’s recommendations 
(Promokine, Germany). The labelling was performed using a reactive succinimidyl-ester of 
the dye of interest. The conjugates result from the formation of a stable covalent amide 
linkage of the dye to the protein. The protein-dye conjugates have fluorescence-excitation 
and fluorescence-emission at wavelengths of interest. Cells (50,000/well) were seeded in a 96 
well plate. Where indicated cells were pre-incubated with EDTA (10mM), (Sigma-Aldrich), 
anti-MR (1 μg/ml), (Abcam, UK), mannan (100μg/ml), (Sigma-Aldrich) or GalNAc-4S 
(1mM), (Sigma-Aldrich) for forty five minutes at 37 °C. Subsequently, cells were incubated 
with 1 or 5 μg/ml of 488 labelled FhTeg at 37 °C for forty five minutes and washed in ice 
cold PBS before analysis using flow cytometry. As control for non-specific binding, cells 
were incubated with 5 μg/ml of FITC-488 labelled BSA. 
2.2.15 Protein Extraction 
Cells were isolated from control or infected spleens, or from cells stimulated overnight with 
antigens, washed twice and total protein was extracted using radio-immunoprecipitation 
assay (RIPA) buffer with protease and inhibitor cocktails added (Table 2.2.13). RIPA buffer 
is a detergent which aids in the lysis of cells and protein solubilisation but does not interfere 
with the activity of the protein and helps prevent protein degradation. A protease inhibitor 
was added to stop degradation of proteins by protease. Phosphatase inhibitor cocktails were 
also added to inhibit enzyme reactions which may degrade or modify proteins. After lysing in 
RIPA buffer the lysates were kept on ice for five minutes and centrifuged at 10000g for five 
minutes. The supernatants were transferred to new tubes and protein concentration was 
analysed by BCA (see section 2.2.3). 
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Table 2.2.13  Protein extraction  
Reagent Volume added Concentration 
RIPA Buffer 100μl   
Protease Inhibitor 1μl 1% 
Phosphatase Inhibitor 
Cocktail 1 
1μl 1% 
Phosphatase Inhibitor 
Cocktail 2 
1μl 1% 
 
2.2.16 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate proteins according to molecular weight using a previously described method 
(Laemmli 1970). SDS is an anionic detergent which denatures proteins and also imparts a 
negative charge evenly to the protein. This allows the proteins to be separated by size using 
acrylamide. 10% acrylamide resolving gels and 5% stacking gels were used (Table 2.3). 
Ammonium persulfate and temed were used to start a reaction in which 
methylenebisacrylamide forms cross links between two acrylamide molecules forming a gel. 
Stacking gels are also prepared which have a lower percentage to allow proteins to stack 
according to their size before being separated. An electric field is placed on the gel and the 
proteins migrate from the negative electrode through the gel towards the positive electrode. 
The larger proteins cannot move through small pores as they move through the gel and so the 
proteins are separated out based on size and charge.  
Protein samples were prepared in SDS-PAGE loading buffer (Table 3) and boiled for 5 
minutes to denature the proteins before being loaded onto the gels. A molecular weight 
marker was also loaded on each gel (LI-COR, UK), to distinguish protein sizes following 
separation. Gels were run at 150V for 1-2 hours using cold SDS-PAGE running buffer (Table 
2.4). 
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Table 2.2.15. Reagents used for 10% acrylamide resolving gels and 5% stacking gels . 
5% Stacking gels 
  
Volume added 10% resolving gels Volume added 
30% Acylamide 670μl 30% Acylamide 4.62ml 
1M Tris-HCL 
(pH6.8) 
625μl 1M Tris-HCL pH 
(8.8) 
3.8ml 
dH2O 2.7ml dH2O 5.6ml 
10% SDS 50μl 10% SDS 150μl 
10% APS 50μl 10% APS 75μl 
Temed 25μl Temed 25μl 
 
 
Table 2.2.14. Components of SDS-Page loading buffer and SDS-Page running buffer.  
SDS-PAGE 
Loading Buffer 
Volume 
added 
Concentration Running 
Buffer 
Volume 
added 
Concentration 
Tris 0.757g 0.625M Tris 3g 25mM 
Glycerol 5ml 50% Glycine 14.4g 192mM 
SDS 1g 10% SDS 1g 0.2% 
Bromophenol 
Blue 
0.01g 0.1% Total  1000ml  
2-
Mercaptoethanol 
0.5ml 5%    
Total  10ml     
 
2.2.17 Western Blot 
Protein samples were run on an SDS-PAGE gel and then transferred to a PVDF membrane 
using an iBLOT (Lifesciences, Ire). Membranes were blocked with 1% skimmed milk to 
block non-specific interactions of primary antibodies or secondary antibodies with the 
membrane, before   antibodies were added which are listed in Table 2.2.16. Blots were 
incubated with an anti-rabbit secondary for 1 hour at room temperature before being 
visualized with a chemiluminescent HRP substrate (Millipore, Ireland), exposed to film and 
processed using an FPM 100A processor (Fuji Film). Protein bands were quantified using 
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ImageJ analysis software (imagej.nih.gov). Levels of protein were normalised to a control 
gene, β-actin and the levels of protein are shown as fold increases over the untreated levels. 
Table 2.2.16. Antibodies used for protein analysis  
Primary Antibody Dilution Size of Product 
RNF128 1:500 48kDa 
β-actin 1:10000 42kDa 
 
 
2.2.18 RNA extraction and cDNA synthesis 
Cells from control or infected spleens or cells treated with antigens were harvested, washed 
twice with PBS and total RNA was extracted using a RNA isolation kit (Roche, UK), 
following manufacturer’s guidelines. Cells were lysed in a lysis/binding buffer and RNAses 
were inactivated. The mixture was added to a high pure filter tube which contains glass fiber 
fleece in a column and the RNA was trapped in this. DNAse was added to the tube to 
eliminate genomic DNA and the RNA was then washed using two wash buffers which both 
contain ethanol to remove impurities and inhibitors which may affect downstream 
applications. The RNA was then eluted from the column using RNAse and DNAse free 
water. The quantity and purity of the extracted RNA was analysed using Nanodrop (Thermo-
Fisher, Ire). cDNA was synthesised using a kit (Roche, UK) following manufacturers 
guidelines (Table 2.6). 1μg of RNA was used as starting material for cDNA synthesis.  
Table 2.6.17. RTPCR reaction conditions  
Temperature Time 
25 degrees 10 minutes 
55 degress 30 minutes 
85 degrees 5 minutes 
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2.2.19 QPCR Gene Array Assays 
RNA from control and infected spleenocytes was isolated using an RNA isolation kit (Roche, 
UK). The RNA from the control and infected samples were pooled and reverse transcribed to 
cDNA (Roche, UK). Samples were added to each well of a 96 well plate containing specific 
genes related to anergy, house-keeping genes and reverse transcription controls. The data was 
analysed using Qiagens online data analysis tool. 
2.2.20 QPCR 
RNA from control and infected spleenocytes was isolated using a high pure RNA isolation kit 
(Roche, UK). The quantity and quality of the RNA was checked using Nanodrop (thermo-
science, Ire). RNA was reverse transcribed to cDNA using random primers and a reverse 
transcription kit (Roche, UK). Primer probes (Roche,U K) with primer efficiency of 2.0 were 
used to analyse gene expression, for the following genes listed in Table 2.2.19 A-B.  Primer 
probe master mix with a 6-carboxyfluorescein (FAM) labelled enzyme was used (Table 
2.2.19C). Three housekeeping genes were used as internal standards, β-actin(NM_007393.3), 
GAPDH (NM_008084.2) and Gusb (β-glucuronidase) (NM_010368.1) Gene expression was 
analysed using a Light Cycler 96 (Roche, UK). Samples were maintained for 10 seconds at 
95°C as initial step, then 15 seconds at 95°C and 60 seconds at 60°C through 40 cycles and 
Pfaffl’s  method was used to determine relative gene expression (Pfaffl 2001). 
Table 2.2.19A. Forward and reverse primer sequences of primers used for qPCR analysis  
(Mouse). 
Gene Name Sense Anti-sense 
β-actin GGATGCAGAAGGAGATTACTGC CCACCGATCCACACAGAGTA 
GAPDH AGCTTGTCATCAACGGGAAG 
 
TTTGATGTTAGTGGGGTCTCG 
 
GusB GATGTGGTCTGTGGCCAAT 
 
TGTGGGTGATCAGCGTCTT 
 
CTLA4 TCACTGCTGTTTCTTTGAGCA 
 
GGCTGAAATTGCTTTTCACAT 
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ICOS AACCTTAGTGGAGGATATTTGCAT 
 
CCTACGGGTAGCCAGAGCTT 
 
RNF128 AAATGCAAGAGCTCAAAGCAG 
 
GCAGCTGAAGCTTTCCAATAG 
 
ITCH TTGATGCGAAGGAATTAGAGG 
 
GGTGTAGTGGCGGTAGATGG 
 
Egr2 CCTCTACCCGGTGCAAGAC GTCAATGTTGATCATGCCATCT 
SOCS3 ATTTCGCTTCGGGACTAGC AACTTGCTGTGGGTGACCAT 
 
 
 
Table 2.2.19B. Forward and reverse primer sequences of primers used for qPCR analysis  
(Human) 
Gene Name Sense Anti-sense 
β-actin TTCCTCCCTGGAGAAGAGCTA CGTGGATGCCACAGGACT 
GAPDH AGCCACATCGCTCAGACAC GCCCAATACGACCAAATCC 
GusB TCGCCATCAACAACACACTC TCTGGACAAACTAACCCTTGG 
CTLA4 TCACAGCTGTTTCTTTGAGCA AGGCTGAAATTGCTTTTCACA 
RNF128 AACACGTGCAGTCAACAAATG TGGGTTGTCAACATGAGGAA 
Egr2 GGAGGGCAAAAGGAGATACC CAGAAAAGCCGTTTTGGAGA 
 
Table 2.2.19C. Working solutions for qPCR 
Component Volume 
Primer Probes master mix 
(FAM) 
10μl 
Primers 2μl 
H2O 3μl 
cDNA 50ng in 5μl 
 
2.2.21 Statistics 
All data were analysed for normality prior to statistical testing by Prism
®
 6.0 (GraphPad 
Software Inc, La Jolla, CA, USA) software. Where multiple group comparisons were made, 
data were analysed using one-way or two way ANOVA. For comparisons between two 
groups, the Student’s t test was used.  In all tests, p < 0.05 was deemed significant. 
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3. Chapter 3. 
High mannose and sulphated glycoproteins on Fasciola 
hepatica surface coat exhibit immune modulatory 
properties independent of the mannose receptor 
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3.1. Introduction 
 
Infection with parasitic worms (helminths) modulates the host immune system by biasing T 
helper (Th) cells towards a Th-2/T-reg immune response (Allen and Maizels 2011, McSorley, 
Hewitson and Maizels 2013), while simultaneously impairing pro-inflammatory Th1/Th17 
immunity. This polarisation is due to the interaction of helminth derived molecules with 
pattern recognition receptors on innate immune cells such as dendritic cells, macrophages and 
mast cells that drive the polarisation of T-cells (Taylor, van der Werf and Maizels 2012a). 
Many helminth proteins and lipids are glycosylated, and the initial interaction of these 
molecules with innate immune cells is via C-type lectin receptors (CLRs) (Vázquez-
Mendoza, César Carrero and Rodriguez-Sosa 2013).  
 
Several reports have pointed to a role for CLRs in mediating immune regulatory processes 
driven by helminth-derived glycoconjugates (Everts et al. 2012, Tundup, Srivastava and Harn 
2012a, van Die and Cummings 2010a). Schistosoma mansoni soluble egg antigens signal 
through several CLRs, dendritic cell-specific intercellular adhesion molecule-3-grabbing non-
integrin (DC-SIGN), Macrophage galactose lectin (MGL) and Mannose receptor (MR), 
inhibiting dendritic cells maturation and influencing the development of Th2 immune 
response (van Liempt et al. 2007). Similarly, Trichuris suis antigens signal through the 
CLRs, MR and DC-SIGN which are involved in inhibiting a pro-inflammatory 
dendritic cell phenotype. Recent studies, demonstrated the direct interaction of MR with 
Fasciola hepatica and S. mansoni derived antigens (Everts et al. 2012). 
 
Tegumental antigens (FhTeg) are released continuously by F. hepatica during infection and 
studies have demonstrated that it exhibits potent Th1 immune suppressive properties in vivo 
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by suppressing serum levels of the Th1 mediators IFNγ and IL-12p70 in the mouse model of 
septic shock. FhTeg-activated dendritic cells and mast cells are hypo-responsive to TLR 
activation thereby suppressing the production of inflammatory cytokines and co-stimulatory 
molecules important in driving adaptive immune responses (Hamilton et al, 2009). FhTeg 
mechanism of action is independent of TLRs and has been linked to the suppression of NF-
κB and MAPK pathway (Vukman et al, 2013) and enhanced expression levels of suppressor 
of cytokine signalling (SOCS) 3, a negative regulator of the TLR and STAT3 pathway. The 
tegument is a biological matrix rich in glycoconjugates that remains continually exposed to 
the host immune system and is unique to each Fasciola species.  
 
The macrophage mannose receptor (MR) is a type-I membrane protein with a cytoplasmic 
domain involved in antigen processing and receptor internalisation and three different types 
of binding domains at its extracellular region, multiple C-type lectin-like carbohydrate-
recognition domains (CRDs) responsible for Ca2+-dependent binding to terminal mannose, 
fucose or N-acetyl glucosamine, a fibronectin type II (FNII) domain involved in collagen 
binding and an N-terminal cysteine-rich (Cys-MR) domain that mediates Ca2+-independent 
binding to sulfated sugars such as SO4-3-Gal or SO4-3/4-GalNAc. Glycomic studies on 
FhTeg have revealed that it is rich in N-glycans with high mannose type terminal structures, 
which contain GlcNAc and/or Man and these structures would have high binding affinity for 
the CRDs on the MR. F. hepatica antigens have been shown to interact with MR (Guasconi L 
et al 2011) and to further expand our knowledge of the immuno-modulatory capacity of 
FhTeg on dendritic cells, this study will focus upon FhTeg-MR interactions.  
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3.2. Experimental Design 
This chapter focuses on the interaction of FhTeg with dendritic cells (generated from 
Balb/c mice) and the role C-type lectin receptors play in this. Firstly the binding of FhTeg 
was examined and a possible role for MR and MGL was investigated by using specific 
antibodies and sugars for the receptors to block the interaction of FhTeg with cells. Cells 
were pre-incubated with EGTA (10mM), anti-MR (1 μg/ml), mannan (100μg/ml), or 
GalNAc-4S (1mM), for forty five minutes at 37 °C. Subsequently, cells were incubated 
with 1 or 5 μg/ml of 488 labelled FhTeg at 37 °C for forty five minutes and washed in ice 
cold PBS before analysis using flow cytometry. As control for non-specific binding, cells 
were incubated with 5 μg/ml of FITC-488 labelled BSA. 
We have previously shown that FhTeg causes the induction of SOCS3 in dendritic cells 
(Vukman, Adams and O'Neill 2013). To investigate if MR plays a role in this and in the 
inhibition of cytokine secretion, cells were incubated with anti-MR (10μg/ml), Mannan 
(100μg/ml) or Gal-NAc-4-S for 30 minutes before the addition of FhTeg (10μg/ml). 
Following 2.5 hours stimulation cells were washed and lysed for RNA analysis. QPCR 
was used to measure the expression of SOCS3. Cells were also stimulated as above but 
after 2.5 hours LPS was added as a bacterial ligand which will enhance IL-12p70 
production from cells, to investigate if using blocking antibodies could reverse cytokine 
secretion as previous studies have shown that FhTeg inhibits LPS mediated IL-12p7o 
production (Hamilton et al. June 2009). Following 18 hours stimulation, supernatants 
were removed and analysed for the production of IL-12p70.  
To investigate the role MR plays in FhTeg/DC interactions, DC’s were generated from 
background (C57bl/6) MR knockout mice and the ability of FhTeg to bind, to enhance 
SOCS3 and to inhibit cytokine secretion was measured as above. 
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3.3. Results 
 
3.3.1. FhTeg binds to DCs in a calcium dependent manner 
From previous studies we know that FhTeg has an inhibitory effect on the maturation of 
dendritic cells after co-incubation with bacterial antigens like LPS (Hamilton et al. June 
2009). To investigate the binding of FhTeg and its possible receptors, FhTeg and BSA were 
labelled with a FITC-488 label. DCs were stimulated for 30 mins with or without EGTA 
(10mM) and then stimulated with FITC-488 labelled FhTeg (1, 5 and 10μg/ml) or BSA 
(10μg/ml) as a control for non-specific binding for 45 minutes.  The cells were washed twice 
and analysed for binding using flow cytometry. FITC-488 labelled BSA showed no 
significant binding compared to unstained cells. FhTeg showed significant binding to cells at 
1μg, 5μg and 10μg (p<0.0001) (Figure 3.3.1). This binding was inhibited by the addition of 
EGTA to cells before incubation with FhTeg (p<0.0001) but the binding was not completely 
blocked to unstained levels (Figure 3.3.1A). 
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Figure 3.3.1. FhTeg binds to dendritic cells and this is calcium dependent. FhTeg significantly binds to 
dendritic cells at 1, 5 and 10μg/ml (p<0.0001). This binding can be inhibited using EGTA for all concentrations 
(p<0.0001). Data is presented as the mean ±SD of one experiment with the mean of triplicate values shown. The 
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experiment was repeated three times and one representative experiment shown. Data analysed using one-way 
anova. 
 
3.3.2. Binding of FhTeg to dendritic cells can be inhibited using sugars and 
antibodies specific to the mannose receptor. 
 
FhTeg is composed of high mannose glycans and both MR and MGL have binding 
specificities for this, we investigated if those receptors are involved with binding of FhTeg to 
dendritic cells and if the binding could be suppressed with antibodies and sugars. Dendritic 
cells were stimulated with 488-FhTeg in the presence or absence of anti-MR (1μg/ml), 
mannan (50μg/ml) or GalNAc-4-sulphate (1mM). FhTeg bound significantly to DC’s 
(p<0.0001), anti-MR, Mannan and GalNAc-4-Sulphate significantly inhibited the binding of 
488-FhTeg (p<0.01) to dendritic cells by both mean fluorescence intensity (MFI) and 
percentage of cells (Figure 3.3.2A-B). 
To examine the role of MGL in binding of FhTeg to DC’s, cells were also incubated with 
antibodies and sugars specific to the MGL receptor, anti-MGL (1μg/ml) and Gal-NAc 
(10μg/ml). FhTeg significantly bound to DC’s (p<0.0001) and both anti-MGL and Gal-NAc 
did not significantly inhibit binding of FhTeg to dendritic. The percentage of cells that FhTeg 
bound to was significantly inhibited using both anti-MGL and Gal-NAc (Figure 3.3.2 C-D). 
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Figure 3.3.2 The mannose receptor has a role to play in the binding of FhTeg to dendritic cells but the 
MGL receptor does not.  A-B. FhTeg significantly binds to DC’s compared to BSA controls (p<0.0001). 
Mannan (p<0.001, P<0.0001), anti-MR (p<0.05) and Gal-4-S (p<0.001, p<0.0001) inhibit the binding of FhTeg 
to DCs. C-D. Anti-MGL and Gal-NAc did not have a significant effect on the binding of FhTeg to DC’s by MFI 
but significantly inhibited the percentage of cells which FhTeg bound to (p<0.05). Data shown is the mean ±SD 
of one experiment with the mean of triplicate values shown. The experiment was repeated three times and one 
representative experiment shown, data analysed using one-way anova. 
 
 
 68 
 
3.3.3. The macrophage galactose lectin does not play a role in the suppressive 
ability of FhTeg 
 
The macrophage galactose lectin (MGL) does not seem to play a role in the binding of FhTeg 
to dendritic cells but there are binding epitopes specific for MGL on the surface of F. 
hepatica (manuscript in preparation). To examine if sugars or antibodies against MGL would 
inhibit the suppressive activity of FhTeg, DC’s were stimulated with Gal-NAc (10μg/ml) or 
anti-MGL (10μg/ml) for 30 mins before the addition of FhTeg for a further two hours, the 
expression of SOCS 3 was measured by qPCR. FhTeg significantly enhances SOCS3 
expression (p<0.05) but neither Gal-NAc nor anti-MGL inhibit this (Figure 3.3.3 A).  
To investigate cytokine responses, DC’s were stimulated with anti-MGL (10μg/ml) for 30 
minutes before the addition of FhTeg (10μg/ml), following a further 2.5 hours stimulation 
LPS (100ng/ml) was added. Cells were incubated over-night and cytokines were measured 
for levels of IL-12p70. FhTeg significantly suppresses IL-12p70 production (p<0.05), the 
addition of anti-MGL does not reverse this (Figure 3.3.3 B). 
 
 
 
 
 
 
 
Figure 3.3.3. The macrophage galactose lectin does not play a role in the suppressive ability of FhTeg. A. 
FhTeg significantly enhances SOCS3 expression compared to PBS (p<0.05) but neither Gal-NAc nor anti-MGL 
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inhibit this. B. LPS significantly enhances IL-12p70 production compared to PBS (p<0.0001) and FhTeg 
significantly suppresses this (p<0.05). The addition of anti-MGL does not reverse FhTeg suppression of IL-
12p70. The data shown is the mean ±SD of two independent experiments. Data analysed using one-way anova. 
 
 
3.3.4. Inhibition of FhTeg with the carbohydrate inhibitor GalNAc-4S 
suppresses SOCS3 expression while mannan reverses FhTeg’s ability to 
modulate cytokine secretion in BMDCs. 
 
In previous studies we demonstrated that FhTeg up-regulates SOCS3 in vitro (Vukman et al, 
2013), a negative regulator of the TLR4 signalling pathway (Morgensen et al, 2009) and here 
we determine if SOCS3 RNA levels can be inhibited  by the addition of GalNAc-4S and 
mannan to DCs in culture prior to stimulation with FhTeg (10 μg/ml). Incubation with 1mM 
GalNAc-4S for 30 min prior to FhTeg stimulation reversed SOCS3 transcription to basal 
levels, whereas mannan did not alter SOCS3 expression (Figure 3.3.4 A). Another property 
of FhTeg is its ability to suppress the LPS-induced production of pro-inflammatory cytokines 
in BMDCs (Hamilton et al, 2009). Pre-incubation of BMDCs with mannan and not GalNAc-
4S prior to LPS and FhTeg stimulation reversed IL12p70 secretion (Figure 3.4.4 B-C).  
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Figure 3.3.4 Inhibition of FhTeg with the carbohydrate inhibitor GalNAc-4S suppresses SOCS3 
expression while mannan reverses FhTeg’s ability to modulate cytokine secretion in BMDCs. A. FhTeg 
significantly enhances SOCS3 expression compared to PBS (p<0.0001). Mannan does not inhibit SOCS3 
expression but GalNAc-4-S does (p<0.001). Data are presented as the mean ± SD of three independent 
experiments. B-C. LPS significantly enhances IL-12p70 production compared to PBS (p<0.0001) and FhTeg 
significantly inhibits this (p<0.0001). Mannan restores IL-12p70 levels but GalNAc-4-S does not. Data are 
presented as the mean ± SD of two independent experiments. Data analysed using one-way anova. 
 
3.3.5. The immune properties of FhTeg are independent of the MR receptor.  
 
Since high mannose and sulphated glycans interact with the MR receptor we obtained 
BMDCs from MR knockout mice to determine the role of FhTeg-MR interactions. In the 
absence of MR there was a statistically significant decrease in the expression of MR on the 
surface of BMDCs (Figure 3.3.5 A-B). However in the absence of MR FhTeg induced 
SOCS3 expression and suppressed LPS induced cytokine expression of BMDCS (Figure 
3.3.5 C-D).    
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Figure 3.3.5 The immune properties of FhTeg are independent of the MR receptor. A. FhTeg binds 
significantly at both 1 and 10μg/ml (p<0.05, p<0.0001) to both background and knockout mice compared to 
BSA. There was a significant difference in binding between background and MR knockout mice at 10μg/ml 
(p<0.05). B. Binding of FhTeg to DC’s from both background and knockout mice was analysed using 
percentage of cells that bound to FhTeg. FhTeg binds significantly to DC’s from both background and knockout 
mice (p<0.0001) and this was significantly inhibited in MR knockout mice (p<0.0001). C. FhTeg significantly 
enhances SOCS3 expression in both background and MR knockout DC’s compared to PBS, with no significant 
differences between the two groups (p<0.01, p<0.001). D. LPS enhanced IL-12p70 production in both 
background and MR knockout DC’s (p<0.0001) and FhTeg significantly inhibited this (p<0.0001). Data are 
presented as the mean ± SD of two independent experiments with 3 mice in each experiment. Data analysed 
using one-way anova for differences within groups, for differences between groups two-way anova was used. 
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3.4. DISCUSSION 
 
We have previously shown that FhTeg has potent anti-inflammatory properties; it can inhibit 
the production of IL-12p70 and TNF-α from dendritic cells when co-stimulated with a wide 
range of TLR ligands, it can also modulate cell surface expression with no enhancement of 
CD80, CD86 or MHCII receptors (Hamilton et al. 2009a). FhTeg also induces SOCS3 
expression in dendritic cells which is a negative regulator of cytokine signalling pathways 
(Vukman, Adams and O'Neill 2013). In this study we have characterised dendritic cells 
following FhTeg stimulation and demonstrated that the mannose receptor is not involved in 
priming the dendritic cell phenotype seen. 
 
We have recently shown that FhTeg-derived N-glycans are composed abundantly of high 
mannose type structures. These glycans are widely distributed on the tegument of adult flukes 
with abundance especially on the spines and suckers (manuscript in preparation). These high 
mannose glycans may have binding specificities to CLRs like MR, MGL, SIGN-R1 or Dectin 
1. The macrophage mannose receptor (MR) is a type-I membrane protein with a cytoplasmic 
domain involved in antigen processing and receptor internalisation and three different types 
of binding domains at its extracellular region, multiple C-type lectin-like carbohydrate-
recognition domains (CRDs), a fibronectin type II (FNII) domain and an N-terminal cysteine-
rich (Cys-MR) domain (Martinez-Pomares 2012). The macrophage galactose type lectin has 
two orthologues in mouse, MGL1 and MGL2. MGL1 has binding specificities for Lewis X, 
galactose and terminal Gal-NAc structures and MGL2 binds terminal Gal-NAc (Tsuiji et al. 
2002). Here we have shown that FhTeg binds to dendritic cells partially in a calcium 
dependent way, as EDTA did not completely block binding of FhTeg to dendritic cells. MR 
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has both calcium dependent and independent binding and as FhTeg is a complex mix of over 
70 proteins some differences in how they may bind was expected. Interestingly, only 
antibodies and sugars specific to the mannose receptor significantly inhibited binding of 
FhTeg to DC’s, antibodies and sugars for MGL had little or no effect on binding. The role of 
CLRs has been studied for a number of helminth infections; MR has been implicated in S. 
mansoni infection and in vitro after stimulation of dendritic cells with antigens. In early 
stages of infection the ES of S. mansoni is rich in glycoproteins which bind to MR, this 
regulates IFN-γ from CD4+ cells and inhibits a Th1 immune response (Paveley et al. 2011), 
similarly S. mansoni derived omega 1 also signals through MR and drives Th2 immune 
responses (Everts et al. 2012). Studies using T. crassiceps antigens showed less binding to 
macrophages generated from MGL1 knockout mice than wild type controls and during 
infection also favoured a Th2 immune response with a higher parasite load than in controls 
(Montero-Barrera et al. 2014). 
 
We have previously shown that FhTeg enhances the expression of SOCS3 in dendritic cells 
(Vukman, Adams and O'Neill 2013). SOCS3 is an intracellular protein regulating the duration 
or intensity of cytokine-induced signal via a negative feedback inhibition mechanism. SOCS 
3-transduced DCs exhibit low expression levels of stimulatory signals (i.e. MHC, CD86,  IL-
12p70 and IFN-γ) and a tolerogenic/DC2 phenotype with decreased ability to induce T cell 
proliferation (Li et al. 2006), similarly to FhTeg-stimulated DCs. SOCS proteins are induced 
via JAK/STAT signaling and, among other signals, stimulation of TLRs (Murray 2007).  Here 
we have shown the reversal of SOCS3 expression using GalNAc-4-Sulphate but not Mannan 
which seems to enhance the expression. This points to sulphated and non-sulphated glycans 
having an immuno-modulatory role in FhTeg/dendritic cell interactions. Using antibodies and 
sugars specific for MGL had no reversal of SOCS3 expression. In previous studies FhTeg has 
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inhibited the TLR activation of dendritic cells by inhibiting the secretion of IL-12p70 and 
TNF-α from LPS stimulated cells (Hamilton et al. June 2009). As we can reverse the 
expression of SOCS3 which may be playing a role in the cytokine suppression we 
investigated if the cytokine suppression could also be reversed.  Pre-incubation with mannan 
reversed IL-12p70 suppression but GalNAc-4-Sulphate did not. As FhTeg is a complex mix 
of over 70 proteins, the mechanism of action of FhTeg may be more complex than affecting 
just one pathway.  
  
Other studies have found the MR receptor to be involved in vivo following F. hepatica 
infection and in vitro following stimulation of macrophages with excretory/secretory products 
(Guasconi et al. 2011). They found that the interaction between macrophages and FhTeg was 
significantly decreased by pre-incubation with mannan or anti-MR blocking antibody in 
binding assays by flow cytometry and they also observed that the high levels of Arginase I 
activity, IL-10 and TGF-β expression induced on peritoneal macrophages by F. hepatica 
infection in vivo or FhES stimulation in vitro were partially inhibited by the use of MR 
blocking antibodies or sugar ligands both in vivo and in vitro. To investigate the importance 
of MR in FhTeg and dendritic cell interactions, DC’s were generated from MR knockout 
mice and a number of experiments were repeated. FhTeg binding to BMDCs was 
significantly reduced but its suppressive effect was not abrogated. An inhibition of IL-12p70 
was still observed when DCs were co-stimulated with FhTeg and LPS and an enhancement of 
SOCS3 was also observed. These results point to a role for MR in binding of FhTeg but not 
to its suppressive ability. This could be due to another role for MR other than signal 
transduction such as cell to cell communication. FhTeg is a complex mix of many proteins so 
it may not work through one receptor but may require a number of receptors to exert its 
influence. A number of studies into helminth infections have used knockout mice to try to 
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identify the receptors responsible for modulating the immune system. Studies using MR 
knockout mice and T. suis infection have shown that although IL-6 production from bone 
marrow derived macrophages generated from MR knockout mice partially depended on MR, 
the clearance of the parasite did not differ in knockout mice compared to wild-type mice 
(DeSchoolmeester et al. 2009b). 
 
As some of the major components of FhTeg are carbohydrates, and we have shown that MR 
plays a role in the binding of FhTeg but not in the signalling pathways, other CLRs may play 
a role in the immunomodulatory effect seen on cells. Several helminth products have been 
shown to signal through CLRs (Tundup, Srivastava and Harn 2012b) and it is thought they 
signal through CLRs as an escape mechanism from the hosts’ immune response (van Die and 
Cummings 2010b).  S. mansoni soluble egg antigens have been shown to signal through 
several CLRs; DC-SIGN, MGL and MR and inhibit DC maturation and induce a Th2 
immune response (van Liempt et al. 2007). The nematode T. suis has also been shown to be 
involved in CLR signalling. Glycans isolated from the parasite signal through MR and DC-
SIGN and induce, as was seen with S. mansoni, a DC phenotype which inhibits bacterial TLR 
activation and the activation of an inflammatory immune response (Klaver et al. 2013). 
Dectin 2 has also been implicated in the induction of IL-1β production from DCs following S. 
mansoni SEA stimulation (Ritter et al. 2010). Further studies need to be completed to identify 
the receptor or receptors responsible for the induction of the signalling pathways in BMDCs 
following FhTeg stimulation. 
 
In this study we have shown that FhTeg binds to dendritic cells in a calcium dependent way 
and the binding can be inhibited by using specific antibodies and sugars for the mannose 
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receptor but MR is not involved in the immunomodulatory effects seen in DC’s following 
FhTeg incubation. We have previously shown that FhTeg induces SOCS3 and inhibits 
cytokine secretion following bacterial ligand stimulation. Here we show that this is 
independent of FhTeg binding through MR, as studies on MR knockout DC’s showed no 
difference in SOCS3 expression and on cytokine secretion. Further studies would need to be 
carried out to identify the receptor or receptors involved in initiating the immune response in 
DC’s following FhTeg stimulation. 
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4. Chapter 4.  
Fasciola hepatica tegumental antigens induce anergic T-
cells via dendritic cells in a mannose receptor dependent 
manner. 
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4.1 Introduction 
 
Helminth parasites can survive within their hosts for many years by suppressing T-cell driven 
protective immune responses and Th1/Th2 mediated pathology through the induction of 
regulatory networks that suppress inflammatory responses (Taylor, van der Werf and Maizels 
2012a, Belkaid and Rouse 2005, McKee and Pearce 2004, Grainger et al. 2010). These 
regulatory networks include regulatory T cells (T-reg) that in the context of helminth 
infection is widely understood. However, less is currently known about regulatory response 
termed in-vivo anergy or adaptive tolerance.  T-reg cells suppress the immune response to 
helminth driven Th1/Th2 immune pathology through the induction of IL-10 and TGF-β. 
Brugia malayi, infection induces a regulatory response with enhanced FoxP3 expression and 
increased cell surface expression of CTLA4, a negative regulator of T-cell function 
(McSorley et al. 2008) while Schistosoma haematobium infection in humans has also been 
associated with FoxP3
+
 T-reg cells with the highest percentage of this cell population 
observed in younger patients (Nausch et al. 2011).   
Chapter 5  
Few studies have examined the role of anergic T-cells during helminth infection. The 
induction of this cells population is thought to be the result of the persistent contact of 
parasite antigen with immune cells during chronic helminth infection (Borkow et al. 2000).  
Anergic T-cells differ from Treg cells in that they do not express FoxP3 or produce IL-10 or 
TGF-β. Instead anergy is defined as a hyporesponsive state with the failure of T-cells to 
proliferate or produce cytokines when re-stimulated with helminth antigens in vitro 
(Schwartz 2003). Anergic T-cells do not secrete IL-2, a factor important for T-cell 
proliferation and effector responses. However, the addition of IL-2 can overcome this hypo-
responsiveness, restoring helminth driven T-cell responses. Gene analysis studies have 
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identified a number of genes including RNF128 (GRAIL), ITCH, Egr2 and 3 and CblB that 
are involved in the induction and maintenance of T-cell anergy (Zheng, Zha and Gajewski 
2008, Harris 2004). The expression of PD1 and CTLA4 by T-cells are also defining markers 
of anergy. T-cell anergy is one of the main causes of T-cell unresponsiveness in Schistosoma 
mansoni infection, mediated by the up regulation of PD-L1 on the surface of macrophages 
(Smith et al. 2004)  and also with the up regulation of RNF128 (GRAIL) in T-cells isolated 
from chronic infection (Taylor et al. 2009).   
Chapter 6  
Fasciola secreted molecules can mimic the immune responses observed during infection, in 
particular, its excretory/secretory products (FhES) which comprise mainly of enzymes induce 
strong Th2/Treg immune responses with enhanced M2 macrophage and mast cell populations 
(Adams et al. 2014). The tegumental coat antigens (FhTeg), Fasciola’s second major antigen 
source are shed every two to three hours which have been demonstrated to impair TLR driven 
immune responses in both dendritic cells and mast cells by suppressing TLR induced 
cytokines secretion  and co-stimulatory marker expression. FhTeg induces SOCS3 a negative 
regulator of the TLR and STAT3 pathway which can explain its immune modulatory 
properties (Vukman, Adams and O'Neill 2013). Little is known about T-cell responses 
following F. hepatica infection or FhTeg stimulation, here we will characterise the T-cell 
responses to FhTeg during infection and following injection over the sternum. 
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4.2 Experimental Design 
 
This chapter investigates the T-cell responses in mice following infection and if the injection 
of FhTeg can mimic this. It also shows a role of FhTeg treated dendritic cells in the induction 
of anergy in CD4
+ 
cells. Firstly mice (Balb/c) were infected by pipetting 20μl of water 
containing 20 metacercariae orally. After two weeks mice were sacrificed by cervical 
dislocation and spleens were removed and re-stimulated with FhTeg (10μg/ml) in the 
presence or absence of IL-2(20ng/ml) to see if an antigen specific immune response could be 
restored, PMA (20ng/ml) and anti-CD3 (10μg/ml) were also used as a positive control. The 
levels of IL-2, IL-5, IL-4, IL-10 and IFN-γ were measured. To investigate if spleenocytes and 
CD4
+
 cells could proliferate, CFSE was used to measure proliferation after re-stimulation 
with FhTeg (10μg/ml) and IL-2 (20ng/ml), annexin V and PI staining was used to ensure 
apoptosis was not the cause of T-cell unresponsiveness.  
 
Studies have shown helminths can induce both anergy and T-reg cells we used a qPCR gene 
array to investigate if genes relating to anergy induction and maintenance were up-regulated 
in spleenocytes isolated from infected mice. To investigate if the fold increases seen were 
significant individual qPCR assays were performed on triplicate samples isolated from 
control and infected mice for a number of genes which were highly expressed on the qPCR 
gene array. Protein levels were also measured to test if the protein levels were elevated. Flow 
cytometric analysis of cell surface markers were also analysed to see if any increase in PD1 
or CTLA4 expression was seen. As lymph nodes are very important in the induction of 
tolerance to food proteins and are an early point of contact for immune cells after the 
ingestion of metacercariae, the levels of PD1 were assessed on cells isolated from lymph 
nodes from 24, 48, 72 hours and 1 week infection.  
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To investigate if FhTeg can mimic infection it was injected over the sternum of mice and 
mice were sacrificed after 72 hours and 1 week time points. Spleenocytes were isolated from 
spleens and re-stimulated with FhTeg (10μg/ml) and IL-2 (20ng/ml) and also PMA (20ng/ml) 
and anti-CD3 (10μg/ml). The levels of PD1 were also analysed by flow cytometry on CD4+ 
T-cells. Protein levels of RNF128 were also analysed to see if its expression was enhanced. 
 
We have previously shown that FhTeg induces an immature dendritic cells phenotype with 
no enhancement of co-stimulatory markers CD80, CD86 or MHC II, and no production of 
cytokines. To investigate if these DCs could drive anergy in CD4
+ 
cells, FhTeg treated DCs 
were co-cultured for 72 hours with CD4
 +
 cells isolated from naïve mice in the presence of 
anti-CD3 (1μg/ml). Supernatants were analysed for the production of IL-2, IL-4, IL-5 and 
IFN-γ and mRNA levels of EGR2 and 3, RNF128, ICOS, CTLA4 and Zap70 were also 
analysed. As FhTeg is rich in mannose rich glycoproteins, the involvement of the mannose 
receptor was investigated. Co-cultures were performed using FhTeg treated DC’s generated 
from both background (C57bl/6) and MR knockout mice and cytokine production and qPCR 
was performed as above. 
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4.3 Results 
4.3.1. Splenocytes isolated from F. hepatica infected mice do not produce 
FhTeg-specific immune responses; however these responses are restored 
following the addition of IL-2. 
 
We have demonstrated that FhES induces strong antigen specific-Th2/Treg immune 
responses in splenocytes isolated form F. hepatica infected mice (Adams et al. 2014). Here, 
antigen specific immune responses to FhTeg were examined in mice following F. hepatica 
infection. Splenocytes isolated from control or infected mice failed to induce FhTeg-specific 
IL-5, IL-4, IL-10 (Figure 4.3.1 B-D) and IFN-γ (Figure 4.3.1 E). The lack of antigen specific 
immune responses could be explained by a lack of antigen specific IL-2 as splenocytes from 
control and infected mice failed to produce significant levels of IL-2 upon FhTeg re-
challenge while stimulation of splenocytes with PMA/anti-CD3 induced significant levels of 
IL-2 in both groups (p<0.0001; Figure 4.3.1 A). The levels of IL-5 (p<0.001), IL-4 (p<0.01) 
and IL-10 (p<0.05) were significantly increased when splenocytes from infected but not 
control mice were challenged with FhTeg in the presence of IL-2 compared to FhTeg alone 
(Fig 4.3.1 B-D).  However, the levels of IFN-γ remained unchanged (Figure 4.3.1 E). 
Splenocytes isolated in mice from all  groups produce significant levels of cytokines when 
treated with PMA/anti-CD3 (Figure 4.3.1 A-D) and no significant differences was observed 
between groups except IFN-γ where significant difference were observed between control 
and infected groups (Figure 4.3.1 E ,p<0.0001) which supports previously published findings 
(O'Neill et al. 2000). 
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Figure 4.3.1. Splenocytes isolated from F. hepatica infected mice do not produce FhTeg-specific immune 
responses; however these responses are partially restored following the addition of IL-2.  A. PMA and 
anti-CD3 significantly enhanced IL-2 production in both control and infected groups (p<0.0001) but FhTeg did 
not. B. The addition of IL-2 significantly enhanced IL-5 (p<0.0001), IL-4 (p<0.01) and IL-10 production 
(p<0.05) but not IFN-γ compared to FhTeg alone.  Data are presented as the mean ±SD of three independent 
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experiments, with three to four mice in each group. Data analysed using one-way anova for differences within 
groups, for differences between control and infected groups, two-way anova was used. 
 
4.3.2. The lack of IL-2 in CD4+ T-cells from F. hepatica infected mice alters 
proliferation but not apoptosis.  
 
IL-2 is essential for the differentiation of effector T-cells into Th-subsets (Liao et al. 2011) 
and is involved in numerous other important roles such as T-cell proliferation or programmed 
cell death (Malek and Castro 2010). Splenocytes isolated from F. hepatica infected mice 
failed to produce significant levels of IL-2 after re-stimulation with FhTeg and therefore it is 
possible that this lack of IL-2 could inhibit CD4
+
 T-cell proliferation or induce programmed 
cell death. To examine the effects of FhTeg on T-cell proliferation splenocytes were isolated 
from infected mice and labelled with CFSE prior to culturing with PBS, FhTeg or PMA/anti-
CD3. IL-2 was also added to examine if this altered the proliferative activity of these cells. 
After 72 hours cells were washed and analysed by flow cytometry with a focus upon the 
number of undivided CD4
+
 cells.  
Chapter 8  
In the control mice the number of undivided CD4
+
 T-cells was 75.5% and while FhTeg in the 
presence of IL-2 enhanced proliferation the difference was not statistically significant 
compared to the PBS group. In contrast CD4
+
 cells isolated from infected mice had 
significantly fewer undivided cells; however a comparable level of proliferation was 
observed between CD4
+
 T-cells stimulated with PBS (28.85%) and FhTeg (26.15%). The 
addition of IL-2 resulted in the number of undivided cells decreasing significantly (p<0.05)) 
and this was also less than the positive control (PMA/anti-CD3 group). CD4
+
 T-cells from 
infected and control mice when stimulated with PMA/anti-CD3 showed a similar level of 
undivided CD4
+ 
T-cells (Fig 4.3.2 A).  
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Chapter 9  
To determine if the lack of IL-2 is inducing cell death or apoptosis, CD4
+
 T-cells were 
stained with annexin V and PI staining for analysis by flow cytometry. Cells treated with 4% 
formaldehyde were used as a positive control and PBS cells were used as a normal indicator 
of cell death. There was no significant difference between FhTeg treated cells or PMA/anti-
CD3 for double staining for annexin V and PI or single PI staining alone (Figure 4.3.2 B) 
confirming that in this model the lack of IL-2 does not induce apoptosis in CD4
+
 T-cells. 
 
 
 
Figure 4.3.2. The lack of IL-2 in CD4
+
 T-cells from F. hepatica infected mice alters proliferation but not 
apoptosis. A. Control cells treated with PBS had undivided cells at 75% the addition of FhTeg +/- IL-2 did not 
significantly alter this. The addition of PMA and anti-CD3 significantly lowered this to less than 20%. Cells 
isolated from infected mice showed a lower percentage of undivided cells treated with PBS and FhTeg at 20% 
but IL-2 significantly lowered this (p<0.05).  B. There was no significant difference in annexin V or PI staining 
in PBS or FhTeg treated cells. Data are presented as the mean ±SD of 2 independent experiments, with three 
mice in each group. Data analysed using one-way anova, for differences between groups, two-way anova was 
used. 
 
 
 87 
 
4.3.3. FhTeg induces markers of anergy in splenocytes isolated from F. hepatica 
infected mice  
 
Splenocytes isolated from infected mice were examined for markers of anergy by initially 
performing a qPCR gene array using pooled control (n=4) and infected samples (n=4) (Figure 
4.3.3A). The results demonstrated enhanced expression of RNF128 (GRAIL), CTLA4 and 
IL-10 (> 5 fold increase) while EGR2 and ICOS had a fold increase of 3.66 and 3.53 
respectively. To confirm these findings the most characterised anergic genes were selected 
and gene expression of RNF128, ITCH, EGR2 and ICOS was measured by qPCR. For 
control genes beta-actin, GusB and GAPDH were used. The gene expression of RNF128, 
ITCH, EGR2 and ICOS were significantly enhanced (p<0.05) with a 70, 5, 60 and 3.5 fold 
increase respectively (Fig 4.3.3B-E). Protein levels of RNF128 were also analysed in control 
and infected splenocytes and a fourfold increase in RNF128 was observed compared to 
uninfected controls (p<0.0001) (Fig 4.3.3F).   
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Control 
A. 
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Figure 4.3.3. FhTeg induces markers of anergy in splenocytes isolated from F. hepatica infected mice. A. 
A qPCR gene array with genes relating to anergy and tolerance was used with four pooled control and four 
pooled infection samples. The x-axis represents the control group and the y-axis represents the infection group.  
B-E. Individual expression of RNF128, ERG2, ITCH and ICOS genes were shown to be significantly enhanced 
in splenocytes from infection samples compared to controls, using qPCR (p<0.05). The data shown is the mean 
±SD of three independent experiments with 3-4 mice in each experiment. F. Protein expression of RNF128 in 
splenocytes isolated from control and infected mice (p<0.0001). Data shown is the mean ±SD of 1 independent 
experiment, with three mice in the group, *p<0.05, **** p<0.001. Student t-test used for differences between 
control and infection. 
 
 
4.3.4. The expression of PD1, CTLA4 and RNF128 were also enhanced in CD4+ 
T-cells isolated from F. hepatica infected mice 
 
CD4
+
 T-cells from control and infected mice were analysed for PD1, CTLA4 and RNF128 
expression using flow cytometry (PD1, CTLA4) and western blot (RNF128). CD4
+ 
T-cells 
isolated from infected mice had a significant increase in the expression of PD1 (P<0.0001).  
and CTLA4 (Figure 4.3.4 A,B), (P<0.05) by flow cytometry while RNF128 protein 
expression was higher in in CD4
+ 
T-cells with an 120 fold increase compared to non-infected 
controls (Figure 4.3.4C), (p<0.05). 
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Figure 4.3.4. The expression of PD1, CTLA4 and RNF128 were also enhanced in CD4
+
 T-cells isolated 
from F. hepatica infected mice. A-B. Both PD1 (p<0.0001) and CTLA4 (p<0.05) were enhanced on CD4
+
 T-
cells from infection compared to control cells. C-D. CD4
+
 T-cells isolated from spleens had a fold increase of 
150 of RNF128 compared to non-infected controls (p<0.05). Data shown is the mean ±SD of 3 independent 
experiments, with three mice in each group, in C one representative experiment shown. Student T-test used for 
differences between control and infection. 
 
 
4.3.5. PD1 is up-regulated on mesenteric lymphnodes after 72 hours of infection 
 
Lymph nodes are critical in initiating and mounting an immune response against foreign 
pathogens (Buettner and Bode 2012). Mesenteric lymph nodes are one of the first areas in 
contact with a pathogen after oral infection and can either mount a response or induce 
tolerance. As our route of infection is oral, mesenteric lymph nodes from control and infected 
mice were pooled and analysed by flow cytometry for PD1 expression after 24 hours, 72 
hours, 1 and 2 weeks. After 24 hours there is no significant change in the levels of PD1 
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expression (Figure 4.3.5 A).  But after 72 hours, 1 week and 2 weeks of infection PD1 is up 
regulated with a peak of MFI after 1 week (Figure 4.3.5 B-D).  
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Figure 4.3.5. PD1 is up-regulated on mesenteric lymph nodes after 72 hours of infection.  Mesenteric 
lymph nodes from control and infected mice were pooled and analysed for PD1 expression by MFI by flow 
cytometry. PD1 is enhanced from 72 hours to two weeks with a peak at one week of infection. Data is shown 
from three control pooled and three infected pooled samples.  
 
 
4.3.6. FhTeg can directly induce anergy in vivo 
 
In previous studies we have shown that when FhTeg is injected into the peritoneum of mice, 
it can mimic the immune response associated with infection by recruiting mast cells and M2-
like macrophages into the peritoneal cavity (Adams et al. 2014). To investigate if FhTeg can 
mimic infection by inducing anergy directly, PBS or FhTeg was injected over the sternum of 
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mice and 1 week later spleens were removed. The splenocytes were re-stimulated as outlined 
in previous assays to determine if cytokine production could be restored with the addition of 
rIL-2.  After 72 hours supernatants were removed and analysed for the production of IL-4, 
IL-5, IFN-γ and IL-2. Similar to infection no levels of IL-2 were observed in splenocytes 
from injected mice after stimulation with FhTeg (Fig 4.3.6 A). After 1 weeks significant 
levels of IL-5 and IL-4 (P<0.0001) and also IFN-γ (P<0.05) were detected after the addition 
of rIL-2 (Fig 4.3.6 B-D). Splenocytes were also examined for markers of anergy and the 
protein expression of RNF128 (Fig 4.3.6 E) and cell surface expression of PD1 (Fig 4.3.6 F) 
were significantly enhanced (p<0.05) in cells from FhTeg injected mice compared to 
controls.  
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Figure 4.3.6. FhTeg can directly induce anergy in vivo. A-D. In splenocytes re-stimulated with FhTeg, no Il-2 
production was observed but significant enhancement of IL-2 was seen after PMA and anti-CD3 stimulation 
(p<0.0001) in both control and injected samples. The levels of IL-5 (p<0.0001), IL-4 (p<0.0001) and IFN-γ 
(p<0.05) were all partially reversed after the addition of IL-2 compared to FhTeg alone. FhTeg alone did not 
RNF128
β-actin
E.
Control           72 Hrs              1 week
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enhance the production of any cytokine measured. E. RNF128 was found to be enhanced after 72 hours and 1 
week in splenocytes isolated from 72 hours and 1 week samples. F. Splenocytes isolated after 1 week were 
analysed by flow cytometry for the expression of PD1 and it was found to significantly enhanced (p<0.05). The 
data shown is the ±SD of two independent experiments with three mice per group. Student T-test used for 
differences between control and infection groups in (F). One way anova used for differences within groups in 
A-D, two way anova used for differences between groups. 
 
 
 
4.3.7. FhTeg activated dendritc cells induce markers of anergy in CD4+ T-cells 
 
We have previously shown that FhTeg stimulated dendritic cells induce a novel cell 
population that are characterised by SOCS3
high
, CD80
low
 andCD86
low
 (Vukman, Adams and 
O'Neill 2013, Hamilton et al. June 2009). It would be interesting to determine if this 
population could induce anergic T-cells. DCs were treated with PBS or FhTeg overnight, 
washed and co-cultured in a 1:10 ratio with CD4
+
 T-cells in the presence of plate bound anti-
CD3. CD4
+
 T-cells were cultured with anti-CD3 on their own as a negative control. 
Following a 72 hour co-culture, supernatants were removed and the levels of IL-2, IL-5, IL-4 
and IFN-γ were measured and  FhTeg DC’s significantly suppressed the production of all 
cytokines tested from CD4
+ 
T-cells, (p<0.05, p<0.0001) (Fig 4.3.7 A-D). The expression of 
RNF128 and CTLA4 were measured using qPCR. The analysis of genes found RNF128, 
(p<0.001) and CTLA4 (p<0.01) were enhanced in CD4
+
 T-cells co-cultured with FhTeg 
treated DCs compared to PBS controls (Fig 4.3.7 D-F). 
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Figure 4.3.7. FhTeg treated dendritic cells induce anergy in CD4
+
 T-cells. A-D PBS treated DC’s promoted 
the production of IL-2 (p<0.0001), IL-5 (p<0.0001), IL-4 (p<0.0001) and IFN-γ (p<0.0001) during a co-culture 
with CD4
+
 T-cells. FhTeg treated DC’s significantly suppressed the production of IL-2 (p<0.01), IL-5 
(p<0.0001), IL-4 (p<0.001) and IFN-γ (p<0.01). E-F. Cells were analysed for the enhancement of RNF128 and 
CTLA4 by qPCR. Both RNF128 (p<0.0001) and CTLA4 (p<0.01) were enhanced following co-culture with 
FhTeg treated DC’s. The data is the mean ±SD of three independent experiments. One way anova was used for 
analysis in A-D, students t-test was used in E-F. 
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4.3.8. The Mannose receptor is enhanced on dendritic cells, following activation 
with FhTeg and is important in the induction of anergy by DCs. 
 
We know that C-type lectin receptors are involved in helminth induced immune responses 
and we have shown that the tegument of F. hepatica comprises of high mannose 
glycoproteins (manuscript in preparation). Here we show that MR expression is enhanced on 
DCs following stimulation with FhTeg (Fig 4.3.8 A) and that CD11c expression is decreased 
(Fig 4.3.8 B). To investigate if enhancement of MR may be involved in cell to cell 
communication between dendritic cells and CD4
+
 T-cells in the induction of anergy, DCs 
were treated with PBS or FhTeg overnight, washed and exposed to Mannan and GalNac-4S 
(two sugars that bind to the binding domains of the MR receptor), prior to co-culturing in a 
1:10 ratio with CD4
+
 cells in the presence of plate bound anti-CD3. CD4
+
 cells were cultured 
with anti-CD3 on their own as a negative control. The expression of RNF128 and CTLA4 
were measured using qPCR. The analysis of genes found RNF128, and CTLA4 were 
enhanced in CD4
+
 cells co-cultured with FhTeg treated DCs compared to PBS controls (Fig 
4.3.8 A-B) and this expression was inhibited in the presence of mannan (p<0.001) and 
GalNac-4s (p<0.01). 
 
DCs were also generated from MR knockout mice and stimulated with PBS or FhTeg 
(10μg/ml) overnight before being washed and co-culturing with CD4+ T-cells in a 1:10 ratio 
with plate bound anti-CD3. After 72 hours, RNA was isolated from cells and analysed for 
RNF128 and CTLA4 expression by qPCR. The absence of MR inhibited the induction of 
both genes in CD4
+ 
T-cells and significantly decreased the expression compared to 
background cells (Figure 4.3.8 D-E) (p<0.05). The suppression of IL-2 was also significantly 
reversed in knockout compared to background controls (Figure 4.3.8 F), (p<0.0001). 
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Figure 4.3.8. The MR receptor is enhanced following activation with FhTeg and is important in the 
induction of anergy by DCs. A-B. FhTeg significantly enhances the expression of MR (p<0.01) and 
significantly decreases the expression of CD11c compared to PBS (p<0.05) on DCs. C. RNF128 was 
significantly enhanced following co-culture with FhTeg treated DC’s compared to PBS (p<0.001) but 
incubation with mannan (p<0.0001) and Gal-4-S (p<0.001) significantly suppressed this. D-E. FhTeg treated 
DC’s from background mice significantly enhanced RNF128 and CTLA4 (p<0.0001, p<0.01) during a co-
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culture with CD4
+
 T-cells but FhTeg treated DC’s from MR knockout mice failed to enhance either RNF128 or 
CTLA4. F. In background mice PBS treated DC’s enhanced IL-2 production (p<0.0001) and FhTeg treated 
DC’s significantly inhibited this (p<0.0001). In MR knockout mice, PBS treated DC’s significantly enhanced 
IL-2 production (p<0.0001) and FhTeg significantly decreased this (p<0.0001) but it was significantly enhanced 
compared to background mice (p<0.0001). The data shown is the mean ±SD of three independent experiments, 
with four mice in background and four mice in knockout group. Students t-test used in A-B, one way anova used 
for comparisons within groups in C-F and two way anova used for comparisons between background and 
knockout mice. 
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4.4. Discussion  
 
Studies examining T-cell responses in other helminth infections report two main regulatory 
phenotypes, FoxP3
+
 T-reg cells or anergic T-cells. FoxP3
+
 T-reg cells are the major cause of 
T-cell unresponsiveness in Brugia malayi, infection (McSorley et al. 2008) while chronic 
Schistosoma mansoni infection can lead to T-cell anergy (Smith et al. 2004). F. hepatica 
infection is typically associated with a polarised Th2/T-reg immune response with a decrease 
in protective Th1 immune responses within hours post infection. To our knowledge this is the 
first study to show that F. hepatica tegumental antigens induce T-cell anergy during F. 
hepatica infection which can be mimicked by the injection of FhTeg. Splenocytes isolated 
from F. hepatica infected or FhTeg injected mice fail to produce IL-2 which can explain this 
lack of antigen specific cytokine responses and the decrease in CD4
+
 T-cell proliferation. 
These responses are re-stored following the addition of IL-2 to cultures. T-cell responses 
when characterised further exhibit phenotypic extracellular and intracellular markers 
typically associated with anergy.  However CD4
+
 T-cells isolated from infected mice showed 
an increase in proliferation which is not generally associated with anergy, although the levels 
of proliferation of PBS and FhTeg from infected groups were significantly lower than the 
positive controls of PMA and anti-CD3. This may be due to the length of infections used and 
further experiments would need to be performed to understand this fully.  
Chapter 10  
CTLA4 and PD1 co-signalling is involved in the induction of anergy (Okazaki and Honjo 
2006, Wells et al. 2001, Butte et al. 2007) and these cell surface markers are enhanced on 
spleenocytes and CD4
+
 T-cells during F. hepatica infection and following injection with 
FhTeg. Signalling through the CTLA4 receptor induces negative regulation of T-cell 
activation which can lead to an un-responsive state in these cells (Greenwald et al. 2001). 
During normal activation CD28 and TCR engagement leads to CD4
+
 T-cell activation 
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promoting IL-2 secretion, proliferation and progress through the cell cycle. Alternatively, 
activation through the CTLA4 pathway results in poor production of IL-2, the loss of 
proliferation and the induction of anergy (Wells et al. 2001). CD4
+ 
T-cells isolated from F. 
hepatica infected mice lose their proliferative ability which can be reversed with the addition 
of IL-2. CTLA4 has been implicated in other helminth infections, studies using lymphatic 
filariasis showed an increase in expression of CTLA4  (Babu et al. 2006, Steel and Nutman. 
2003) and also during both acute and chronic infection of  S. mansoni a CTLA4 positive 
population of CD4
+
 T-cells is enhanced (Walsh, Smith and Fallon 2007). 
Chapter 11  
PD1 is also a negative regulator of T-cell responsiveness leading to diminished proliferation 
and cytokine secretion (Okazaki and Honjo 2006). Similar to CTLA4, its enhanced 
expression supports our key finding that FhTeg induces anergic T-cells. In other studies PD1 
has been shown to play a role in T cell hypo-responsiveness seen during S. mansoni infection 
(Van et al. 2013) and also was elevated during filariasis (Babu et al. 2006). PD1 expression is 
also associated with T-cell exhaustion (Wherry 2011) which is mostly centred on CD8
+ 
T-
cells. Exhausted T-cells cannot produce cytokines but can produce some IFN-γ. In our 
studies, IFN-γ production is not observed when splenocytes from infected or injected mice 
are stimulated with FhTeg and in the case of infection even after the addition of IL-2. 
Similarly, FhTeg re-stimulated cells do not exhibit other characteristics associated with 
exhausted T-cells such as high deletion of cells and apoptosis which further supports its role 
in the induction of anergy.  
Chapter 12  
Studies on anergic T-cells have uncovered a complex mechanism involving a number of 
negative regulators (Lechner 2001) including EGR2, EGR3 and the E3-ubiquitin ligases, 
RNF128, ITCH and CblB (Mueller 2004a). Both EGR2 and EGR3 are involved in the 
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induction and maintenance of T-cell anergy (Safford et al. 2005). EGR2 inhibits IFN-γ and 
IL-2 production and enhances the expression of CblB. Studies have shown that a full anergic 
state cannot be achieved without this latter gene (Harris 2004) as studies in CblB knockout 
mice have shown that anergy cannot be induced in vivo or in vitro in the absence of CblB 
(Jeon 2004). In our study we have observed a 60 fold increase of EGR2 in splenocytes 
isolated from a two week infection. EGR3 was not increased at this time point; however this 
was not surprising given that it is involved in the early signalling events. Similarly, an 
increase in CblB or ITCH expression was not observed at later time points (Venuprasad 
2010). RNF128 was highly expressed at the mRNA and protein level following F. hepatica 
infection and injection with FhTeg.  RNF128 has been implicated in helminth infections 
previously, with an increase in expression seen after chronic S.mansoni infection (Taylor et 
al. 2009) and high expression of this gene alone is enough to convert a naïve CD4
+ 
T-cell into 
an anergic phenotype (Seroogy et al. 2004).  
Chapter 13  
This is the first study to show that F. hepatica released antigens can directly induce anergy, 
although a recent paper reported FhES to induce anergic T-cells, however the definition was 
based upon IL-10 secreting CD4
+
 cells that express CTLA4 (Guasconi, Chiapello and Masih 
). From our definition we would consider this to be a T-reg rather than an anergic T-cell. It is 
not surprising that FhTeg and FhES induce different immune responses during infection as 
proteomic analysis demonstrates that FhTeg mainly comprises of a rich source of 
glycoproteins while FhES comprises of released gut enzymes (Wilson et al. 2011, van 
Rossum, Barrett and Brophy 2001). It was previously shown that these antigens induce 
different M2 like macrophage subsets in vitro and in vivo (Adams et al. 2014) while studies 
in mast cells show that FhTeg in vivo induces significantly higher masocytosis compared to 
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FhES (Vukman et al. 2013a). Further studies are required to investigate the interaction of 
these antigens on immune cells.  
Chapter 14  
FhTeg modulates dendritic cell function by inducing a novel DC phenotype characterised by 
SOCS3
high
, CD80
low
, CD86
low 
(Vukman, Adams and O'Neill 2013, Hamilton et al. June 
2009). Studies during Heligmosomoides polygyrus infection have found a dendritic cell 
population which has a low expression of CD11c and were defined as being 
tolerogenic and enhancing regulatory T-cells (Smith et al. 2011) . FhTeg stimulated 
DC’s phenotype was further characterised as having an enhanced expression of MR with 
decreased expression of CD11c observed. However, neither PGE2 nor PGD2 were secreted 
by DCs following stimulation with FhTeg. This immature phenotype that fails to respond to 
TLR and non-TLR activation (Vukman et al. 2013a, Dowling et al. February 2010) drives 
anergic T-cells in vitro as measured by enhanced RNF128 and CTLA4 by RNA and 
supressed cytokine expression in anti-CD3 stimulated CD4
+
 T-cells. These findings support 
the hypothesis that FhTeg induces an anergic like DC given its effect upon CD4
+
 T-cells.  To 
our knowledge there are few examples of anergic DC’s characterised with the exception of 
DC’s isolated from children with severe malnutrition and endotoxemia which were found to 
be anergic and inhibited T-cell proliferation (Hughes et al. 2009). Immature DC’s have also 
been implicated in the induction of anergy, BMDC’s cultured in GM-CSF with high levels of 
LPS induced anergy in vitro (Lutz et al. 2000) and also DC’s treated with IL-10 to induce 
semi-mature DC’s have been shown to induce anergy in both CD4+ and CD8+ T-cells (Sato, 
Yamashita and Matsuyama 2002). 
Chapter 15  
These anergy enhancing DCs highly express MR, a type-I membrane protein with a 
cytoplasmic domain involved in antigen processing, receptor internalisation and three 
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different types of binding domains. Its binding domain consists of  multiple C-type lectin-like 
carbohydrate-recognition domains (CRDs) responsible for Ca
2+
-dependent binding to 
terminal mannose, fucose or N-acetyl glucosamine, a fibronectin type II (FNII) domain 
involved in collagen binding and an N-terminal cysteine-rich (Cys-MR) domain that mediates 
Ca
2+
-independent binding to sulfated sugars such as SO4-3-Gal or SO4-3/4-GalNAc 
(Martinez-Pomares 2012). We have shown that the action of FhTeg is independent of MR so 
the lack of anergy induction in DC’s generated from knockout mice is not from the inhibition 
of binding or engagement of the receptor on the DC (manuscript in preparation). CTRs also 
have other important functions, including cell to cell communication, DC-SIGN which binds 
through its ligand ICAM3, mediates initial binding of DC’s with T-cells and helps stabilise 
binding through the TCR (Geijtenbeek et al. 2000). MR has been shown to bind through 
CD45 on CD4
+
 cells (Marti´nez-Pomares et al. 1999), and here we show that blocking MR 
with specific sugars before co-culture with CD4
+
 T-cells inhibits the induction of anergy. 
This was confirmed using DCs generated from MR knockout mice, as the absence of MR led 
to a significant decrease in the induction of RNF128 and CTLA4 compared to background 
mice. This is the first study to show that MR is involved in anergy induction in CD4
+
 cells 
through communication between dendritic cells and CD4
+
 T-cells. Other studies have shown 
MR’s involvement in anergy but this has been through binding of antigens through MR and 
cross presentation to CD4
+
 T-cells (Chieppa et al. 2003) and not through the binding of MR 
to its counter receptor on the CD4
+
 T-cell. 
Chapter 16  
This study demonstrated a novel mechanism for the T-cell unresponsiveness observed during 
F. hepatica infection and after injection with FhTeg. During infection, anergy is the main T-
cell response observed when examining adaptive immune responses to FhTeg as a lack of 
cytokine responses and proliferation and can be reversed with the addition of IL-2 to cultures. 
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Markers of T-cell anergy such as CTLA4 and PD1 are also increased and we also have an up-
regulation of genes relating to anergy induction and maintenance, RNF128, EGR2, ICOS and 
ITCH. The injection of FhTeg over the sternum can mimic the effect of infection and 
dendritic cells treated with FhTeg can induce anergy associated genes and cytokine 
suppression in CD4
+ 
cells in-vitro which is dependent on the mannose receptor. 
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5.  Chapter 5 
FhTeg induces anergy directly in CD4
+
 cells 
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5.1. Introduction 
 
CD4
+
 T-cells are an important group of cells which control the outcome of the immune 
response. Activation of CD4
+
 T-cells requires three signals from antigen presenting cells and 
this includes presentation of peptides through MHC class II, signals via co-stimulatory 
molecules and releases of cytokines. These signals influence the differentiation of naïve 
CD4
+
 cells into different subsets such as Th1, Th2, Th17, T-regs or anergic T-cells (Yamane 
and Paul 2013). Following this, most CD4
+
 cell subsets proliferate and produce cytokines 
which in concert with the environment already created by the APCs, further supports the 
differentiation of CD4
+
 and other immune cell subsets. However, anergic T-cells, induce a 
state of hypo-responsiveness where cytokine secretion and proliferation is suppressed but this 
can be reversed by the addition of recombinant or exogenous IL-2 (Schwartz 2003).  
Anergic T-cells are often found following chronic infection or after multiple exposures to 
antigens (Taylor, van der Werf and Maizels 2012a). The signalling mechanism for anergy is 
usually started by insufficient signals from APCs which are either not fully matured or cannot 
present antigens correctly. Two signals are needed for normal activation, receiving signal one 
only can lead to anergy (Sadegh-Nasseri et al. 2010). The characteristics of anergic T-cells 
are a lack of production of IL-2 which in turn leads to a suppression of proliferation and a 
block in the cell cycle at the G1 phase (Powell, Bruniquel and Schwartz 2001).  A number of 
genes are also involved in the induction and maintenance of T-cell anergy, the E3 ubiquitin 
ligases play a major role, EGR2 and 3 have been found to be involved in the induction of 
anergy and the levels of EGR2 stay elevated after the initial stimuli (Harris 2004), RNF128 or 
GRAIL is also crucial for anergy induction (Seroogy et al. 2004).  
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Anergy can also be directly induced in CD4
+
 T-cells using a number of different methods. 
Stimulation with anti-CD3 antibody followed by a brief resting period and subsequent re-
stimulation with PMA (Schwartz 1990) or by the addition of Ionomycin directly to cells 
(Heissmeyer 2004). Few antigens have been shown to directly interact with CD4
+
 T-cells to 
elicit an immune response; however super-antigens are produced by pathogenic microbes like 
bacteria which can cause non-specific activation of T-cells. This occurs through binding to 
both MHC class II molecules on APCs and to the TCR receptor on CD4
+ 
T-cells 
simultaneously, causing uncontrolled proliferation and production of cytokines from CD4
+ 
T-
cells. Following this a number of cells undergo apoptosis and the remaining cells are 
functionally unresponsive (Seth et al. 1994). They also can induce anergy in CD4
+
 memory 
cells directly by binding the TCR and inducing negative signalling pathways and are used by 
pathogens as a defence mechanism to the hosts’ immune response (Watson, Mittler and Lee 
2003).  
In the previous chapter we have shown that FhTeg (either during infection or following 
injection) is associated with the induction of anergy in vivo as measured by a lack of cytokine 
responses and proliferation following re-stimulation which can be reversed with the addition 
of IL-2 to culture. Markers of T-cell anergy such as CTLA4 and PD1 were enhanced on the 
surface of CD4
+
 T-cells and these cells expressed genes relating to anergy induction and 
maintenance (RNF128, EGR2, ICOS and ITCH). Dendritic cells treated with FhTeg can 
induce anergy associated genes and cytokine suppression in CD4
+ 
T-cells in-vitro. As there 
are antigens which can influence T-cell activation directly the aim of this study was to 
investigate the direct interaction of FhTeg with CD4
+
 T-cells.  
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5.2. Experimental Design 
 
The aim of this study was to investigate if FhTeg directly interacts with naïve CD4
+ 
T-cells 
and if the mannose receptor plays a role in this interaction. Firstly we investigated if FhTeg 
can directly induce anergic CD4
+
 T-cells, CD4
+
 T-cells were isolated from naïve (Balb/c) 
mice. These cells were stimulated with FhTeg (10μg/ml) for 2 and 24 hours and RNA was 
isolated from cells, reverse transcribed to cDNA and used in qPCR gene array assays for the 
expression of genes relating to tolerance and anergy. From these results there were a number 
of genes highly expressed after two hours and to check if these were significantly expressed, 
individual qPCR assays were performed. The expression of PD1 and CTLA4 were also 
measured by flow cytometry by directly stimulating CD4
+
 T-cells with FhTeg overnight. The 
phosphorylation of PKC-θ at 30mins, 1 hour and 2 hours was also investigated. To examine 
if FhTeg could inhibit cytokine secretion from CD4
+
 cells, they were incubated with FhTeg 
(10μg/ml) for 2.5 hours before the addition of PMA (20ng/ml) and anti-CD3 (10μg/ml). After 
72 hours supernatants were removed and analysed for IL-5 and IFN-γ production. To 
investigate if FhTeg would have an effect on proliferation, CD4+ cells were labelled with 
CFSE and stimulated with PBS, FhTeg (10μg/ml) or PMA (20ng/ml) and anti-CD3 
(10μg/ml) for 72 hours, cells were then analysed by flow cytometry. As some genes that were 
highly expressed on the qPCR gene arrays were related to the production of GMCSF and 
PGE2 the levels of these cytokines were measured following PBS, FhTeg (10μg/ml) or PMA 
(20ng/ml) and anti-CD3 (10μg/ml) following a 24 and 72 hour stimulation. 
 
The binding efficiency of FhTeg on CD4
+
 cells was measured, FhTeg and BSA (a non-
specific binding control) was fluorescently labelled with a FITC-488 label. CD4
+
 cells were 
stimulated with 1 and 5 (μg/ml) of FhTeg and analysed by flow cytometry. To check if the 
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binding was calcium dependent and if MR was involved, cells were pre-incubated for 30 
mins with EDTA (10mM) and Mannan (50μg/ml), GalNAc-4-sulphate (1mM) and anti-MR 
(10μg/ml) before the addition of FhTeg (1 and 5μg/ml). Finally to show the mannose receptor 
is on CD4
+
 cells, they were analysed by flow cytometry. 
To investigate if MR plays a role in the immune-suppressive effect of FhTeg on CD4
+
 cells, 
cells were stimulated with PBS or FhTeg (10μg/ml) with or without Mannan (50μg/ml) for 
24 hours, spun down and washed twice before the addition of fluorescently labelled 
antibodies for PD1 and CTLA4 or their isotype controls. Cells were then analysed by flow 
cytometry. Studies in MR knockout and background mice (C57bl/6) were carried out to 
investigate the effect of FhTeg in the absence of MR. Binding was measured by stimulating 
CD4
+ 
cells from C56BL6 background and MR knockout mice were stimulated with BSA 
(10μg/ml) or FITC-labelled FhTeg (10μg/ml) for 45 mins before being analysed by flow 
cytometry. The expression of and PD1 was also measured following a 24 hour stimulation 
with PBS or FhTeg (10μg/ml). The levels of CblB and EGR3 were also measured in 
knockout and background CD4
+
 cells following a 2 hour stimulation with FhTeg (10μg/ml). 
 
Finally the role of FhTeg treated CD4
+
 cells on dendritic cells ability to secrete IL-12p70 
were examined. CD4
+
 cells were stimulated with PBS or FhTeg for 24 hours, before being 
washed twice and co-cultured with dendritic cells for a further 24 hours. The dendritic cells 
were re-isolated and rested before being re-challenged with LPS (100ng/ml). Supernatants 
were removed after 18 hours and analysed for IL-12p70 production. 
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5.3. Results 
5.3.1. FhTeg can directly induce the expression of anergic markers on CD4+ T-
cells 
 
As we have previously shown that infection with F. hepatica and the injection of the 
tegumental antigen can cause anergy we wanted to investigate if FhTeg could induce anergy 
directly in CD4
+
T-
 
cells. CD4
+
 T-cells isolated from spleens of naive mice were stimulated 
with PBS or FhTeg (10μg/ml) for 2 and 24 hours. After the indicated time points cells were 
washed and lysed for RNA analysis. A qPCR gene array with genes relating to anergy was 
used to analyse cDNA from 2 and 24 hour treated cells. After two hours the array showed an 
increase in a number of genes which are involved in anergy induction which are listed in 
Table 1, and no increase in FoxP3 expression which is commonly seen in conventional T-reg 
cells (Figure 5.3.1A).  
Table 5.3.1. The fold changes seen in the 2 hour qPCR gene array for genes associated with anergy induction 
and maintenance.  
Gene Fold change 
CblB 3.4 
Ccl3 4.3 
CD40 -2.53 
CSF 368 
Egr2 4.3 
Egr3 8.2 
ICOS 2.8 
PD1 3.22 
Ptgs2 5.11 
 
After 24 hours the gene expression is quite different with only a small number of genes 
having a high expression including CSF2 (14.5), LEP (6.7), Early growth response gene 3 
(EGR3) (2.26) and PTGS2 (4.9). IL-2 was down-regulated with a fold regulation of -2.2 
(Figure 5.3.1B).  To determine if the genes are significantly enhanced, individual qPCR 
analysis of a number of genes was performed following a 2 hour stimulation. Egr2 and 3, 
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CTLA4, ICOS ITCH and CblB were analysed (Figure 5.3.1C-H) and their fold increases are 
summarised in Table 5.3.1B.  
Table 5.3.1B The fold changes seen in the 24 hour qPCR gene array for genes associated with anergy induction 
and maintenance.  
Gene Fold Change 
Egr2 2.5 
Egr3 3.3 
CTLA4 3.0 
ICOS 2.4 
ITCH 1.7 
CblB 1.6 
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Figure 5.3.1.  FhTeg causes the expression of anergic genes in CD4
+ 
T-cells following stimulation. CD4
+
 T-
cells were stimulated with PBS or FhTeg (10μg/ml) for 2 and 24 hours. A qPCR array was used to analyse a 
number of genes. The data is presented as the result of one independent experiment. C-D. Individual genes were 
analysed after 2hrs. FhTeg significantly enhanced the expression of EGR2 (p<0.001), EGR3 (p<0.0001), 
CTLA4 (p<0.01), ICOS (p<0.001), ITCH (p<0.0001) and CblB (p<0.01) compared to PBS. The data is 
presented as the mean ±SD for three independent experiments. Data was analysed using the student t-test. 
 
5.3.2. FhTeg causes the up-regulation of PD1 and CTLA4 on CD4+ T-cells  
 
PD1 and CTLA4 were shown to be enhanced on the 2 hour qPCR gene array. To investigate 
if the cell surface expression of these markers was significant, CD4
+
 T-cells were incubated 
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with PBS or FhTeg (10μg/ml) to cultures. After 24 hours the cells were washed and stained 
for PD1 or CTLA4 (total). Cells which received FhTeg alone showed a significant increase in 
expression of PD1 (P<0.001) (Figure 5.3.2A). CTLA4 total, surface and intracellular 
expression, was also up-regulated on CD4
+
 T-cells after treatment with FhTeg (P<0.01) 
(Figure 5.3.2B).   
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Figure 5.3.2. FhTeg enhances the expression of PD1 and CTLA4 on CD4+ T-cells A-B FhTeg significantly 
enhances the expression of PD1 (p<0.0001) and CTLA4 (p<0.01) on CD4
+
 T-cells following an overnight 
stimulation. The data shown is the mean ±SD of three independent experiments. Data analysed using the student 
t-test. 
 
5.3.3. FhTeg does not induce the phosphorylation of PKC-theta in CD4+ T-cells 
 
The activation of CD4
+
 T-cells requires the initiation of a number of signalling pathways 
which in turn lead to the activation of the transcription factor NFκB and a T-cell specific 
immune response. Important signalling modulators which lead to the activation of NFκB are 
PKC-theta, AP1 and in conjuction with calcium signalling NFAT. To determine if FhTeg 
would induce any of these transcription factors, CD4
+
 cells were stimulated with PBS, FhTeg 
(10μg/ml) or PMA (20ng/ml) and anti-CD3 (10μg/ml) for 30 mins, 1 and 2 hours. Protein 
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levels of PKC-θ were measured. The phosphorylation or activated state of PKC-θ was seen 
for samples which received both PMA and anti-CD3 (Figure 5.3.3 3,6,9) but not in FhTeg 
samples (Figure 5.3.3 2,5,8).  
 
Figure 5.3.3. FhTeg does not induce the phosphorylation of PKC-theta in CD4
+
 T-cells. Protein levels of 
PKC-θ were measured. FhTeg fails to induce the phosphorylation of PKC-theta in CD4+ T-cells following a 30 
min, 1 hour  and 2 hour stimulation. Lane 1,4,7 PBS, Lane 2,5,8 FhTeg, Lane 3,6,9 PMA/anti-CD3.  
 
5.3.4. FhTeg inhibits the PMA/Anti-CD3 activation of CD4+ T-cells  
 
CD4
+
 T-cells were incubated with FhTeg (10μg/ml) for 2.5 hours before the addition of PMA 
(20ng/ml) and anti-CD3 (10μg/ml). After 72 hours supernatants were removed and the levels 
of IL-5 and IFN-γ were measured using ELISA. Viability was measured using trypan blue 
staining. Cells which received PMA and anti-CD3 produced high levels of IFN-γ and IL-5 
but co-stimulation with FhTeg significantly reduced the production of IFN-γ (p<0.0001) and 
IL-5 (p<0.001) FhTeg did not cause the production of either cytokine (Figure 5.3.4 A-B).  
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Figure 5.3.4. FhTeg inhibits the PMA/anti-CD3 activation of CD4
+
 T-cells. A-B. PMA and anti-CD3 
significantly enhanced the production of IL-5 and IFN-γ from CD4+ T-cells compared to PBS (p<0.0001), 
FhTeg significantly inhibited the production of IFN-γ (p<0.0001) and IL-5 (p<0.001) when co-stimulated with 
PMA/anti-CD3. The data is presented as the mean ±SD of one experiment, this experiment was repeated three 
times and one representative experiment is shown. Data analysed using one-way anova. 
 
5.3.5. FhTeg inhibits the PMA/anti-CD3 induced proliferation in CD4+ T-cells 
 
 FhTeg inhibits the production of cytokines from CD4
+
 cells following a 72 hour stimulation; 
this may impact the cells ability to proliferate. To investigate if FhTeg would inhibit 
proliferation in CD4
+
 T-cells, cells were labelled with CFSE (10μM) and incubated with 
PBS, FhTeg (10μg/ml) in the presence or absence of PMA (20ng/ml) and anti-CD3 
(10μg/ml). Following a 72 hour incubation, cells were washed and analysed by flow 
cytometry. Cells which had received PMA and anti-CD3 showed a high level of proliferation 
with only 6% of cells un-divided; although FhTeg and PMA/anti-CD3 cells had undivided 
cells of 13% the following generation had a very high percentage at 59% (Figure 5.3.5 A).  
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Figure 5.3.5. FhTeg inhibits the proliferation of CD4
+
 T-cells. FhTeg inhibits CD4
+
 T-cell proliferation but 
this was not significant.  The data shown is representative of one experiment which was repeated three times. 
 
5.3.6. FhTeg does not induce the production of GMCSF or PGD2 from CD4+ 
cells, but enhances the production of PGE2 
 
FhTeg induces a very significant enhancement of the expression of CSF2 after 2 and 24 
hours, with fold increases of 368 and 14.9 respectively. The gene CSF codes for the 
production of GMCSF, to investigate if the high expression of CSF2 at mRNA level induced 
high levels of GMCSF after 24 and 72 hours, CD4
+
 T-cells were stimulated with FhTeg 
(10μg/ml) in the presence or absence of PMA (20ng/ml) and anti-CD3 (10μg/ml). 
Supernatants were removed after 24 and 72 hours and assessed for GMCSF production. Cells 
which received PBS or FhTeg alone did not produce significant levels of GMCSF after both 
24 or 72 hours but cells which received PMA and anti-CD3 did (p<0.0001) and interestingly  
FhTeg significantly inhibited the production at both time points. (Figure 5.3.6 A-B)  
The gene PTGS2, which codes for the enzyme Cox2, was also highly expressed following 
FhTeg stimulation after 2 and 24 hours with fold increases of 5.11 and 4.87. To investigate if 
the high expression of PTGS2 would lead to either PGD2 or PGE2 to be produced, CD4
+ 
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cells were stimulated for 24 and 72 hours with PBS and FhTeg (10μg/ml) or PBS and FhTeg 
(10μg/ml) in the presence or absence of PMA (20ng/ml) and anti-CD3 (10μg/ml). 
Supernatants were analysed for the production of PGD2 and PGE2 using commercially 
available EIA Elisa kits.  After 24 and 72 hours there were no levels of PGD2 expressed in 
any samples but there was a significant increase in the levels of PGE2 produced after 24 
hours in FhTeg samples and after 72 hours in FhTeg/PMA-antiCD3 samples (P<0.0001 and 
p<0.01) (Figure 5.3.6 C-D). 
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Figure 5.3.6.  FhTeg does not induce the production of GMCSF or PGD2 from CD4
+
 T-cells, but enhances 
the production of PGE2.  A. PMA and anti-CD3 enhanced the production of GM-CSF from CD4
+
 T-cells after 
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24 (p<0.0001) and 72 hours (p<0.0001) compared to PBS and FhTeg significantly inhibited this at both time 
points (p<0.0001, p<0.001). C-D. PGE2 levels were enhanced following stimulation with FhTeg after 24 and 72 
hours compared to PBS controls (p<0.0001, p<0.01). The data shown is the mean ±SD of three independent 
experiments. Data analysed using one-way anova. 
 
5.3.7. FhTeg binds to CD4+ T-cells and this binding can be suppressed by the 
addition of mannan and GalNAc-4-Sulphate to cultures. 
 
FhTeg was labelled with a FITC 488nm fluorophore label which can be used to detect 
binding by flow cytometry and by fluorescent microscopy. As a control BSA was also 
labelled with the FITC fluorophore to check for unspecific binding. Cells were incubated 
with PBS, the sugar mannan (10ug/ml) or GalNAc-4-Sulphate (1ug/ml) for 45 minutes and 
then PBS, 488-BSA or 488-FhTeg at two different concentrations, 1ug/ml and 5ug/ml, was 
added to the cells for a further 45 minutes. The cells were then washed, counter stained for 
CD4
+
 APC and analysed by flow cytometry. 488-BSA did not show any specific binding to 
CD4
+
 T-cells but the 1 and 5ug of 488-FhTeg showed significant binding to CD4
+
 T-cells, 
(Figure 5.3.7 A) (P<0.05 and 0.005) . The percentage of cells that showed binding to FhTeg 
was 7% for 1μg and 15% for 5μg (Figure 5.3.7 C-E).  This binding was suppressed in the 1ug 
FhTeg cultures by the addition of mannan (P<0.01), GalNAc-4-sulphate (P<0.05) and a 
combination of both to cells (Figure 5.3.7 B -D) (P<0.01).  
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Figure 5.3.7. FhTeg binds to CD4+ cells and this binding can be reversed using mannan and Gal-4-
Sulphate. A-B. FhTeg significantly binds to CD4
+
 T-cells at 1μg/ml using both MFI and percentage of cells 
measured (p<0.0001), the addition of mannan (p<0.01), GalNAc-4-S (p<0.05) and a combination of both 
(p<0.01) can inhibit the binding. C-D. FhTeg binds at 5μg/ml to CD4+ T-cells (p<0.001), this can be inhibited 
by the addition of Mannan and GalNAc-4-S combined (p<0.05) but not on their own. The data shown is the 
mean ±SD of two independent experiments which were done in triplicate. Data analysed using one-way anova. 
 
5.3.8. The C-type lectin MR is on the surface of CD4+ T-cells  
 
Mannan and GalNAc-4-S have binding specificities to the C-Type lectin, the mannose 
receptor. As both of these compounds have inhibited binding of FhTeg to CD4
+
 cells, it was 
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decided to investigate if the MR receptor is on the surface of CD4
+
 T-cells. CD4
+
 T-cells 
were isolated from spleens of naive mice and stained for MR, counterstained for CD4 and 
analysed by flow cytometry. The MR receptor was found to be on a small percentage of 
CD4
+
 T-cells by flow cytometry (Figure 5.3.8A), with a significant increase in MFI (p<0.05) 
and in the percentage of cells (Figure 5.3.8B)   (p<0.0001).  The percentage of cells which 
expressed the MR receptor was small at only 4%.  
To investigate if the MR receptor was involved in the signalling events following FhTeg 
stimulation, CD4
+
 T-cells were stimulated with Mannan (10μg/ml) for 30 minutes before the 
addition of FhTeg (10μg/ml) for 24 hours. CD4+ T-cells were then washed and 
counterstained for CD4 and analysed for the expression of PD1 and CTLA4. FhTeg 
significantly enhances the production of PD1 and CTLA4 (p<0.01) and mannan significantly 
inhibits this (p<0.05, 0.01), (Figure 5.3.8 C-D). As FhTeg inhibits the production of IL-5 
from CD4
+
 T-cells when stimulated with PMA and anti-CD3, the ability of Mannan and 
GalNAc-4-Sulphate was examined. CD4
+
 T-cells were stimulated with Mannan (10μg/ml) or 
GalNAc-4-Sulphate (1μg/ml) for 30 minutes before the addition of FhTeg (10μg/ml) for 2.5 
hours. Following this, PMA (20ng/ml) and anti-CD3 (10μg/ml) was added and the cells were 
incubated for 72 hours, supernatants were then removed and analysed for the production of 
IL-5 by commercial ELISA.  PMA and anti-CD3 significantly enhanced the production of IL-
5 (p<0.0001) and FhTeg inhibited this (p<0.0001). The addition of Mannan and GalNAc-4-
Sulphate did not reverse this (Figure 5.3.8 E). 
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Figure 5.3.8. The C-type lectin Mannose Receptor is on the surface of CD4+ T-cells. A-B. MR was found to 
be significantly expressed on CD4
+
 T-cells compared to isotype controls (p<0.05, p<0.0001). Data analysed 
using student t-test. C-D. FhTeg significantly enhanced the expression of PD1 on CD4
+
 T-cells (p<0.01) and 
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Mannan significantly inhibits the expression (p<0.05). FhTeg also enhanced the expression of CTLA4 (p<0.01) 
and mannan significantly inhibited this (p<0.01). E. PMA and anti-CD3 significantly enhanced the production 
of IL-5 from CD4
+
 T-cells (p<0.0001) and FhTeg significantly inhibited this (p<0.0001). Mannan does not 
reverse the suppressive effect of FhTeg on IL-5 production. The data shown is the mean ±SD of three 
independent experiments. Data analysed using one way anova. 
 
5.3.9. The Mannose receptor is not involved in the immune-modulatory 
effect of FhTeg on CD4
+ 
T-cells 
 
We have previously shown that FhTeg is rich in glycoproteins and has a high percentage of 
mannose rich glycans which may have a high affinity to bind to the mannose receptor 
(Manuscript in prep). We also showed that binding of FhTeg to CD4
+
 cells can be blocked 
using anti-MR and mannan. To evaluate if the mannose receptor is playing a part in FhTeg 
and CD4
+
 cell interaction, cells were isolated from background and knockout mice. To 
investigate if FhTeg can still bind to CD4
+
 cells in the absence of MR, binding assays were 
carried out using fluorescently labelled FhTeg. Cells were stimulated for 45 mins with PBS, 
FITC labelled BSA or FhTeg (10μg/ml), cells were then washed and binding was determined 
by flow cytometry. Both background and MR knockout mice showed comparable levels of 
binding to FhTeg in terms of the percentage of cells that bound (Figure 5.3.9A), there was no 
statistical difference between the two groups. 
PD1 was highly expressed following a 24 hour stimulation with FhTeg on CD4
+
 cells. To 
measure PD1 expression, CD4
+
 cells isolated from background and MR knockout were 
stimulated with PBS or FhTeg (10μg/ml) for 24 hours, washed and stained with both CD4 
and PD1 antibodies, cells were then analysed for PD1 expression by flow cytometry. The 
expression of PD1 was enhanced in both background and knockout mice but this was not 
statistically significant (Figure 5.3.9 B). 
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To investigate if we still get an up-regulation of genes related to anergy in CD4
+
 cells isolated 
from MR knockout mice, CD4
+
 cells from background and knockout mice were stimulated 
for 2 hours and RNA was isolated from the cell pellets. QPCR was used to measure the levels 
of CblB and EGR3, as these genes have been found to be highly expressed after FhTeg 
stimulation in Balb/C mice. FhTeg induced both CblB and EGR3 in both background and 
knockout mice, with a significant difference between the two groups for CblB (Figure 5.3.9 
C-D) (*p<0.05, ****p<0.0001). 
We had enhanced expression of PGE2 in CD4
+
 cells following a 24 hour FhTeg stimulation, 
to evaluate if MR knockout mice would still produce PGE2, cells were stimulated from both 
background and MR knockout for 24 hours and the levels of PGE2 were measured in the 
supernatant.  In background mice there were significant levels of PGE2 but in the absence of 
MR, there were no significant levels of PGE2 produced (Figure 5.3.9 E) (****p<0.0001). 
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Figure 5.3.9 The Mannose receptor is not involved in the immune-modulatory effect of FhTeg 
on CD4
+ 
T-cells. A. FhTeg binds significantly to CD4+ T-cells isolated from background and MR knockout 
mice (p<0.0001). B. There was no significant enhancement of PD1 on CD4
+
 T-cells isolated from background 
and MR knockout cells; there was a trend of enhancement seen in both groups. C-D. Both CblB and EGR3 were 
significantly enhanced from CD4
+
 T-cells isolated from both background (p<0.001, p<0.0001) and MR 
knockout mice (p<0.0001). E. FhTeg significantly enhanced the production of PGE2 from CD4
+
 T-cells isolated 
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from background mice compared to PBS (p<0.001) but this was diminished in MR knockout mice. The data 
shown is the mean ± SD of two independent experiments. Data analysed using one way anova. 
 
5.3.10. FhTeg treated CD4+ cells modulate dendritic cells ability to produce     
IL-12p70 
CD4
+ 
T-cells have been shown to influence DC’s and other T-cells directly. T-reg cells can 
directly down-regulate co-stimulatory markers on APCS and inhibit their ability to present 
antigen (Cederbom, Hall and Ivars 2000, Misra et al. 2004, Tadokoro et al. 2006, Oderup et 
al. 2006).  To investigate if FhTeg treated CD4
+
 T-cells can directly modulate DC’s, CD4+ 
cells were treated with PBS or PMA (20ng/ml) and anti-CD3 (10μg/ml) in the presence or 
absence of FhTeg (10μg/ml) overnight before being washed and co-cultured with DC’s for a 
further 18 hours. DC’s were then separated from CD4+ T-cells and rested before being re-
challenged with LPS (100ng/ml). Supernatants were analysed for the production of IL-12p70 
by commercial ELISA. DC’s which had been co-cultured with FhTeg treated CD4+ cells 
showed impaired ability to produce IL-12p70 when re-challenged with LPS, cells which had 
received PMA and anti-CD3 alone produced significant levels of IL-12p70 (p<0.01) but 
FhTeg significantly decreased this (p<0.01) (Figure 5.3.10 A). 
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Figure 5.3.10 FhTeg treated CD4+ cells modulate dendritic cells ability to produce IL-12p70. PMA and 
anti-CD3 stimulated CD4
+
 T-cells significantly increase the production of IL-12p70 from DC’s (p<0.01) but 
FhTeg significantly inhibits this (p<0.01). The data shown is the mean ±SD of three independent experiments, 
(**p<0.01). Data analysed using one way anova. 
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5.4. Discussion 
 
Fasciola hepatica infection leads to a Th2/T-reg response in the host with an inhibition of a 
protective Th1 response. The major antigens of F. hepatica, the excretory secretory products 
and the tegumental coat have been shown to have a wide range of effects on different cell 
types. FhES causes the alternative activation of macrophages (Donnelly et al. 2005) and the 
priming of a Th2 immune response from T-cells. We are interested in the tegumental coat and 
have demonstrated that it induces a number of novel cell populations including dendritic 
cells, macrophages and mast cell. To our knowledge this is the first study to demonstrate that 
FhTeg has a direct effect on CD4
+
 cells, inducing an anergic like CD4
+
 cell population.  
 
FhTeg induces an anergic like CD4
+
 cell that expresses Early growth response gene 2 and 3 
(EGR2/3), CblB, and ITCH, genes that are associated with anergy. EGR2 is an important 
regulator of the induction of anergy (Harris 2004) as studies on EGR2 knockout mice have 
shown that full induction of anergy cannot be achieved without the full expression of the 
gene (Zheng et al. 2012). EGR3 is also involved in the induction and maintenance of the 
anergic phenotype and both genes lead to diminished IL-2 production and an increase in 
CblB expression which leads to negative regulation of T-cell activation (Harris 2004, Safford 
et al. 2005).  
 
The E3 ubiquitin ligases have a major role to play in the maintenance of anergy, RNF128, 
CblB and ITCH promote the ubiquitination and degradation of the proteins PKC-θ and 
phospholipase C-γ and this leads to an inhibition of the calcium signalling pathway which in 
turn promotes anergy in the cell (Heissmeyer 2004). While we have shown an up-regulation 
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of this gene during infection and also in CD4
+
 cells following stimulation with FhTeg 
stimulated dendritic cells, we did not observe an up-regulation of RNF128 in our cells at the 
2 hour time point but we did observe it at an earlier time point of 1 hr (Appendix C). Here we 
also have an increase in CblB expression; CblB inhibits actin re-organisation which impairs 
the formation of an active immunological synapse (Doherty et al. 2010). 
 
We have found the up-regulation of several genes which may impair T-cell responses by 
inhibiting the activation of NFκB and its signalling molecules PKC-θ and AP1. PKC-θ is a 
protein kinase which is involved in the maturation and activation of CD4
+
 cells and the 
subsequent proliferation and initiation of a T-cell specific immune response. Here we have 
shown that FhTeg does not induce the activation of PKC-θ, which may explain the lack of 
proliferation and production of cytokines seen in CD4
+
 cells following stimulation. NFAT is 
also critical in the activation of cells, in conjunction with calcium influx, it travels to the 
nucleus and upregulates the transcription of a number of genes needed for activation (Soto-
Nieves et al. 2009), but in the absence of AP1, NFκB transcription cannot proceed and 
instead negative regulators are transcribed.  
 
Activation and differentiation of CD4
+ 
cells is typically induced by APCs through binding of 
MHC II or other co-stimulatory markers like CD80 or CD86 to receptors on the T-cell like 
the T-Cell Receptor (TCR) or CD28 and a second signalling cascade through CD3 is also 
needed for activation. During anergy induction, insufficient signals from APCs consisting of 
signal one only or signalling through receptors like PD1 or CTLA4 can cause negative 
signalling pathways in the cell. CD80 (B7-1) and CD86 (B7-2) can bind to CTLA4 and have 
a 20 to 50 fold higher specificity for CTLA4 than CD28 delivering negative signals to T-cells 
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(Linsley et al.). Signalling through CTLA4 can predominantly happen if the expression of the 
co-stimulatory markers is low on the APC rather than after activation with antigens which 
positively enhance the expression (Greenwald et al. 2001). Here we have induced high 
CTLA4 expression directly by stimulation with FhTeg rather than through APC co-
stimulation. The enhanced expression inhibits proliferation and IL-2 production and may help 
to keep the cell in a hypo-responsive state. PD1 is another cell surface marker which is used 
to create negative signals in T-cells. Signalling through PD1 by its receptors PD-L1 or PD-L2 
creates unresponsiveness in cells by affecting IL-2 production and proliferation (Carter et al. 
2002, Fife et al. 2009).  
 
Incubation with the sugar mannan which binds the MR receptor before stimulation with 
FhTeg inhibited this enhanced expression of CTLA4 and PD1 on CD4
+
 cells. MR is a type-I 
membrane protein with a cytoplasmic domain involved in antigen processing and receptor 
internalisation and three different types of binding domains at its extracellular region. It 
features multiple C-type lectin-like carbohydrate-recognition domains (CRDs) responsible for 
calcium dependent binding to terminal mannose, fucose or N-acetyl glucosamine (Gazi and 
Martinez-Pomares 2009)a fibronectin type II (FNII) domain involved in collagen binding 
(Martinez-Pomares et al. 2006) and an N-terminal cysteine-rich (Cys-MR) domain that 
mediates calcium-independent binding to sulfated sugars (Leteux et al. 2000). Previously we 
have shown that MR is on the surface of mast cells and it plays a role in B. pertussis 
signalling (Vukman et al. 2013c) and similarly there have not been any studies to date to our 
knowledge on investigating if MR is on the surface of CD4
+
 cells. As we have been able to 
inhibit the binding of FhTeg to cells using sugars which bind to MR and also to inhibit the 
up-regulation of CTLA4 and PD1 we investigated if MR was on the surface of CD4
+
 cells. 
Using flow cytometry we have found that MR is on a small percentage of CD4
+ 
T-cells. 
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FhTeg directly induces genes relating to anergy induction and maintenance and inhibits the 
expression of PKC-θ in CD4+ cells and here we have shown this impairs the cells ability to 
proliferate and to produce cytokines. The levels of IL-5 and IFN-γ were unchanged in FhTeg 
samples compared to PBS but following pre-incubation with FhTeg, the levels of cytokines 
produced is significantly decreased compared to PMA and anti-CD3. This is in keeping with 
our previous studies as dendritic cells when pre-incubated with FhTeg before LPS stimulation 
they have diminished production of inflammatory cytokines like IL-12p70 and TNF-α 
(Hamilton et al. 2009b) and FhTeg stimulated cells either following F. hepatica infection or 
immunisation fail to secret cytokines.  FhTeg also inhibited the cells ability to proliferate 
which lower percentages of cells in all generations seen following pre-incubation with 
FhTeg. 
 
FhTeg can induce the expression of genes relating to anergy induction, promote the 
enhancement of negative cell surface markers and inhibit cytokine secretion, we have shown 
previously that FhTeg binds to dendritic cells and this can be blocked with the addition of 
antibodies and sugars for the mannose receptor but the mannose receptor did not play a role 
in the signalling events following binding. Here by fluorescently labelling FhTeg, we have 
shown that it can also bind directly to a percentage of CD4
+
 cells. We also show that using 
antibodies and sugars that bind the mannose receptor, we can inhibit this binding but studies 
using MR knockout mice have shown that binding still occurs to CD4
+
 cells isolated from 
knockout mice and that in the absence of the receptor the inhibitory effect of FhTeg is still 
seen. Further studies would need to be completed to identify the receptor involved on CD4
+
 
cells which is involved in the signalling events following FhTeg stimulation. 
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In this study we have demonstrated that FhTeg has a direct effect on CD4
+ 
cells, with an 
increase in expression of PD1 and CTLA4 and an up-regulation of a number of genes 
involved with anergy. Using the sugar mannan the binding of FhTeg and the up-regulation of 
CTLA4 and PD1 can be inhibited. To our knowledge this is the first study to show the 
presence of MR on the surface of CD4
+
 cells but it does not play a role in the induction of 
anergy in these cells. This study opens up a new area of study in helminth biology on CD4
+ 
cells and the effect of glycan helminth products which may have a direct effect on cells 
through unknown receptors. 
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6. Chapter 6. 
 
FhTeg modulates human PBMC’s via CD4
+
 cells 
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6.1. Introduction 
 
Helminth infections affect up to a third of the world’s population with prevalence in the 
developing world, infection is rarely fatal but can lead to anaemia, weight loss and a 
susceptibility to bystander infections (Hotez et al. 2008). We have previous studies on mouse 
models using the helminth parasite F. hepatica. Infection leads to anergic T-cell responses 
and this can be mimicked by the injection of the tegumental antigens. FhTeg also causes the 
alternative activation of macrophages in vivo which impair cytokine secretion from CD4
+
 
cells (Adams et al. 2014)  and inhibits Th1 immune responses in mast cells (Vukman et al. 
2013b). Studies on dendritic cells also show an inhibition of dendritic cells maturation and 
function following stimulation with bacterial ligands (Hamilton et al. June 2009) with an 
increase in SOCS3 expression (Vukman, Adams and O'Neill 2013). These FhTeg treated 
DCs induce anergy in CD4
+
 T-cells via the mannose receptor.  
But infection with helminths parasites have some advantages and studies are ongoing into the 
use of whole worm and helminths products on inflammatory disorders such as multiple 
sclerosis (MS), inflammatory bowel disease (IBD), allergy, psoriasis and rheumatoid arthritis. 
Studies using whole worm therapy have shown potential such as multiple sclerosis and 
irritable bowel syndrome (Finlay, Walsh and Mills 2014) but whole worm therapy isn’t 
always an option as complications can occur such as invasion of the parasite into other organs 
and when treatment is considered for immune-compromised individuals, pregnant women or 
for children.  
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There have been studies on helminths and the effect their antigens have on immune cells 
isolated from PBMCs.  Studies in lymphatic filariasis using CD14
+
 cells shown an increase in 
IL-1β when cells were re-challenged with LPS from control individuals but cells from 
infected patients showed a decrease in IL-1β production, the cells ability to adhere was also 
diminished (Sasisekhar et al. 2004). Studies investigating lymphocyte responses from Brugia 
malayi infected individuals show a decrease in cytokine secretion and an increase in anergy 
factors (Babu et al. 2006) and studies using ES-62 from filarial nematodes induced anergy in 
Jurkatt T-cells (Harnett et al. 1998). To our knowledge there are no studies on the effect of 
FhTeg on PBMCs and here we will investigate the response of PBMCs, CD14
+
 and CD4
+
 
cells to FhTeg. 
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6.2. Experimental Design 
 
PBMCs were isolated from human buffy coat blood packs sourced from the Irish Blood 
Transfusion Service, St James’ Hospital, Dublin, using density gradient centrifugation. A 
range of blood types were used for these studies. For binding studies cells were plated in 
a 96 well plate at 50,000 cells per 50μl, 1,5 or 10 μg/ml of 488 labelled FhTeg was added 
to cells at 37 °C for forty five minutes and cells were subsequently washed in ice cold 
PBS before analysis using flow cytometry. As control for non-specific binding, cells were 
incubated with 10 μg/ml of FITC-488 labelled BSA. As FhTeg bound to human PBMCs 
and in particular to both CD14 and CD4
+
 cells, the modulatory role of FhTeg on cells was 
measured. PBMCs were plated at 1x10
6 
cells per ml and stimulated with FhTeg (10μg/ml) 
for 2.5 hours before the addition of LPS (100ng/ml) or PMA (20ng/ml) and Ionomycin 
(1μM). Brefaldin A was added to inhibit the excretion of cytokines for analysis by 
intracellular staining. Following a 4 hour stimulation cells were labelled with FITC 
labelled CD11c and CD14, fixed and lysed for staining with APC labelled TNF-α 
antibody. As FhTeg inhibited the production of TNF-α from cells following a short 
stimulation PBMCs were stimulated as above but with no Brefaldin A overnight and 
supernatants were removed, the levels of TNF-α were measured using commercially 
available ELISA.  
As FhTeg inhibited the production of TNF-α both intra-cellular and following an 
overnight incubation the effect of FhTeg was tested on populations isolated from PBMCs, 
CD14 and CD4
+
 cells were isolated and stimulated with FhTeg (10μg/ml) for 2.5 hours 
before the addition of LPS (100ng/ml) to CD14
+
 cells and PMA (20ng/ml)/Ionomycin 
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(1μM) to  CD4+ cells. Following incubations of 18 and 72 hours respectively 
supernatants were removed and cytokines were analysed by ELISA. 
From studies conducted in mouse models, we have shown that dendritic cells treated with 
FhTeg induce anergy in a mannose dependent manner and to investigate if this could be 
replicated with CD14
+
 cells, they were incubated with PBS or FhTeg overnight before 
being washed and co-cultured with CD4
+
 T-cells in a 1:10 ratio with plate bound anti-
CD3 (1μg/ml). Following a 72 hour culture cells were removed, washed and lysed for 
analysis of CTLA4 expression and supernatants were analysed for the production of IFN-
γ by ELISA.  
The effect of FhTeg on CD4
+
 cells was also investigated by stimulating cells for 2 hours 
with FhTeg (10μg/ml) and analysing the expression of CTLA4, RNF128 and EGR2. The 
modulatory capacity of these cells was also analysed by treating CD4
+
 cells with FhTeg 
(10μg/ml) for 24 hours before washing and co-culturing with CD14+ cells for a further 24 
hours. The CD14
+
 cells were then re-isolated and challenged with LPS (100ng/ml) for a 
further 24 hours, supernatants were collected and analysed for the production of TNF-α. 
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6.3. Results 
 
6.3.1. FhTeg binds to PBMCs and inhibits the production of TNF-α 
 
We have previously shown that FhTeg binds to dendritic cells generated from mouse but to 
our knowledge no studies have shown the effect of FhTeg on PBMCs. Cells were isolated 
from whole blood by gradient centrifugation and plated at 50,000 cells per well in a 96 well 
plate. Cells were treated with PBS, FITC labelled FhTeg (1, 5 and10 μg/ml) or FITC labelled 
BSA (10μg/ml) for 45 mins before the binding of FhTeg was analysed using flow cytometry. 
The binding of FhTeg to the whole PBMC population was measured. FhTeg binds 
significantly to PBMCs as a whole population (Figure 6.3.1 A-B) (P<0.01, P<0.0001), 
compared to BSA.  
FhTeg can inhibit cytokine production from dendritic cells from mouse which have been pre-
treated with FhTeg before being challenged with bacterial ligands (Hamilton et al. June 
2009). To investigate if FhTeg would have similar effects on human PBMCs, cells were 
stimulated with FhTeg (10μg/ml) 2.5 hours prior to the addition of LPS (100ng/ml) or PMA 
(20ng/ml) and Ionomycin (1mM). Brefaldin A was added to inhibit the excretion of cytokines 
to enable intracellular staining for TNF-α. The addition of FhTeg before LPS inhibited the 
production of TNF-α from both LPS and PMA/Ionomycin stimulated cells (Figure 6.3.1 C-
D).  
To investigate the modulatory capacity of FhTeg on cytokine secretion following an 
overnight stimulation, cells were stimulated with FhTeg (10μg/ml) for 2.5 hours before the 
addition of LPS (100ng/ml) or PMA (20ng/ml) and Ionomycin (1μg/ml) for 24 hours, 
supernatants were removed and analysed for TNF-α production by commercially available 
ELISA. Both LPS and PMA/Ionomycin significantly enhanced the production of TNF-α from 
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PBMCs (p<0.0001) but FhTeg significantly inhibited the production of TNF-α from both sets 
of cells (p<0.05, p<0.0001) (Figure 6.3.1 E-F).  
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Figure 6.3.1. FhTeg binds to human PBMCS and inhibits the production of TNF-α. A-B. FhTeg binds 
significantly to PBMCs as a whole population at 5μg/ml (p<0.01) and 10μg/ml (p<0.0001) compared to BSA. 
C-D. Both LPS and PMA/Ionomycin enhanced the production of TNF-α from PBMCs compared to PBS but the 
addition of FhTeg inhibited this using intra-cellular staining. E-F. Both LPS and PMA/Ionomycin significantly 
enhanced the production of TNF-α from PBMCs compared to PBS (p<0.0001) but FhTeg significantly inhibited 
this (p<0.05, p<0.0001). The data shown is the mean ±SD of four independent experiments, donor number n=4. 
Data analysed using one way anova. 
 
6.3.2. FhTeg does not inhibit the production of TNF-α from CD14+ cells 
 
As FhTeg targets multiple cell types in mouse including inhibiting dendritic cells (Hamilton 
et al. June 2009), mast cells (Vukman et al. 2013a) and macrophages, CD14
+
 cells were 
isolated from PBMCs and the ability of FhTeg to bind to CD14
+
 cells was investigated.  Cells 
were treated with PBS, FITC labelled FhTeg (1, 5 and10μg/ml) or FITC labelled BSA 
(10μg/ml) for 45 mins before the binding of FhTeg was analysed using flow cytometry. 
FhTeg significantly binds to CD14
+
 cells stimulated with 10μg of FITC-labelled FhTeg 
(p<0.01) (Figure 6.3.2 A) and binds significantly to a small percentage of less than 10% of 
cells at both 5 and 10μg/ml (Figure 6.3.2.B) (p<0.01).  
We have previously shown that FhTeg enhances the expression of SOCS3 in dendritic cells, 
to examine if FhTeg would induce SOCS3 in CD14
+
 cells; cells were isolated from PBMCs 
and stimulated with PBS or FhTeg (10μg/ml) for 2 hours. FhTeg significantly enhances the 
expression of SOCS3 (p<0.0001) (Figure 6.3.2 C). To examine cytokine responses from 
CD14
+
 cells following FhTeg stimulation, PBMCs were stimulated with FhTeg (10μg/ml) 2.5 
hours before the addition of LPS (100ng/ml), Brefaldin A was also added to enable 
intracellular staining. Following a 4 hour stimulation, cells were fixed, lysed and the levels of 
TNF-α were measured using flow cytometry. CD14+ cells gated on from a whole PBMC 
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population were inhibited following pre-incubation with FhTeg (Figure 6.3.2 D). To examine 
cytokine responses following a 24 hours stimulation, CD14
+
 cells were stimulated with PBS 
or FhTeg (10μg/ml) 2.5 hours before the addition of LPS (100ng/ml),  supernatants were 
removed from cells and the levels of TNF-α and IL-1β were measured. LPS induced 
significant levels of IL-1β (p<0.0001) but not TNF-α from CD14+ cells. FhTeg did not inhibit 
the production of either cytokine from CD14
+
 cells but significantly increased the production 
of TNF-α (p<0.01) and IL-1β (p<0.0001) from cells (Figure 6.3.3A-B).  
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Figure 6.3.2. FhTeg does not inhibit cytokine secretion from human CD14
+ 
cells. A-B. FhTeg significantly 
binds to a small percentage of CD14
+
 cells at 5 and 10μg compared to BSA (p<0.01). C. FhTeg significantly 
enhanced the production of SOCS3 (p<0.0001) from CD14
+
 cells compared to PBS. D. LPS enhances TNF-α 
production but FhTeg inhibits this from CD14
+
 cells when in the larger PBMC population. E-F. FhTeg 
significantly increased the production of TNF-α (p<0.001) and IL-1β (p<0.0001) compared to both PBS and 
LPS. The data is presented as the mean ±SD of three independent experiments, donor number n=3, **p<0.01, 
****p<0.0001. 
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6.3.3. FhTeg inhibits the production of cytokines from CD4+ T-cells 
 
FhTeg binds to PBMCs as a whole and to CD14
+
 cells. To investigate if FhTeg would bind to 
CD4
+ 
T-cells, PBMCs were and incubated with 1, 5 and 10μg of FITC-labelled FhTeg. CD4+ 
T-cells were gated on and the binding of FhTeg to the CD4
+
 population was measured. There 
was significant binding of FhTeg to CD4
+
 cells by both MFI and percentage of cells (p<0.01, 
P<0.0001) (Figure 6.3.3 A-B). FhTeg can inhibit the production of TNF-α from PBMCs as a 
whole population but not from CD14
+
 cells, to examine if FhTeg would inhibit CD4
+
 cells 
ability to produce cytokines,  CD4
+
 cells were isolated from PBMCs and stimulated with 
FhTeg (10μg/ml) 2.5 hours before the addition of PMA (20ng/ml) and Ionomycin (1mM). 72 
hours later supernatants were removed and analysed for the production of TNF-α and IL-2. 
PMA and Ionomycin induced significant levels of the two cytokines (p<0.0001), the addition 
of FhTeg significantly inhibited this, (Figure 6.3.3 C-D) (p<0.0001). 
 
.   
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Figure 6.3.3. FhTeg inhibits the production of cytokines from CD4+ cells.  A-B. FhTeg binds significantly 
to CD4
+
 T-cells at 5 and 10μg/ml (p<0.01, p<0.0001). C-D. PMA/Ionomycin stimulation significantly enhanced 
the production of TNF-α (p<0.0001) and IL-2 (p<0.0001) production compared to PBS but FhTeg significantly 
inhibited this (p<0.0001). The data is presented as the mean ±SD of three independent experiments, donor 
number n=3, **p<0.01, ****p<0.0001. Data analysed using one way anova. 
 
6.3.4. FhTeg induces genes relating to anergy in CD4+ T-cells  
 
CD4
+
 T-cells isolated from PBMCs were stimulated with PBS or FhTeg (10μg/ml) for two 
hours. Cells were then washed and RNA was isolated from cell pellets. The levels of CTLA4 
and RNF128 were measured. The level of both CTLA4 and RNF128 were significantly 
enhanced with a fold increase of 1.5 and 3.5 respectively (p<0.001, p<0.05). 
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Figure 6.3.4. FhTeg induces genes relating to anergy in CD4
+
 T-cells.  FhTeg significantly enhances the 
expression of both CTLA4 and RNF128 genes on CD4
+
 T-cells compared to PBS, p<0.001, p<0.05. The data 
shown is the mean ±SD of three independent experiments, donor number n=3. Data analysed using student t-
test. 
 
 
6.3.5.  FhTeg treated CD14+ cells do not negatively modulate CD4+ cells 
 
As FhTeg does not inhibit TNF-α or IL-1β production from CD14+ cells isolated from 
PBMCs, their ability to modulate CD4
+
 cells was investigated. CD14
+
 cells were isolated by 
positive selection from PBMCs and stimulated with PBS or FhTeg (10μg/ml) overnight. 
Cells were then washed twice and co-cultured in a 1:10 ratio with CD4
+
 cells from both the 
same and different donors with plate bound anti-CD3 (1μg/ml). Following a 72 hour 
stimulation, supernatants were removed and RNA was isolated from cell pellets. The levels 
of IFN-γ were measured using commercially available ELISA. CD14+ cells pre-treated with 
FhTeg do not inhibit the production of IFN-γ from CD4+ cells, isolated from either the same 
or different donors (Figure 6.3.5 A-B).  The levels of CTLA4 were measured in CD4
+
 cells 
following co-culture and there was no significant difference in the levels of CTLA4 in either 
group (Figure 6.3.5 C-D) 
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Figure 6.3.5. FhTeg treated CD14
+
 cells do not negatively modulate CD4+ cells. A-B. Co-culture of CD14
+
 
cells with CD4
+
 cells showed no significant differences in the levels of IFN-γ compared to PBS controls. In A, 
the same donor was used for both CD4 and CD14
+
 cells, in B a different donor was used for CD4
+
 and CD14
+
 
cells. C-D. No significant differences in the expression of CTLA4 were seen in either group compared to PBS 
controls. The data shown is the mean ±SD of three independent experiments, donor number n=3. 
6.3.6. FhTeg treated CD4+ cells modulate CD14+ cells and inhibit cytokine 
secretion upon re-stimulation with LPS 
 
CD14
+
 cells ability to produce TNF-α is inhibited while part of a larger PBMC population 
once pre-incubated with FhTeg but isolated CD14
+ 
cells are not inhibited by FhTeg upon LPS 
stimulation, these CD14
+
 cells also do not modulate CD4
+
 cells so the ability of CD4
+
 cells to 
modulate CD14
+ 
cells directly was investigated. CD4
+
 cells were stimulated with PBS or 
FhTeg (10μg/ml) overnight, washed and co-cultured with CD14+ cells in a 1:1 ratio for 24 
hours, CD14
+
 cells were then re-isolated and rested in fresh medium overnight before being 
re-challenged with LPS (100ng/ml). Supernatants were then removed after 24 hours and the 
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production of TNF-α was measured. FhTeg treated CD4+ cells significantly inhibited the 
production of TNF-α from CD14+ cells when re-stimulated with LPS (p<0.05). 
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Figure 6.3.6 FhTeg treated CD4+ cells modulate CD14+ cells and inhibit cytokine secretion upon re-
stimulation with LPS. Co-culture with FhTeg treated CD4
+
 cells significantly inhibited the production of TNF-
α from re-stimulated CD14+ cells, (p<0.05). The data shown is the mean ±SD of three independent experiments, 
donor number n=3. Data analysed using student t-test. 
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6.4. Discussion 
 
Helminth parasites infect up to a third of the worlds population, with the majority of these 
people in the developing world. Infection is rarely fatal but can lead to anaemia, weight loss 
and a susceptibility to bystander infections such as malaria. But infection with helminths can 
have advantages and studies are underway into whole worm therapy into multiple sclerosis 
and irritable bowel syndrome (Finlay, Walsh and Mills 2014) and studies are also ongoing 
into using helminths products as therapeutics in the treatment of MS (Zheng et al. 2008, 
Kuijk et al. 2012a), IBD, allergy, psoriasis and rheumatoid arthritis. (Heylen et al. 2014, 
Whary et al. 2001). To further advance these studies, the mechanism of immune modulation 
by helminths needs to be investigated. Here we showed how the tegumental antigens of F. 
hepatica interact with human PBMCs and modulate cytokine secretion and cell activation. 
 
We have previously shown in mouse studies that FhTeg binds to dendritic cells and to CD4
+
 
cells, here we have also shown that FhTeg can bind to PBMCs as a whole population and also 
to both CD14 and CD4
+
 cells. The effect of FhTeg on DC’s, macrophages and mast cells 
from mice has been well studied (Adams et al. 2014, Vukman et al. 2013b, Vukman et al. 
2013a, Vukman, Adams and O'Neill 2013). FhTeg inhibits dendritic cell maturation and 
cytokine secretion when challenged with bacterial ligands (Hamilton et al. June 2009) and 
here FhTeg inhibited TNF-α secretion from PBMCs as a whole population using both 
intracellular staining and ELISA to show the suppression.  
 
PBMCs consist of a number of cell types including monocytes and CD4
+ 
cells (Geissmann et 
al. 2010), we have shown that FhTeg induces the alternative activation of macrophages in 
 148 
 
vivo (Adams et al. 2014) and induces anergy in CD4
+
 cells both in vivo and in vitro. As 
FhTeg inhibited cytokine secretion in both PBMCs as a whole and from CD14
+
 cells intra-
cellular, we examined responses of both CD14 and CD4
+
 cells to FhTeg. Interestingly, 
CD14
+
 cells were not inhibited by pre-treatment with FhTeg, their production of TNF-α and 
IL-1β was enhanced, whereas CD4+ cells were inhibited upon pre-treatment with FhTeg with 
significantly less cytokines produced in response to PMA and Ionomycin activation. The 
response of PBMCs to F. hepatica tegumental antigens in experimental infections of cattle 
showed a loss of proliferation and IL-2 production from the fifth week of infection and the 
authors concluded that this was not due to the macrophage population (Oldham and Williams 
1985).  Other studies in helminth infections have shown roles for CD14
+
 cells, in lymphatic 
filariasis, CD14
+
 cells isolated from control and infected individuals showed markedly 
different responses, cells isolated from control and endemic normal patients showed an 
increase in IL-1β when cells were re-challenged with LPS but cells from infected patients 
showed a decrease in IL-1B production and inhibited the adherence of CD14
+ 
monocytes 
compared to controls (Sasisekhar et al. 2004). Further studies would need to be completed to 
investigate the effects of F. hepatica infection on monocytes in vivo.  
 
 
We have shown previously that FhTeg treated dendritic cells can induce anergy in CD4
+
 
cells, inhibiting cytokine secretion and inducing RNF128 and CTLA4 in cells. Macrophages 
isolated from FhTeg injected mice also inhibit cytokine responses from CD4
+
 cells (Adams et 
al. 2014). The inhibitory capacity of FhTeg treated CD14
+
 was measured by co-culturing 
with CD4
+
 cells isolated from the same or a mismatched donor. The secretion of IFN-γ was 
unchanged in both PBS and FhTeg treated cells and neither group had a significantly higher 
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level of CTLA4 expression. This may point towards the CD4
+
 cells population playing a role 
in cytokine suppression seen in PBMCs as a whole and not CD14
+
 cells. 
 
The suppression of CD4
+
 cells cytokine secretion is similar to results we have previously 
shown in mouse studies. To investigate if FhTeg could induce anergy directly in CD4
+
 cells 
isolated from PBMCs, cells were stimulated with FhTeg directly and the levels of CTLA4 
and RNF128 were measured and showed an increase for both genes. CTLA4 is a receptor 
found on the surface of T-cells which binds its ligands CD80 and CD86 on APCs (Linsley et 
al.). Signalling through CTLA4 induces negative regulators including SHP1/2 which inhibit 
CD28 and TCR co-signalling and IL-2 production (Greenwald et al. 2001). RNF128 is also 
involved in anergy induction (Seroogy et al. 2004). A loss of IL-2 production leads to no 
phosphorylation of Akt and activation of mTOR. This leads to subsequent GRAIL expression 
inhibiting proliferation (Whiting et al. 2011). Studies investigating lymphocyte responses 
from Brugia malayi infected individuals show an impairment in cytokine secretion and an 
increase in anergy factors such as CblB and ITCH (Babu et al. 2006) and studies using ES-62 
from filarial nematodes induced anergy in Jurkatt T-cells via the TCR receptor (Harnett et al. 
1998) but to our knowledge this is the first study to show that F. hepatica tegumental 
antigens can directly induce anergy in CD4
+
 T-cells isolated from PBMCs without prior 
priming of cells in vivo by infection. 
 
As FhTeg inhibits cytokine secretion from CD14
+
 cells when they are in the whole PBMC 
population but not when isolated as a single population, and they do not inhibit T-cell 
responses from CD4
+
 cells, we investigated if it was the CD4
+
 population modulating the 
CD14
+
 cells. CD4
+
 cells were stimulated with PBS or FhTeg overnight before co-culturing 
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with CD14
+
 cells for a further 24 hours. CD14
+ 
cells were then re-isolated and re-challenged 
with LPS to see if the CD4
+
 cells had inhibited their ability to produce TNF-α. Interestingly, 
following culture with FhTeg CD4
+
 cells, CD14
+
 cells ability to produce TNF-α was 
significantly inhibited. T-cells have been shown to modulate APCs, in previous studies T-reg 
cells down-regulate co-stimulatory markers on APCS and inhibited their ability to present 
antigen successfully to naive CD4
+
 T-cells (Cederbom, Hall and Ivars 2000, Misra et al. 
2004, Tadokoro et al. 2006, Oderup et al. 2006). Anergic CD4
+
 cells have also been shown to 
modulate APCS by affecting their ability to present antigens or by inducing apoptosis in 
DC’s. The effect of FhTeg on CD4+ cells is important as there are a number of diseases 
which are T-cell mediated and FhTeg or molecules isolated from it may be used as 
therapeutics in the treatment of these conditions.   
 
Graft versus host disease is a complication encountered following an allogenic transplant, 
usually of bone marrow or stem-cells. T-cells which are present in the transplanted graft 
recognise the hosts tissues and cells as antigens and mount an immune response. This can 
lead to damage to liver, skin and can cause vomiting, diarrhoea and severe abdominal pain 
(Przepiorka et al. 1995). The engraftment of donor T-cells is needed for most transplants to 
be successful, this is to prevent host versus graft occurring and it can also be beneficial for 
some cancer treatments as the donor T-cells can have an anti-tumour effect (Ringdén et al. 
2009). Using helminths products may be helpful in the treatment of cases of GVHD as in the 
case of FhTeg, it would target the whole PBMC population through the donor CD4
+
 cells and 
may reduce the occurrence and severity of the disease. Some studies have shown that 
helminths can be protective in GVHD, studies using Heligmosomoides polygyrus showed that 
infection reduced GVHD related mortality and inflammatory cytokine secretion while also 
maintaining graft versus tumour (Li et al. 2015). Studies with our collaborators have shown a 
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reduction in weight loss and disease score in GVHD once donor PBMCs were pre-treated 
with FhTeg before given to mice compared to mice which received PBMCs alone (see 
appendix 9.4). The mechanism of FhTeg in preventing GVHD seems to be by stopping donor 
CD4
+
 cells from engrafting in the host which would not be favourable for the treatment of 
GVHD as donor CD4+ T-cells are needed to stop the hosts CD4
+
 T-cells from attacking the 
graft; but points towards FhTeg possibly being useful in cases like organ transplantation. 
 
This study is the first to show the modulatory effects of F. hepaticas tegumental antigens on 
human PBMCs. FhTeg inhibits the secretion of TNF-α from PBMCs as a whole population 
and from CD4
+
 cells but not from CD14
+
 cells. The FhTeg treated CD14
+
 cells also do not 
negatively regulate CD4
+
 cells, with no inhibition of IFN-γ or enhancement of CTLA4. 
FhTeg modulates PBMCs by targeting CD4
+
 cells with an increase in the expression of the 
negative regulators CTLA4 and RNF128 and these cells can negatively regulate CD14
+
 cells 
by inhibiting their ability to secrete TNF-α following re-challenge with LPS. This study will 
help further our understanding of how F. hepatica modulates the immune system and how it 
may be used as a therapeutic in the future. 
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7. Chapter 7- Final Discussion  
This study sheds new light on the immune-modulatory role of Fasciola hepatica infection 
and its tegumental antigens on both dendritic cells and CD4
+
 T-cells from both mouse and 
human PBMCs. The study has shown a number of novel findings including characterisation 
of the T-cell responses during infection as anergic and following injection of FhTeg. The 
effect of FhTeg on dendritic cells is independent of the mannose receptor and the effect of 
FhTeg on CD4
+
 T-cells from both mouse and human origin. The following discussion will 
highlight key findings from the study and discuss future studies which are required. 
 
7.1. F. hepatica induces anergy in CD4+ T-cells following infection and injection of 
FhTeg 
T-cells are crucial players in both the innate and adaptive immune response. Once they 
recognise antigens being presented by APCs through MHC class I and II along with 
environment factors, they can differentiate into a number of subsets including Th1, Th2, 
T-reg and anergic to name a few (Adam, Schweitzer and Sharpe 1998, Gamper and 
Powell 2010). Th1 cells are characterised by the production of inflammatory cytokines, 
IFN-γ and TNF-α and drive inflammation, whereas Th2 cells produce anti-inflammatory 
cytokines such as IL-5 and IL-4. T-reg’s “turn off” or dampen the immune response by 
producing cytokines like IL-10 and TGF-β but anergic cells do not produce any cytokines 
or proliferate upon re-stimulation but are still key mediators in self-versus non-self-
recognition and help to control auto-immunity (Schwartz 2005, Sakaguchi 2004). 
 
 During helminth infections, T-reg cells are the most prominent response observed. 
Studies using Brugia malayi have shown T-reg cells to express enhanced FoxP3 and 
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increased cell surface expression of CTLA4, a negative regulator of T-cell function 
(McSorley et al. 2008). Another helminth, Schistosoma haematobium has also been 
associated with T-reg cells (Nausch et al. 2011). Helminth infections are also associated 
with anergic T-cells that are most commonly associated with chronic infection which may 
be due to the persistence of parasite antigen and the constant contact of the cells with the 
antigens.  During S. mansoni  infection, anergy is the main T-cell response seen, mediated 
by the up-regulation of PD-L1 on the surface of macrophages (Smith et al. 2004) and 
RNF128 (GRAIL) in T-cells isolated from chronic infection. Here they show that T-cell 
anergy following chronic infection is driven by RNF128 expression (Taylor et al. 2009). 
This demonstrates that during F.hepatica infection, T-cell anergy is the main T-cell 
response observed with the rescue of cytokine secretion with IL-2 and the up-regulation 
of a number of genes involved in anergy induction and maintenance like RNF128, CblB 
and ITCH and no enhancement of FoxP3, IL-10 or TGF-β. Further studies would need to 
be carried out to investigate if T-cell anergy is observed in natural models of infection in 
sheep/cattle or in patient samples from endemic areas of infection. 
 
 
Fasciola hepatica has two main sources of antigen, its excretory/secretory molecules 
(FhES), which it releases constantly which consists of mostly enzymes, and its 
tegumental antigens. FhTeg is a complex mix of glycoproteins and is in constant contact 
with the hosts’ immune cells. We have previously shown that injection of FhTeg into the 
peritoneal cavity of mice mimics infection by recruiting mast cells and indirectly inducing 
alternative activation of macrophages (Adams et al. 2014, Vukman et al. 2013a). Here we 
have shown that injecting FhTeg over the sternum also induces anergy with an increase in 
PD1 and RNF128 seen in splenocytes and a reversal of cytokine suppression with IL-2. 
 154 
 
FhTeg was also injected into the peritoneal cavity and anergy was also seen, although the 
response was not as strong as seen with infection or after injection over the sternum 
(Appendix A). The effect of FhTeg differs to that of FhES (Figure 7.1), the injection of 
FhES into the peritoneal cavity induces the alternative activation of macrophages and this 
can be mimicked by thioredoxin peroxidase, this also resulted in the alternative activation 
of Raw 264.7 macrophages with high levels of IL-10 and PGE2 (Donnelly et al. 2005) 
and another component of FhES,  peroxiredoxin, also induced alternative activation of 
macrophages (Donnelly et al. 2008). The injection of FhES also recruits mast cells to the 
peritoneal cavity as does FhTeg but the response to FhTeg was significantly higher than 
FhES (Vukman et al. 2013a). We know from proteomic studies that there antigen sources 
vary hugely in the antigenic make-up while much is published on FhES further studies are 
required to identify what are the bioactive molecules that drive anergy.  
 
Figure 7.1. The difference between FhES and FhTeg on immune cells.  FhES and FhTeg differ in their 
actions on immune cells. Both FhES and FhTeg induce M2-like macrophages with Arg expression 
enhanced but differ in cytokine expression, FhES induces IL-10, PGE2 and TGF-β but FhTeg does not. 
FhTeg also induces the expression of RELMα but FhTeg does not. The action of FhTeg differs to FhTeg as 
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FhTeg induces an MR high and SOCS3 high population. The effect of FhES has yet to be determined on 
mast cells.  
 
7.2. FhTeg induces a novel dendritic cell population  
 
We have previously shown that dendritic cells when treated with FhTeg do not respond to 
LPS stimulation, with a decrease in both IL-12p70 and TNF-α production and no 
enhancement of co-stimulatory markers (Hamilton et al. June 2009). These dendritic cells 
remain immature despite LPS stimulation. Here we have further investigated the 
mechanism of action of FhTeg on dendritic cells generated from bone marrow. Following 
FhTeg stimulation, DC’s have an enhancement of the expression of the mannose receptor 
high and a decrease in CD11c expression. Other studies have also shown a change in 
expression of CD11c following interaction with helminth antigens. During H. polygyrus 
infection, a change in CD11c expression in dendritic cells was observed (Smith et al. 
2011). We have shown that FhTeg is rich in high mannose glycans (manuscript in prep). 
As MR is enhanced following FhTeg stimulation, the binding efficiency of FhTeg was 
examined after pre-treatment with a number of sugars and antibodies which would bind 
both MR and MGL. Pre-incubation with anti-MR, mannan and GalNAc-4-Sulphate 
significantly inhibited the binding of FhTeg to DC’s and this was also in a calcium 
dependent manner as EDTA also inhibited the binding of FhTeg but using sugars for 
MGL, GalNAc and anti-MGL the binding could not be inhibited. 
 
To investigate if inhibiting binding of FhTeg to DC’s using mannan and GalNAc-4-
Sulphate would reverse the effect of FhTeg, both inhibiters were used and the levels of 
SOCS3 and IL-12p70 were measured. GalNAc-4-Sulphate inhibited the enhancement of 
SOCS3 in DC’s but mannan did not, interestingly GalNAc-4-Sulphate did not reverse IL-
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12p70 suppression but Mannan did. Mannan is a simple polysaccharide which is isolated 
from Saccharomyces cerevisiae. It has binding specificities for MR but also any other 
high mannose binding receptors which include SIGNR1 and Dectin 2. MR has been 
shown to be involved in the induction of negative signalling pathways following helminth 
infection, studies with products excreted/secreted by Taenia crassiceps triggered cRAF 
phosphorylation through MGL, MR, and TLR2 (Terrazas et al. 2013) also during S. 
mansoni infection MR has been shown to play a role in IFN-γ production (Paveley et al. 
2011).  To confirm that MR had a role to play in the signalling response seen after FhTeg 
treatment, MR knockout mice were used. The knocking out of MR did not have any 
significant effect on the induction of SOCS3 or IL-12p70 production but did have an 
effect on binding. FhTeg is a complex mix of over 70 proteins, many of which are 
glycoproteins so the signalling may not be due to one CTR, it may be due to a number of 
receptors working together. It may not be possible to find one receptor which FhTeg may 
bind through. Further studies would need to be completed to find bioactive components of 
FhTeg and what receptors they may signal through, rather than looking at FhTeg as a 
whole. Other studies also need to be carried out on other high mannose binding receptors 
such as SIGN-R1, as FhTeg is mannose rich to fully understand the mechanism of action 
of FhTeg on DC’s.  
 
7.3. C-type lectin receptors influence CD4+ T-cell differentiation  
To prime an effective immune response, crosstalk must occur between different cell 
types. This can be in the form of cell to cell contact or via soluble mediators released 
from cells. The communication between dendritic cells and CD4
+
 cells is crucial in 
initiating a response against antigens. Generally dendritic cells encounter antigens and 
present them to CD4
+
 cells on MHC class I or II molecules and also use secondary signals 
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like binding of the ligands CD80 or 86 to their respective receptors. This along with 
cytokines released can push CD4
+
 cells towards a number of different subsets including 
Th1, Th2, Th17 or T-reg (Yamane and Paul 2013).  
 
We have previously shown that mast cells treated with FhTeg and co-cultured with CD4
+ 
cells, impair their ability to produce cytokines and this is due to signalling through 
ICAM1 (Vukman et al. 2013b), macrophages isolated following injection of FhTeg also 
impair CD4
+ 
cells ability to produce cytokines (Adams et al. 2014). Dendritic cells treated 
with FhTeg and LPS produce significantly less IL-12p70 and TNF-α than with LPS 
alone, and these cells drive T-cell anergy by a reduction in IL-2, IL-5, IL-4 and IFN-γ 
production and an enhancement of the expression of RNF128 and CTLA4 in CD4
+ 
cells 
following co-culture. DC’s have been implicated in driving anergy as DC’s isolated from 
children with severe malnutrition and endotoxemia were found to be anergic and inhibited 
T-cell proliferation (Hughes et al. 2009) but most studies have focused on immature DC’s 
driving anergy, studies using BMDC’s cultured in GM-CSF with high levels of LPS 
induced anergy in vitro (Lutz et al. 2000). Further studies are required to investigate if 
dendritic cells isolated from F. hepatica infected mice would induce anergy in naive 
CD4
+
 cells.  
 
The induction of anergy by FhTeg treated DC’s was also found to be in an MR dependent 
manner as DC’s generated from MR knockout mice inhibited the induction of anergy 
(Figure 7.1). MR is a type-I membrane protein with a cytoplasmic domain involved in 
antigen processing and receptor internalisation and three different types of binding 
domains at its extracellular region (Martinez-Pomares 2012). Most studies on MR have 
focused on its ability as an antigen recognition receptor but few have looked at its ability 
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to promote immune responses through communication with its counter ligand or receptor 
CD45, (Marti´nez-Pomares et al. 1999) which has numerous roles in T-cell development 
and is both a positive and negative regulator of T-cell function (Saunders and Johnson 
2010). Studies examining if engagement of CD45 by MR is responsible for inducing 
anergy in CD4
+
 cells would need to be performed. Preliminary results have shown that 
using a blocking anti-body for CD45 inhibited the cells ability to produce cytokines and 
had a significant decrease in the expression of CTLA4 and RNF128 in controls 
(Appendix B), further investigation is needed to examine this further as studies using 
silencing RNA or studies in CD45 knockout mice may give us further insights into how 
MR modulates CD4
+
 cells through DCs. 
 
 
Figure 7.2 Mechanism by which MR expression influences CD4+ cells differentiation.  Dendritic cells 
treated with FhTeg have an enhanced expression of MR, and subsequent co-culture with CD4
+
 cells induces 
anergy with an increase in RNF128, CTLA4 and a decrease in production of IL-5, IL-2, IL-4 and IFN-γ. The 
loss of MR inhibits the induction of anergy. 
 159 
 
 
7.4. FhTeg induces anergy directly in CD4+ T-cells 
 
Studies on the effects of FhTeg on immune cells have mostly concentrated on its effects 
on dendritic cells (Vukman, Adams and O'Neill 2013, Hamilton et al. June 2009), 
macrophages (Adams et al. 2014) and mast cells (Vukman et al. 2013b, Vukman et al. 
2013a) and their subsequent effects on CD4
+
 cells, but to our knowledge no studies have 
been completed on the effect of FhTeg on CD4
+
 cells directly. In general, activation of 
CD4
+
 cells requires three signals, signal one from antigen presenting cells and this 
includes presentation of peptides through MHC class II, signal two via co-stimulatory 
molecules and signal three either inflammatory or anti-inflammatory cytokines. These 
signals influence the differentiation of naïve CD4
+
 cells into different subsets such as 
Th1, Th2, Th17, T-regs or anergic T-cells (Yamane and Paul 2013). Following this, most 
CD4
+
 cells proliferate and produce cytokines which can further help other cells to 
differentiate and to mount an immune response. 
 
There are instances where CD4
+
 cells can be directly influenced to differentiate without 
the help of an APC. Studies using super-antigens have found that binding of the antigen 
directly to the TCR can induce negative signalling pathways in memory cells; this is used 
by pathogens as a defence mechanism to the hosts’ immune response (Watson, Mittler 
and Lee 2003). Binding of the super-antigen to the TCR and to MHC II receptors on an 
APC simultaneously can also cause non-specific activation of T-cell, causing 
uncontrolled proliferation and production of cytokines. Following this a number of cells 
undergo apoptosis and the remaining cells are functionally unresponsive (Seth et al. 
1994).  
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Here we have shown that FhTeg has a direct effect on CD4
+ 
cells, inducing an anergic 
like cell with the up-regulation of CblB, EGR2 and 3, ITCH and RNF128, FhTeg also 
inhibits the production of cytokines. These genes were also enhanced during infection and 
following injection of FhTeg. The ability of FhTeg to directly interact with CD4
+
 cells 
may be important in understanding how F.hepatica modulates the hosts’ immune 
response. FhES is another antigen secreted by F.hepatica; it would be interesting to 
examine the effect it would have on CD4
+
 cells directly. Other studies have shown that 
FhES inhibits the proliferation of sheep PBMCs and down-regulates the expression of 
CD4 on T-cells, this was found to be due in part to the action of cathepsin L cleaving the 
CD4 receptor, further studies to examine its action on CD4
+
 cells are required (Prowse et 
al. 2002).  
 
To understand the mechanism by which FhTeg induces anergy in CD4
+
 cells, the 
presence of MR on CD4
+
 cells was investigated. Although MR was found to be expressed 
on CD4
+
 cells, knocking out the receptor did not reverse the suppressive effect of FhTeg. 
Studies on CLRs mainly focus on APCs like dendritic cells and macrophages, further 
studies would need to be completed to investigate other possible receptors which may be 
on CD4
+
 cells and which may be contributing to the induction of anergy or other possible 
mechanisms such as FhTeg binding to the TCR receptor and inducing signal one alone to 
T-cells and inducing anergy. 
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7.5. FhTeg modulates human PBMCs via CD4+ T-cells 
 
Helminth infections affects up to a third of the world’s population with a high percentage 
of those affected in the developing world. Infection is rarely fatal but can lead to anaemia, 
weight loss and a susceptibility to bystander infections (Hotez et al. 2008).  Studies using 
FhTeg and its immune-modulatory role have mainly focused on its interactions with cells 
from murine origin; here we investigated the effect of FhTeg on different cell types 
isolated from PBMCs and on PBMCs as a whole population. In our mouse studies, 
dendritic cells stimulated with FhTeg before being challenged with LPS produced 
significantly lower levels of IL-12p70 and TNF-α than cells which had received LPS 
alone (Hamilton et al. June 2009), it also inhibits mast cells ability to drive Th1 responses 
(Vukman et al. 2013b) and in chapter 5 we showed that FhTeg inhibits the PMA and anti-
CD3 activation of CD4
+
 cells directly from naive mice. Here we show that FhTeg inhibits 
the LPS and PMA/Ionomycin activation of PBMCs, with an inhibition of TNF-α 
production.  
 
As PBMCs consist of a wide range of cell types including, CD4
+
 lymphocytes and CD14
+
 
monocytes, the effect of FhTeg on both cell types was investigated. CD14
+
 is expressed 
mainly by a subset of monocytes, but it can also be expressed by dendritic cells and is 
involved in the binding of LPS (Schütt 1999).  Studies involving lymphatic filariasis have 
shown CD14
+
 cells isolated from control and endemic normal patients showed an 
increase in IL-1β when cells were re-challenged with LPS but cells from infected patients 
showed a decrease in IL-1β production.  The adherence of CD14+ monocytes compared to 
controls was also inhibited (Sasisekhar et al. 2004). Here we have shown that FhTeg does 
not inhibit CD14
+
 cells ability to produce TNF-α or IL-1β, but it did inhibit CD4+ cells 
ability to produce TNF-α, IL-2 and enhanced the expression of CTLA4 and RNF128.  
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FhTeg negatively regulated PBMCs as a whole population but not CD14
+
 cells, we have 
previously shown that dendritic cells treated with FhTeg induces anergy in CD4
+
 cells 
and macrophages isolated from the peritoneal cavity of mice injected with FhTeg impair 
CD4
+
 cells (Adams et al. 2014). CD14
+
 cells do not induce CTLA4 in CD4
+
 cells isolated 
from the same donor or impair their ability to produce IFN-γ. The ability of FhTeg treated 
CD4
+
 cells to modulate CD14
+
 cells was examined and they impair the cells ability to 
produce TNF-α when re-challenged with LPS. This result may lead to FhTeg being used 
as a possible therapeutic for a number of CD4
+ 
mediated diseases. Studies are ongoing 
into the treatment of a number of conditions with helminths molecules, studies on MS 
(Zheng et al. 2008, Kuijk et al. 2012a) , IBD, allergy, psoriasis and rheumatoid arthritis. 
(Heylen et al. 2014, Whary et al. 2001) are all ongoing.   
 
Another CD4
+
 cell mediated disease is graft versus host disease; GVHD is a condition 
which occurs after an allogenic transplant. T-cells which are present in the transplanted 
graph recognise the hosts tissues and cells as foreign and mount an immune response. 
This can lead to damage to organs and can cause vomiting, diarrhoea and severe 
abdominal pain (Przepiorka et al. 1995). The engraftment of donor T-cells is needed for 
most transplants to be successful, this is to prevent host versus graft occurring and to 
ensure graft rejection is not seen and so finding ways to combat both GVHD and HVGD 
and to extend transplant longevity is important. Some treatments to prevent GVHD are 
pharmacological agents but these require long term use and suppress the immune system, 
leaving patients with compromised immunity. Other areas under investigation are trying 
to induce T-cell anergy or T-reg cells that have impaired responses to host cells only and 
do not impair other T-cell responses. A study inducing GVHD in control and 
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Heligmosomoides polygyrus infected animals showed that infection suppressed recipient 
T-cell inflammatory responses and inhibited GVHD (Li et al. 2015), this study used 
infection as a source of antigen and only was successful when host T-reg cells were 
generated, this may not always be possible as using whole worm treatment may not 
always be a viable option.  
 
Work completed by our collaborators to investigate if FhTeg could be used to prevent 
GVHD has shown that mice which received PBMCs alone developed GVHD but pre-
treatment of PBMCs significantly prolonged survival and lowered the pathological score 
of GVHD (Appendix D). Although this is promising as a treatment for GVHD, the study 
showed that FhTeg impaired the donor cells engraftment and this would be needed for the 
impairment of recipient cells, and so would not be suitable as a possible treatment. It 
would be interesting to see what role FhTeg would play in a model of organ transplant 
such as a skin transplant, as FhTeg may prevent the rejection of the graft. 
 
Studies using mouse models have given great insight into mechanisms of helminth 
infections and other models of disease. Although we have gained knowledge using mouse 
models, there are differences between mice and human immune systems. Studies have 
shown that generally mice show similar results to human studies and genomic studies 
have shown approximately 300 unique genes for one species or the other (Initial 
sequencing and comparative analysis of the mouse genome. 2002).   Experimental 
autoimmune (allergic) encephalomyelitis (EAE) is a widely used model for MS in mice. 
This mimics the demyelination seen in central and peripheral nerves in MS. Studies using 
this model in mice showed promising results using IFN-γ and a decrease in symptoms and 
using blocking antibodies to IFN-γ exacerbated the disease.  Translating this to human 
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models, the addition of IFN-γ to human patients exacerbated the disease and trials had to 
be stopped (Panitch et al. 1987). Mouse models are also generally conducted in pathogen 
free areas and as such do not mimic the everyday pathogens that humans would encounter 
which could also alter trials. Further work needs to be carried out to investigate if what 
we see in mouse models of infection, injection and in vitro is comparable with what is 
seen naturally in sheep, cattle and humans. 
 
7.6. Final Conclusion  
 
This thesis has presented novel mechanisms by which F. hepatica modulates the host 
immune response both during infection and by its tegumental antigens.  It has also shown 
how CD4
+
 T-cells play a role in modulating other cells and how this may impact on 
investigations into new therapies using helminths molecules. From these studies, it is hoped 
additional investigations will be carried out to further our knowledge on how F. hepatica 
modifies cells of the immune system to survive within the host and on how its tegumental 
antigens may be used as therapeutics or vaccines. 
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9. Appendix 
 
9.1. Appendix A. Injection of FhTeg into the peritoneal cavity induces anergy 
 
We have previously shown that FhTeg injected into the peritoneal cavity recruits mast cells 
and macrophages (Adams et al. 2014, Vukman et al. 2013a). To investigate if FhTeg would 
mimic infection and induce anergy, PBS or FhTeg (10μg in 100μl) was injected three times a 
week for three weeks. Splenocytes were re-stimulated with PBS or FhTeg (10μg/ml) in the 
presence or absence of IL-2 or PMA (20ng/ml) and anti-CD3 (10μg/ml). Following a 72 hour 
stimulation, supernatants were removed and the levels of IL-5, IL-4 and IFN-γ were 
measured using ELISA. No significant levels of IL-5 were produced in controls, but 
significant levels of IL-4 and IFN-γ were produced (Figure 9.1 A-C)(p<0.0001). FhTeg 
induced significant levels of IL-5 but not IL-4 or IFN-γ in splenocytes isolated from injected 
mice (p<0.01) (Figure 9.1A-C). The addition of IL-2 significantly reversed the levels of IL-5 
and IL-4 but not IFN-γ, (Figure 9.1 A-C) (p<0.0001). RNA was also isolated from 
splenocytes and a qPCR array was performed to look for genes relating to anergy. Table 9.1 
summarises the fold changes, 
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Table 9.1 Fold changes seen in splenocytes isolated from FhTeg injection compared to controls 
 
 
 
 
 
 
 
 
The injection of FhTeg did induce small fold changes in expression of genes that were seen to 
be highly expressed during infection but they were much smaller changes. The injection of 
FhTeg into the sternum to mimic infection is not a good method, injection over the sternum 
gives a higher response. 
 
Gene Name Fold Change 
CTLA4 1.84 
EGR2 1.68 
FoxP3 1.52 
ICOS 1.54 
ITCH 1.21 
RNF128 1.88 
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Figure 9.1 Injection of FhTeg into the peritoneal cavity induces anergy. PBS or FhTeg was injected into the 
peritoneal cavity three times a week for three weeks, splenocytes were isolated and re-stimulated with PBS or 
FhTeg (10μg/ml) with or without IL-2 (20ng/ml) or PMA (20ng/ml) and anti-CD3 (10μg/ml).A-C. Supernatants 
were analysed for the presence of IL-5, IL-4 and IFN-γ. D. A qPCR gene array shows the difference in gene 
expression in splenocyres. The data shown is the mean ±SD of four independent experiments,  (**p<0.01, 
****p<0.0001). 
 
 
9.2. Appendix B. Anti-CD45 inhibits CD4+ cells ability to produce cytokines 
 
BMDCs generated from mannose receptor knockout mice fail to induce anergy in CD4
+
 cells 
by inhibiting IL-2 suppression and RNF128 and CTLA4 enhancement. MR has been shown 
to bind to CD45 on T-cells (Marti´nez-Pomares et al. 1999), to investigate if blocking CD45 
would have any effect on anergy induction, CD4
+
 cells were incubated with PBS or anti-
CD45 (10μg/ml) for 30 mins before being washed and co-cultured with anti-CD3 (1μg/ml) 
and  dendritic cells which had been cultured with PBS or FhTeg over night . Following a 72 
hour stimulation, supernatants were removed and analysed for the production of IL-5 and 
IFN-γ and RNA was extracted from cells and the level of RNF128 was measured using 
qPCR. Cells which received anti-CD45 blocking anti-body and were subsequently cultured 
with PBS treated cells produced significantly less IL-5 and IFN-γ than controls (Figure 9.2 
A-B) (p<0.0001), FhTeg treated cells produced significantly higher levels of IL-5 and IFN-γ 
than PBS cells (Figure 9.2 A-B) (p<0.01, p<0.0001). 
 
The level of RNF128 was measured and compared to PBS control cells which had received 
no anti-CD45, the levels of RNF128 in anti-CD45 treated cells was significantly lower than 
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in untreated PBS controls (Figure 9.2 C) (p<0.0001). Anti-CD45 is involved in both positive 
and negative regulation of CD4
+
 cells function (Saunders and Johnson 2010), the blocking 
antibody may have inhibited normal crosstalk between DC’s and CD4+ cells, it also could 
have triggered negative signalling pathways by binding the receptor. Further studies would 
need to be completed to investigate this further. 
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Figure 9.2 Anti-CD45 inhibits CD4
+
 cells ability to produce cytokines. CD4
+
 cells were cultured with anti-
CD45 antibody (10μg/ml) before being washed and co-cultured with anti-CD3 (1μg/ml) and dendritic cells 
stimulated with either PBS or FhTeg. Following a 72 hour co-culture, supernatants were removed and analysed 
for the production if IL-5 and IFN-γ, the levels of RNF128 was also measured using qPCR. The data shown is 
the mean ± SD of one independent experiment, (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001). 
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9.3. Appendix C. FhTeg enhances the expression of genes relating to anergy from 1 
hour stimulation but not at earlier time points. 
 
To investigate if FhTeg would induce genes relating to anergy at an earlier time point than 
two hours, CD4
+
 cells were stimulated with PBS or FhTeg (10μg/ml) for 30 mins and 1 hour. 
RNA was isolated from cell pellets and qPCR was used to determine the expression of  
EGR2, 3 and RNF128. FhTeg did not induce EGR2, 3 or RNF128 following a 30 min 
stimulation (Figure 9.3 A,C,E ) but all genes were significantly enhanced following a 1 hour 
stimulation (Figure 9.3 B,D,F) (p<0.05, p<0.001). 
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Figure 9.3. FhTeg enhances the expression of genes relating to anergy from 1 hour stimulation but not at 
earlier time points.  CD4
+
 cells were stimulated with PBS or FhTeg for 30 mins or 1 hour and the levels of 
EGR2,3 and RNF128 were measured using qPCR. FhTeg does not induce any gene following a 30 min 
stimulation but significatly enhances all genes following a 1 hour stimulation. The data shown is the mean ±SD 
of one independent experiment. (*p<0.05, **p<0.01). 
 
 
9.4. Appendix D. FhTeg is protective against GVHD  
 
To investigate if FhTeg would be protective in a humanised model of graft versus host 
disease, PBMCs were isolated from whole blood and stimulated over night with FhTeg 
(10μg/ml). The PBMCs were then injected into the tail vein of whole body irradiated 
humanised NSG mice. As controls, mice received PBMCs which had been stimulated with 
PBS and a group received PBS only. The mice were monitored over a period of one month 
for signs of GVHD which included weight changes and dermatitis. Animals which received 
PBS treated PBMCs had a significantly higher loss of body weight up to 15 days post-
transplant (p<0.05, p<0.01, p<0.001) and had a higher pathological score for the entire study 
compared to FhTeg treated PBMCs. FhTeg also prolonged the survival of recipients 
compared to PBS treated PBMCs (p<0.001). PBS controls had no significant changes in body 
weight or pathological score (Figure 9.4 A-C).  
High levels of TNF-α in serum of patients is a maker of GVHD {{550 Korngold,Robert 
2003}}, to investigate if FhTeg would reduce the levels of TNF-α, serum from mice from 
controls and FhTeg treated PBMCs were measured for TNF-α production. Mice which 
received PBS alone had no significant levels of TNF-α, mice which had received PBMCs 
treated with PBS had significant levels of TNF-α and FhTeg significantly suppressed this 
(Figure 9.4 D) (p<0.01). 
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Figure 9.4. Fh-Teg PBMC significantly prolonged survival and reduced pathological score in GvHD mice.  
PBS control mice are represented by diagonally lined bars, mice which received PBMC are represented by white 
bars and mice which received Fh-Teg PBMC are represented by black bars. Statistical significance was 
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determined using student t test where * < 0.05, ** < 0.005 and *** < 0.001. n=5, n=18 for PBMC, n=21 for Fh-
Teg PBMC. 
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http://www.malariajournal.com/content/12/1/5Background
Plasmodium falciparum malaria accounts for approxi-
mately 250–300 billion clinical cases of malaria world-
wide and is highly endemic in Africa [1]. Approximately
one in every five child deaths in Africa are due to mal-
aria with the risk of cerebral malaria being highest in
children aged two to four years. Natural acquired im-
munity rarely occurs before two years and its develop-
ment is associated with increasing age, which correlates
with a reduction in mortality rates due to the more se-
vere forms of P. falciparum infection [2]. It is, therefore,
important that immune responses in young children are
examined in order to further define immunological asso-
ciation with P. falciparum infection.
Malaria infection is predominantly characterized by a
T helper 1 (Th1) response and the production of pro-
inflammatory cytokines such as IL-12-p70, interferon
gamma (IFN-γ) and tumour necrosis factor (TNF).
These inflammatory cytokines are considered critical in
controlling parasitaemia, especially during the early
stages of P. falciparum infection [3,4]. Conversely dur-
ing chronic malaria infection, if these robust inflamma-
tory responses are not tightly regulated, they can lead to
immunopathology and severe forms of malaria [5,6].
Regulatory cytokines, including interleukin (IL)-10 and
transforming growth factor beta (TGF-β) were shown to
be important in dampening down T helper (Th) 1
inflammatory responses associated with immune pa-
thology in the more severe forms of P. falciparum in-
fection [5,6]. There also a range of other mediators,IL-10
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Figure 1 Plasmodium falciparum parasitaemia was positively associat
the plasma of infected children. Mean plasma levels of (A) IL-10 and (B)
n=51), medium (1,000-10,000; n=65) and high (>10,000; n=22) mean parasi
(n=89). *, p ≤0.05; **, p ≤0.01 and ***, p ≤0.001 (ANOVA). Parasitaemia was
variables was assessed using regression analysis. p <0.05 was deemed signsuch as IL-17, IL-4, nitric oxide, C-C chemokine
RANTES, matrix metalloproteinases 8 (MMP8s) and
tissue inhibitor of metalloproteinases 1 (TIMP1) that
have been linked to disease severity in malaria-infected
individuals [7-9].
Malaria infection is strongly influenced by the release
of inflammatory mediators from innate immune cells
where early interactions between blood-stage parasites
and these are critical in controlling parasitaemia and the
subsequent elimination of infection [5,6]. Innate immune
cells including antigen presenting cells, such as dendritic
cells, and macrophages are an early source of pro-
inflammatory cytokines, such as IL-12 and TNF. Other
innate immune cells such as natural killer cells and
γδ-T-cells are an early source of IFN-γ. These cells,
through the release of inflammatory mediators and from
cell-to-cell contact with naïve T-cells, also shape the
adaptive immune response.
This is the first study to assess immune responses
during uncomplicated malaria infection in Nigerian
pre-school children in four semi-urban villages near Ile-
Ife, Osun State, Nigeria [10]. Plasmodium falciparum
infection is endemic in this region with a high preva-
lence in pre-school children [11]. Recent studies have
also shown a 25% prevalence of Ascaris lumbricoides in
this cohort [12]. Since helminth infection can impact
upon the outcome of malaria infection [13-15] the po-
tential impact of A. lumbricoides upon P. faliciparum
parasitaemia and its associated immune responses were
examined.IL-10
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ificant.
Noone et al. Malaria Journal 2013, 12:5 Page 3 of 9
http://www.malariajournal.com/content/12/1/5Methods
Study design and participants
231 blood samples were obtained from children at the
final time point in a double-blind placebo-controlled
randomized trial on children aged 39–73 months in four
semi-urban villages, Akinlalu, Ipetumodu, Moro and
Edunabon, near Ile-Ife, Osun State, Nigeria. Details of the
study area, design and participants were published previ-
ously [10]. This current sub-study was to examine immune
responses associated with P. falciparum infection and
examine the impact of A. lumbricoides. Data were available
on children’s age and infection status for P. falciparum
and A. lumbricoides infection. Children who suffered from
severe malaria were treated and excluded from the studyCD54
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Figure 2 Malaria infection was associated with decreased CD14+ perc
not HLA-DR+ and CD36+ cell populations. PBMCs were stained extracell
CD56 (F) cell expression for each group (low (<1,000; n=51), medium (1,00
of blood)) was determined by flow cytometry and compared to endemic cand therefore only individuals with uncomplicated malaria
were included (malaria parasitaemia and fever >37.5°C)
[10]. The study protocol was approved by the Ethics
and Research Committee, Obafemi Awolowo University
Teaching Hospitals’ Complex, Ile-Ife, Nigeria.
Isolation of peripheral blood mononuclear cells
Ten ml of blood (in tubes containing heparin) was
obtained from 231 children, ranging in age from 39–73
months. Peripheral blood mononuclear cells (PBMCs)
and plasma were obtained following histopaque (Sigma-
Aldrich, St Louis, MO, USA) density gradient centrifuga-
tion. PBMCs were collected and stored in liquid nitrogen
and plasma samples were stored at −80°C.HLA-DR
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Human IFN-γ, IL-10, TGF-β, TNF, IL-4 and IL-12p70
Opti-EIA kits (BD Biosciences) and human IL-17,
RANTES, MMP-8 and TIMP-1 DuoSet ELISA Develop-
mental Kits (R&D, Minneapolis, MN, USA) were used to
quantify cytokine, chemokine and metalloproteinase
levels in plasma samples as described per manufacturers
instructions. NO levels were also measured in plasma
using the Greiss Reagent System (Promega, Madison,
WI, USA).Flow cytometry and in vitro culture
The following mAbs were used for cells surface staining
and intracellular cytokine staining: FITC-conjugated
anti- CD4, CD14, CD36, CD56, IFN-γ; PE-conjugated
anti- γδTCR, CD54, IL-10; and APC-conjugated anti-
CD3, CD11c, HLA-DR, IL-2 and TNF (eBiosciences,
San Diego, CA, USA). Isotype controls included FITC-
conjugated mouse IgG1, IgM, IgG2a, IgG2b; PE-
conjugated mouse IgG1, IgG2b and APC-conjugated
mouse IgG1, IgG2b and rat IgG2a (eBiosciences).
PBMCs were thawed and cultured in complete RPMI
containing 10% FCS (foetal calf serum), 1% L-glutamine
and 1% penicillin/streptomycin solution (Bio-sciences
Ltd, Co. Dublin, Ireland). For intracellular cytokine
staining, PBMCs were stimulated with 50 ng/ml PMA
(Phorbol 12-myristate 13-acetate) and 1 mg/ml ionomy-
cin for 4 h and to block cytokine secretion, 10 mg/ml
Brefeldin A (Sigma) was added to the culture media.
Cells were then washed and stained with cell surface
mAbs, fixed with 4% PFA and permeabilized with 0.2%
saponin (Sigma), before incubation with antibodies for
IL-12, IFN-γ, IL-10 and TNF cytokines. Appropriately
labelled isotype-matched antibodies were used as con-
trols. Acquisition was performed using a FACSCalibur0
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Figure 3 Malaria infection was not correlated with an increase in the
populations. PBMCs were stimulated for 4 h with PMA and ionomycin. Ce
and CD4 and were intracellular stained for IFN-γ, IL-2, IL-10 or TNF. Approp
were gated on the lymphocyte population and the percentage of positive
65) and high (>10,000; n = 22) mean parasite density (per μl of blood) werflow cytometer (BD Biosciences), and analysis of results
performed using FlowJo software (Tree Star). A sample of
gating strategy for T Cells in shown in Additional file 1.
PBMCs (1 × 106 cells/ml) from a cohort of children
were also cultured on a 24-well plate with mycoplasma
free P. falciparum parasites (at a ratio of 1:5), which
were extracted from cell culture by saponin lysis (0.15%),
were kindly provided by Dr Alison Creasey, University
of Edinburgh, Scotland. After three days, cell culture
supernatants were harvested and frozen for subsequent
measurement of IFN-γ, IL-10, and IL-5 by commercial
ELISA.
Statistical analysis
All data were analysed using SPSS 15 for windows. Per-
centage data were normalized prior to analysis by Arcsin
transformation. Skewed data were normalized prior to
analysis by log transformation. For differences between
multiple groups, one-way ANOVA with Post-hoc testing
by Tukey’s HSD test was used. For data with more than
one factor, factorial ANOVA was used. Association
between variables was assessed using regression analysis.
For differences between two treatments 2-tailed Student t-
test was used. In all tests, p <0.05 was deemed significant.
Results
Plasmodium falciparum parasitaemia was positively
associated with IL-10 and negatively associated with IL-
12p70 levels in the plasma of infected children
Children infected with P. falciparum were divided into
groups based upon the mean P. falciparum density per
μl of blood (uninfected (n = 89), low density (<1,000, n
= 51), medium density (1,000-10,000, n = 65) and high
density (>10,000, n = 22)) to determine if an association
exists between parasitaemia and plasma immune factors/IL-10 CD4/IL-2 CD4/TNF
secretion of IFN-γ, TNF, IL-10 and IL-2 in mitogen-activated T-cell
lls were washed and stained for cell surface expression of γδTCR, CD3
riate isotype controls were included to define parameter gates. PBMCs
cells for each group (low (<1,000; n = 51), medium (1,000-10,000; n =
e also compared to uninfected endemic controls (EC).
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Figure 4 PBMCs from infected individuals did not secrete
antigen specific immune responses. PBMCs (1x106 cells/ml) from
malaria infected (n=23) and non-infected (n=7) children were
stimulated with medium (Med), mycoplasma free P. falciparum
parasites (at a ratio of 1:5) (malaria antigen) and PMA/anti-CD3. After
three days IFN-γ, IL-10, and IL-5 were measured in supernatant by
commercial assay.
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Figure 5 Ascaris lumbricoides infection did not impact upon
Plasmodium falciparum parasitaemia. Mean P. falciparum density
(per μl of blood) was measured from malaria infected (MAL) and
Ascaris and malaria co-infected (ASC+MAL) children by Giemsa
stained blood slides (n = 109 for MAL; n = 32 for ASC+MAL) NS =
non-significant.
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between IL-10 (low density (p ≤0.01), medium (p ≤0.001)
and high density (p ≤0.001) (Figure 1A) and IL-12p70
levels (Figure 1B; high density p ≤0.05) was observed.
Regression analysis revealed that increases in IL-10 were
significantly associated with increased P. falciparum
parasitaemia (P ≤0.001, Figure 1C), however, IL-12p70
was not negatively associated with P. falciparum parasi-
taemia (P ≤0.067, Figure 1D). Nitric oxide, IFN-γ, TNF
IL-17, IL-4 and TGF-β, RANTES, MMP-8 and TIMP-1
in plasma was not associated with P. falciparum parasi-
taemia (Additional file 2).Malaria infection was associated with a decrease in the
percentage of monocytes and enhanced percentages of
CD11c+, CD54+, CD56+ but not HLA-DR+ and CD36+ cell
populations
Previous studies have shown that P. falciparum infec-
tion is associated with changes in antigen presenting
cell populations (APCs) [16]. Here, the percentage of
CD14+ monocytes (precursor dendritic cells (DCs)/
macrophage) in PBMCs for each group were examined.
All groups displayed significantly lower percentages of
CD14+ cells (<4%) compared to endemic controls
(5-7%) (Figure 2A; P ≤0.01 for all infected groups). To
dissect the APC subsets associated with malaria infec-
tion specific surface markers including HLA-DR (indi-
cative of an active infection), CD11c (myeloid marker
found on DCs), CD54 (also known as ICAM-1)
(Intercellular Adhesion Molecule 1, is important for
lymphocyte-APC binding and has been shown to be
upregulated on APC during malaria infection) and
CD36 (involved in phagocytosis of malaria infected red
blood cells) were examined [17-21]. The percentage of
CD54+ populations were associated with high density
P. falciparum parasitaemia only (Figure 2B; P ≤0.01)
while the percentage of CD11c+ populations were
associated with medium (P ≤0.01) and high (P ≤0.01)
but not low density P. falciparum parasitaemia
(Figure 2C). No association was observed between
HLA-DR+ (Figure 2D) and CD36+ cells (Figure 2E) and
parasitaemia.
Since an increase in IFN-γ was not detected in
plasma cells that are known to produce IFN-γ were
examined to determine if there was a decrease in this
population. Early IFN-γ is important in the control of
P. falciparum parasitaemia and studies have shown
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Figure 6 Ascaris lumbricoides infection did not alter the percentage of CD14+ CD11c+, CD54+, CD56 HLA-DR+ and CD36+ cell
populations in-co-infected individuals. PBMCs were stained extracellularly for CD14 (A), CD54 (B) CD11c (C), HLA-DR (D), CD36 (E) and CD56
(F) cell expression for each group Ascaris infection only (ASC), Malaria infection only (MAL) and co-infected (ASC + MAL) was determined by flow
cytometry and compared to endemic controls (EC). * p ≤0.05; ** p ≤0.01 (ANOVA) and MAL group was compared to the ASC + MAL group (no
significant differences).
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cells (NK) and other leukocytes expressing the CD56 mar-
ker are good sources of IFN-γ [22]. The percentage of
CD56+ cells in PBMCs were measured and these cells
were positively associated with P. falciparum parasitaemia
with significant increases in cell percentages for medium
(P ≤0.05) and high density P. falciparum parasitaemia
(P ≤0.05) (Figure 2F).
Malaria infection was not associated with increased
secretion of IFN-γ, TNF, IL-10 and IL-2 in mitogen-
activated T-cell populations and no parasite specific
immune responses were detected
PBMCs were polyclonally activated with PMA and iono-
mycin and intracellular cytokine staining for IFN-γ,IL-10, IL-2 and TNF was performed. In order to evaluate
the phenotype of the T cells present, cells were also
stained for CD3, CD4, and γδ T-cells. All groups
expressed significantly high levels of IFN-γ and TNF and
low, but significant, levels of IL-10 and IL-2 following
stimulation. There were no differences observed between
the groups (Figure 3).
PBMCs (1×106 cells/ml) from malaria infected (n=23)
and non-infected (n=7) individuals were stimulated with
mycoplasma free P. falciparum parasites (at a ratio of 1:5)
and after three days IFN-γ, IL-10, and IL-5 were measured
in supernatant. No parasite specific immune responses
were detected while cPBMCs were capable of secreting all
cytokines tested in response to our positive control PMA/
anti-CD3 (Figure 4).
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Figure 7 Ascaris lumbricoides infection did not alter IFN-γ, TNF, IL-10 and IL-2 expression in mitogen-activated T-cell populations.
PBMCs were stimulated for 4 h with PMA and ionomycin. Cells were washed and stained for cell surface expression of γδTCR, CD3 and CD4 and
were intracellular stained for IFN-γ, IL-2, IL-10 or TNF-a. Appropriate isotype controls were included to define parameter gates. PBMCs were gated
on the lymphocyte population and the percentage of positive cells for each group Ascaris infection only (ASC), Malaria infection only (MAL) and
co-infected (ASC + MAL) was determined by flow cytometry and compared to uninfected endemic controls (EC) and MAL group was compared
to the (ASC + MAL).
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impact upon Plasmodium falciparum parasitaemia or its
associated immune responses
The data was reanalysed taking into account Ascaris
infection (uninfected (n=69), Ascaris only (n=21),
malaria only (n=109), Ascaris and malaria (n=32)). The
prevalence of A. lumbricoides was 23% and all A.
lumbricoides-infected children had a low intensity infec-
tion (<3,700 eggs per gram (epg)). Plasmodium falci-
parum percentages in the blood were calculated in the
malaria-infected and co-infected individuals and no
differences in P. falciparum parasitaemia were observed
between the malaria-infected and co-infected groups
(Figure 5). Furthermore, no differences were observed in
immune responses between the malaria-infected and
co-infected groups for all parameters tested (Additional
file 3; Figures 6 and 7).
Discussion
This study provides valuable insights into the immune
responses associated with malaria infection in pre-school
Nigerian children from 39–73 months. Studies looking
at the immunological parameters in this age group are
important given that the highest malaria mortality rates
occur in children under five years [1]. Studies have
shown that immune responses to malaria infection are
established early in life and furthermore different ethnic
groups respond differently to malaria infection and this
is also established early in life [23]. There is little
evidence of natural acquired immunity to malaria in
children under two years as neonates less than 30 days
old and children up to one year have reduced IFN-γ pro-
ducing capacity [1]. No increase in IFN-γ levels wasobserved in the plasma of these children and this con-
tradicts previous studies in children where increased
levels of plasma IFN-γ were observed [1]. In addition, a
number of other factors associated with active malaria
infection were not observed in these children.
Significantly high levels of IL-10 in plasma was
observed from malaria-infected children and this corre-
sponded with a reciprocal decrease in IL-12p70 levels,
similar to that reported in other studies [24]. Regression
analysis revealed a positive association between P.
falciparum parasitaemia and IL-10. IL-10 is a known
antagonist of this pro-inflammatory cytokine [25] and
recurrent malaria infection can induce an immunosup-
pressive environment through secretion of high levels of
IL-10, thus inhibiting Th1 responses and facilitating
parasite persistence [26]. Intracellular IL-10 was not
detected in polyclonally stimulated T-cell subsets from
malaria-infected children when compared to endemic
controls. PBMCs from malaria infected children when
stimulated with P. falciparum parasites did no exhibit
antigen specific immune responses. Previous studies
have reported that T-cell responses can be weak in
young children infected with malaria and this lack of
responses could explain why this age group is most sus-
ceptibility to infection [2].
The significant reduction in monocyte percentages in
the infected groups compared to endemic controls was
observed. Other reports have also shown a decrease in
monocytes percentages during active parasitic infection
[27]. During infection, circulating monocytes may be
required at a higher rate to replenish resident macro-
phages and DCs. Alternatively, parasitic infections may
induce monocyte apoptosis which could explain the
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the decreases in monocytes there was an increase in
CD11c+ and CD54+ DCs in the infected individuals. The
presence of predominantly mature CD11c+ DCs popula-
tion may explain the lack of T-cell responses observed in
young children as mature CD11c+ DC population lose
its ability to phagocytose antigens which is necessary for
presentation to effector and memory T-cells [17,18]. The
increases in the percentage of CD54+ cells supports
previous findings which demonstrated a link between
increased CD54 expression and disease severity [28].
CD54 was previously shown to be upregulated on acti-
vated DCs, monocytes and other APCs during malaria
infection in children and it is a known receptor that can
bind P. falciparum erythrocyte membrane protein 1
[21]. CD11c and CD54 are expressed by many cell types
and further analysis would shed light on the specific cell
subset observed during infection.
Both γδ T cells and NK cell express CD56+ and this sur-
face maker increased in the malaria-infected children. NK
cells and γδT cells are thought to be critical in protection
from malaria infection [29,30]. Depletion of these cells in
murine malaria models has led to increased parasitaemia
and delayed resolution of infection, emphasising their
importance in early IFN-γ production [30,31]. While these
cells are more likely to act as accessory IFN-γ secreting
cells to effector T cells there was no increase in IFN-γ
detected in the plasma of infected children. However,
recently, these cells have also been shown to act as APCs
and compensate for DCs in certain situations and further
studies would be required to determine the role of this
subset [31,32]. While an increase in CD56 cell population
was observed, further studies are required to determine
the CD56 population subset and examine if these cells
secrete IFN-γ.
While the study region is endemic for A. lumbricoides,
no differences in immune parameters were observed
between the co-infected groups compared to the P.
falciparum-infected group only. Perhaps no differences
were observed because children had a low intensity
A. lumbricoides infection, as was demonstrated in a
previous report study by Nacher et al. (2000). More-
over, since infection resides in the gut, perhaps only the
medium and high intensity infection can alter the
immune response systemically. Ascaris lumbricoides
infection can be protective in the more severe forms of
P. falciparum infection [33] and since individuals with
severe malaria infection were excluded from the study
an association could not be determined.
Conclusion
This data corroborates previous reports examining im-
mune responses in malaria-infected children by showing
that increases in IL-10 were positively associated withincreased P. falciparum parasitaemia. Increases in innate
immune cell populations that were previously associated
with disease severity in malaria-infected individuals was
also demonstrated [19,21,33]. Given that there are so few
immunological studies in this age group, these findings
could be useful in defining immune responses associated
with increasing malaria parasitaemia in young children
and therefore markers of disease susceptibility. It is esti-
mated that 87% of children below the age of five are
infected with malaria in the Osun State in south-western
Nigeria [34], and validating these methodologies is import-
ant for future studies in this area. For example, birth to
age five is an important range for the administration
and study of many prophylactic paediatric vaccines and
World Health Organization recommendations for routine
immunization within this age group in Nigeria include
both measles and yellow fever vaccines [35].
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Additional file 1: Sample of gating strategy for T Cells. Shown is a
PBMC sample stimulated with 50 ng/ml PMA and 1 mg/ml ionomycin for
4 h in the presence of BFA (10 mg/ml). Cell subsets were identified as
CD3 cells and then analysed for expression of cytokines and markers
γδcells.
Additional file 2: The average age, parasitemia, cytokine, nitric
oxide (NO), RANTES, metalloproteinase (MMP) type 8 and tissue
inhibitor of metalloproteinase (TIMP) type 1 plasma concentrations
from the study cohort classified according in infection status
(uninfected, Ascaris only, malaria only, Ascaris and malaria.
Additional file 3: The average age, cytokine, nitric oxide (NO),
RANTES, metalloproteinase (MMP) type 8 and tissue inhibitor of
metalloproteinase (TIMP) type 1 plasma concentrations from the
study cohort classified according to P falciparum parasitaemia.
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ABSTRACT
Mast cells are crucial in the development of immunity
against Bordetella pertussis, and the function of TLRs in
this process has been investigated. Here, the interaction
between mast cells and B. pertussiswith an emphasis on
the role of CLRs is examined. In this study, two CLRs,
MGL and MR, were detected for the first time on the sur-
face of mast cells. The involvement of MR and MGL in the
stimulation of mast cells by heat-inactivated BP was in-
vestigated by the use of blocking antibodies and specific
carbohydrate ligands. The cell wall LOS of BP was also
isolated to explore its role in this interaction. Mast cells
stimulated with heat-inactivated BP or BP LOS induced
TNF-, IL-6, and IFN- secretion, which was suppressed
by blocking MR or MGL. Inhibition of CLRs signaling dur-
ing BP stimulation affected the ability of mast cells to pro-
mote cytokine secretion in T cells but had no effect on
the cell-surface expression of ICAM1. Blocking MR or
MGL suppressed BP-induced NF-B expression but not
ERK phosphorylation. Syk was involved in the CLR-medi-
ated activation of mast cells by BP. Bacterial recognition
by immune cells has been predominantly attributed to
TLRs; in this study, the novel role of CLRs in the BP–mast
cell interaction is highlighted. J. Leukoc. Biol. 94:
439–448; 2013.
Introduction
B. pertussis is a Gram-negative coccobacillus that causes the respi-
ratory infection, whooping cough [1]. Despite being preventable
by vaccination, pertussis causes nearly 300,000 deaths in children
every year, mainly in developing countries [2]. The incidence of
whooping cough in Europe has increased as a result of the
change in national immunization programs from the whole-cell
vaccine to acellular vaccine [1]. Vaccination can induce protec-
tion against infection by inducing strong Th1/Th2 immune re-
sponses; however, the acellular vaccine induces a polarized Th2
immune response [2, 3] and confers protection for a limited
time only [3]. Better understanding of the interaction of B. per-
tussis with innate immune cells may lead to the development of a
more effective vaccine that induces lifelong immunity.
Mast cell-induced Th1 immune responses are crucial in the
clearance of protozoan and bacterial infection, such as Escherichia
coli [4], Leishmania major [5], and Pseudomonas aeruginosa [6]. Acti-
vation of mast cells during vaccination contributes to the develop-
ment of protective Th1 immunity [7], and these cells are crucial
in the effectiveness of vaccination against anthrax [8] and Helico-
bacter infection [9]. In vitro B. pertussis induces IL-6 and TNF-
release from mast cells, while in vivo, early TNF- production is
delayed in mast cell-depleted mice infected with B. pertussis [10].
Despite the crucial role of mast cells in the clearance of bacterial
infection from the lung and in mediating protective Th1 im-
mune responses [11, 12], only few studies have examined the
interaction of mast cells with B. pertussis [10].
TLRs were shown to be critical in the recognition of the B.
pertussis outer membrane. The strain-specific endotoxin com-
ponent of the bacteria’s outer membrane, the LOS, is the key
TLR4 initiator of inflammatory immune responses [13, 14].
The thick bacterial coat of glycoconjugate structures in the
form of polysaccharidic capsules, peptidoglycans, LPS, and
other glycolipidic moieties [15] are PAMPs that can activate
other PPRs, such as [16] CLRs [17]. The signaling pathways of
TLRs and CLRs are complex, and the crosstalk between the
receptors allows immune cells to develop pathogen-specific
immune responses [18].
CLRs play a key role in immunity against bacterial infection
as a result of their calcium-dependent interaction with patho-
gen-associated glycan epitopes [19]. MR binds to carbohy-
drates, such as mannose, N-acetylglucosamine, and fucose.
These saccharides can be found on the surfaces of microor-
ganisms, including E. coli, P. aeruginosa, and Mycobacterium tu-
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berculosis [20]. Another important CLR, MGL, has been re-
ported to bind to GalNAc motifs on filoviruses, Campylobacter
jejuni and Schistosoma mansoni [17, 21]. Some bacteria can in-
teract with more than one CLR, and the restricted expression
of CLRs on immune cell subsets can contribute to the differ-
ent immune responses [22].
Upon carbohydrate binding, CLRs have the ability to trigger
the immune machinery by antigen internalization and presen-
tation onto the MHC molecule or by modulation of the TLR-
mediated signaling pathway [20]. Differences in sugar-binding
ability and ligand specificity of the various CLRs are conferred
by highly conserved CRDs. The ubiquitous expression of CLRs
by most cell types, including macrophages and DCs [17], to-
gether with organism-specific differences in glycosylation
among pathogens, make the CLRs a central defense system in
innate immunity.
To date, the study of CLRs expressed on mast cells is in its
infancy. Mast cells express a specific CLR, MAFA [23], later
found also in NK cells and human basophils [24]. Stimulation
of MAFA leads to the inhibition of FcRI-induced activation of
mast cells [25]. Other CLRs, such as Mincle and Dectin-1,
were also shown to be expressed by mast cells, although ex-
pression levels are very low [26, 27]. These two CLRs, also
present on macrophages and DCs, play important roles in anti-
fungal immunity [28]. Upon CLR ligand binding, ITAM and
ITAM-like signaling pathways can be activated, promoting the
recruitment of Syk, which results in the activation of cellular
proliferation, differentiation, and migration [29].
We reported recently that mast cells stimulated with heat-
inactivated BP secrete proinflammatory cytokines, such as
TNF- and IL-6, and display enhanced expression of ICAM1.
BP-stimulated mast cells promote cytokine secretion in T cells.
BP induces the activation of two members of the TLR4 signal-
ing pathway, ERK and NF-B [30]. In this study, we investi-
gated the interaction between mast cells and B. pertussis with
an emphasis on the role of CLRs. Better understanding of this
interaction may lead to the development of a more efficient B.
pertussis vaccine and may advance our understanding of the
complex interactions between PPR crosstalk in activating in-
nate immune responses.
MATERIALS AND METHODS
Animals and antigens
C57BL/6 mice, 6–8 weeks old, were purchased from Charles River (Car-
rentrilla, Ireland). Mice were kept under specific pathogen-free conditions
at the Bioresource Unit, Faculty of Health and Science, DCU (Ireland). All
mice were maintained according to the guidelines of the Irish Department
of Children and Health. Ethical approval for mice experiments was ob-
tained from the DCU Ethics Committee and the Irish Department of Chil-
dren and Health.
Heat-inactivated BP (Tohama I) was a kind gift from Professor Bernie
Mahon (National University of Ireland Maynooth, Ireland) [31]. Bacteria
number was determined by measuring OD, and protein concentrations
were determined using a BCA protein assay kit (Pierce, Thermo Fisher Sci-
entific, Dublin, Ireland).
Isolation, maturation, and characterization of BM and
PCMCs
BMMCs were generated from the femoral and tibia BM cells of C57BL/6
mice and maintained in complete IMDM (Gibco, Life Technologies, Carls-
bad, CA, USA) in the presence of 10% heat-inactivated FCS (Gibco, Life
Technologies), 100 u/ml penicillin/streptomycin (Sigma-Aldrich, Arklow,
Ireland), and 30% WEHI-3 conditioned IMDM medium (TIB-68; American
Type Culture Collection, Manassas, VA, USA) as a source of the murine
growth factor IL-3 for 4 weeks [32]. PCMCs were obtained using a protocol
described previously [33]. Briefly, C57BL/6 mice were i.p.-injected with 10
ml sterile PBS, and then the obtained peritoneal cells were cultured in
RPMI-1640 medium, supplemented with 10% FCS and 100 u/ml penicil-
lin/streptomycin, L-glutamine (2 mM; Sigma-Aldrich), 10 ng/ml mouse
rIL-3 (Calbiochem, Merck, Darmstadt, Germany), and 30 ng/ml recombi-
nant mouse stem cell factor (Sigma-Aldrich) at 37°C. Forty-eight hours
later, nonadherent cells were discarded and replaced by fresh culture me-
dium for a further 7 days. In both preparations, 95% of the total cells
were identified as mast cells on the basis of the c-kit (Clone 2B8; eBio-
science, Hatfield, UK) and FcRI (Clone MAR1; eBioscience) cell-sur-
face expression or Kimura staining [34]. Cell number and viability were
monitored using trypan blue staining (Sigma-Aldrich). -Hexosamini-
dase release from mast cells was measured as described previously [33]
to test functionality.
Stimulation of mast cells for ELISA and flow cytometry
BMMCs or PCMCs were cultured with anti-MR (Abcam, Cambridge, UK)
or anti-MGL (Hycult Biotech, Uden, The Netherlands)-blocking antibodies
(1 g/ml), EGTA (10 mM), mannan (50 g/ml), and GalNAc (50 mM; all
from Sigma-Aldrich) or Syk inhibitor (10 M; piceatannol; Enzo Life Sci-
ences, Exeter, UK), 30 min before stimulation with PBS or BP (100 bac-
teria/cell) for 24 h. Levels of TNF-, IL-6, IFN-, and IL-10 cytokines
were measured in supernatant by commercial ELISA (BD Biosciences,
Oxford, UK).
Cells were incubated for 15 min with CD16/CD32 (FcIII/II; BD Biosci-
ences) to block FcR before flow cytrometric analysis and were stained with
PE/FITC/allophycocyanin-conjugated anti-FcRI, anti-CD117, and anti-
CD206 (MR; Clone MR5D3; BioLegend, London, UK) and anti-MGL
(Clone ER-MP23; AbD Serotec, Kidlington, UK) or the appropriate IgG
isotype control for 30 min at 4°C in the dark. mAb binding was analyzed by
flow cytometry (FACSAria; BD Biosciences) in the presence of DNAse
(Roche, Manheim, Germany) to avoid aggregation, using FACSDiva (BD
Biosciences), FlowJo (Treestar, Ashland, OR, USA), and Flowing Software
(Cell Imaging Core, Turku Centre for Biotechnology, Finland).
Coculture studies and cytokine measurements
CD4 T cells were isolated using the MACS CD4 T cell isolation kit
(Miltenyi Biotec, Surrey, UK). Purity of isolates was determined by flow cy-
tometry (FITC-conjugated CD4; Clone L3T4; BD Biosciences); only prepa-
rations with 95% CD4 T cells purity were used in this study. PCMCs
were cultured in the presence of anti-MR- or anti-MGL-blocking antibodies
(1 g/ml) for 30 min before stimulation with PBS or BP (100 bacteria/
cell) for 24 h. Washed, stimulated PCMCs were added to CD4 cells (in a
1:1 ratio) in plates coated with anti-CD3 (1 g/ml; BD Biosciences), cocul-
tured for 72 h, and supernatants were tested for IFN-, IL-4, IL-5, and
IL-10 by commercial ELISA (BD Biosciences).
Protein extraction and Western blot analysis
BMMCs were cultured with anti-MR- or anti-MGL-blocking antibodies for
30 min and then stimulated with BP (100 bacteria/cell) for 15 min. Total
protein was extracted from cell lysates using RIPA buffer containing pro-
tease and phosphatase inhibitor cocktails (both from Sigma-Aldrich). Pro-
tein samples (10–40 g) and prestained protein markers (SeeBlue Plus2;
Invitrogen, Paisley, UK) were separated by 10% SDS-PAGE and blotted
onto 0.45 m Immobilon-P polyvinylidene fluoride membranes (Millipore,
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Carrigtwohill, Ireland). Membranes were probed, according to standard
Western blot protocol, using anti-phospho-ERK (Cell Signaling Technology,
Danvers, MA, USA), anti-total-ERK (Cell Signaling Technology), and anti-
phospho-NF-B p65 (Ser 276), and anti--actin (BioLegend) primary
antibodies and peroxidase-conjugated anti-rabbit IgG secondary anti-
body (Sigma-Aldrich). Proteins were visualized by incubation with a
chemiluminescent HRP substrate (Millipore), exposed to film, and pro-
cessed using an FPM 100A processor (Fuji Film, Tokyo, Japan). Protein
bands were quantified using ImageJ analysis software (imagej.nih.gov).
Levels of phospho-ERK and NF-B p65 were normalized to total-ERK
and -actin and expressed in arbitrary units as percentage increases
over the medium control levels.
Isolation of BP LOS
Isolation of BP LOS was performed according to a protocol described pre-
viously [13]. Briefly, 1  1011 cells of heat-inactivated BP were suspended
in 3 ml 0.1 mg/ml proteinase K (Roche) in PBS and incubated for 1.5 h at
56°C. After incubation, the mixture was subjected to acetone precipitation
and the pellet solubilized in 1 ml sterile PBS. Reaction completion was
evaluated by 16% SDS-PAGE, followed by silver staining [35]. The contami-
nating presence of proteinase K in the crude LOS preparation was re-
moved by centrifugation [36] (Avanti J-26 XP centrifuge; Beckman Coulter,
Fullerton, CA, USA) at 40,000 g for 4 h at 4°C in a fixed angle rotor (Beck-
man JA-20). The LOS-containing pellet and the acetone-precipitated super-
natant were dissolved in 300 l sterile PBS. Purified LOS was separated on
16% SDS-PAGE and stained by the silver nitrate method.
Stimulation of mast cells by LOS
BMMCs were stimulated with anti-MR- and anti-MGL-blocking antibodies (1
g/ml), 30 min before stimulation with this LOS preparation (1 u/ml;
equal to 100 bacteria/cell) for 24 h. Supernatants were tested for TNF-
and IL-6 cytokines, as described above. As a result of the presence of traces
of proteinase K in LOS preparation, the effect of proteinase K on cytokine
secretion was also evaluated as an additional control.
Statistics
All data were analyzed for normality before statistical testing by Origin 6.1
(OriginLab, Northampton, MA, USA) software. Where multiple group com-
parisons were made, data were analyzed using one-way ANOVA. For com-
parisons between two groups, the Student’s t-test was used. In all tests, P 
0.05 was deemed significant.
RESULTS
MR and MGL are expressed by mast cells
Previous studies have reported the expression of MAFA [37],
Dectin-1, and Mincle [27] on mast cells. Here, the expression of
MGL and MR on BMMCs (Fig. 1A–C; MR: P	0.05; MGL:
P	0.01) and PCMCs (Fig. 1D–F; MR: P	0.01; MGL: P	0.01) was
examined by flow cytometry, revealing that these CLRs are ex-
pressed significantly by mast cells when compared with isotype
controls. However, BMMCs and PCMCs, when stimulated with
heat-inactivated BP for 24 h, did not display enhanced expression
of these receptors (MR: P0.12; MGL: P0.91; data not shown).
BP-induced TNF-, IL-6, and IFN- secretion in mast
cells is reduced in the presence of anti-MR- or anti-
MGL-blocking antibodies
As MR and MGL are expressed by mast cells, CLR involvement in
the interaction of BP with mast cells was investigated. Stimulation
of BMMCs induced TNF- and IL-6 secretion (Fig. 2A and B;
P	0.05). The levels of TNF- (MR: 74.610.5%, P	0.05; MGL:
29.04.5%, P	0.01) and IL-6 (MR: 88.01.4; MGL: 91.13.4%,
P	0.01) were reduced significantly when BMMCs were treated
with anti-MR- or anti-MGL-blocking antibodies before BP stimula-
Figure 1. MR and MGL are expressed by mast cells. Cell-surface expression of MR (B and E) and MGL (C and F) was measured by three-color
(FcRI, c-kit, and CLR) flow cytometry on BMMCs (A–C) and PCMCs (D–F). Data are presented on histograms (A and D) and as the mean  sd
of three independent experiments. **P 	 0.01 compared with isotype control group. FITC-A, FITC-area; MFI, mean fluorescence intensity.
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tion (Fig. 2A and B). MR- and MGL-blocking antibodies were
added together, 30 min before treatment of BMMCs with BP.
BP-induced TNF- (12.11.6%, P	0.05), and IL-6 (52.431.7%,
P	0.05) secretion was suppressed significantly by the blocking
antibodies; however, further suppression was not observed in the
presence of the two antibodies (data not shown).
As PCMCs are more mature mast cells than BCMCs, studies
were repeated to demonstrate that similar results would be ob-
tained. Stimulation of PCMCs with BP for 24 h induced secretion
of TNF-, IL-6, IFN- (P	0.01), and IL-10 (P	0.05) cytokines
(Fig. 2C–F). The levels of TNF-, IL-6, and IFN- were reduced
significantly when PCMCs were treated with anti-MR (TNF- and
IL-6: P	0.05; IFN-: P	0.01)- or anti-MGL-blocking antibody for
30 min before BP stimulation (Fig. 2C–E). IL-10 secretion
by PCMCs was not impaired in the presence of either of the
antibodies (anti-MR: P0.18; anti-MGL: P0.80; Fig. 2F).
Anti-MR- and anti-MGL-blocking antibodies reverse T
cell activation by BP-primed mast cells
BMMCs and PCMCs were stimulated with BP in the presence or
absence of anti-MR- or anti-MGL-blocking antibodies for 24 h, as
described above. BP-activated mast cells were cocultured with
naïve CD4 T cells, and cytokine secretion was measured. As co-
culture of mast cells with naïve CD4 cells in the presence of
Figure 2. Blocking of MR and MGL suppresses BP-induced cytokine secretion in mast cells. BMMCs (A and B) and PCMCs (C–F) were treated
with anti-MR- or anti-MGL-blocking antibody (1 g/ml), 30 min before stimulation with BP (100 bacteria/cell) for 24 h. TNF- (A and C), IL-6
(B and D), IFN- (E), and IL-10 (F) secretion was measured with commercial ELISA. Data are presented as the mean  sd of three independent
experiments. *P 	 0.05 and **P 	 0.01 compared with control group; P 	 0.05 and P 	 0.01 compared with control BP-stimulated group.
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anti-CD3 is reported to promote cytokine secretion per se [38–
41], PBS-primed BMMCs/PCMCs were also used in the coculture
experiments as controls. CD4 cells, cocultured with BMMCs, se-
creted significant levels of IL-10 and IFN- (P	0.05; Fig. 3A and B).
IFN- secretion was suppressed significantly when BMMCs
were treated with anti-MR (68.33.3%, P	0.01)- or anti-
MGL (18.05.1%, P	0.01)-blocking antibodies before BP
stimulation and coculture. Levels of IL-10 did not change
significantly (Fig. 3A and B).
As per the previous experiment, the results were confirmed
with PCMCs (Fig. 3C–F). CD4 T cells cocultured with BP-stimu-
lated PCMCs secreted higher levels of IFN- (P	0.05), IL-10
(P	0.05), and IL-5 (P	0.05) than the control group (Fig. 3C–E),
whereas IL-4 levels remained unchanged (P0.55; Fig. 3F).
When PCMCs were pretreated with anti-MR or anti-MGL
before BP stimulation, they no longer secreted significant
levels of IFN- (anti-MR: P0.41; anti-MGL: P0.12) and
IL-5 (anti-MR: P0.13; anti-MGL: P0.12) in coculture
compared with controls (Fig. 3C and E). However only
PCMCs treated with anti-MGL no longer secreted IL-10 com-
pared with controls (Fig. 3D).
ICAM1 expression on mast cells is not altered by anti-
MR- and anti-MGL-blocking antibodies
As ICAM1 expression is important in T cell–mast cell commu-
nication and was previously shown to be enhanced on mast
Figure 3. Anti-MR- and anti-MGL-blocking antibodies interfere with BP-induced T-cell activation by PCMCs. BMMCs (A and B) and PCMCs (C–F)
were treated with anti-MR- and anti-MGL-blocking antibody (1 g/ml), 30 min before stimulation with BP (100 bacteria/cell) for 24 h. Cells were
washed and cocultured with naïve CD4 T cells (1:1) for 72 h. IFN- (A and C), IL-10 (B and D), IL-5 (E), and IL-4 (F) secretion was measured
with commercial ELISA. Data are presented as the mean  sd of three independent experiments. *P 	 0.05 and **P 	 0.01 compared with con-
trol group; P 	 0.01 compared with control BP-stimulated group.
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cells following BP stimulation [30] (Fig. 4), the involvement of
CLRs in ICAM1 expression was investigated. PCMCs were
treated with anti-MR- or anti-MGL-blocking antibodies before
stimulation with BP for 24 h. BP enhanced ICAM1 expression
in all groups, with no significant effect as a result of blocking
of MR or MGL (P0.97; Fig. 4).
BP-induced TNF- and IL-6 secretion by mast cells is
reduced in the presence of glycans (mannan and
GalNAc) and EGTA
To fully validate that the observed suppression of cytokine se-
cretion is a result of effective blocking of Ca2-dependent
CRDs on CLRs, BMMCs were treated with mannan (50 g/ml,
MR ligand), GalNAc (50 mM, MGL ligand), or EGTA (10 mM,
Ca2 ligand) for 30 min before stimulation with BP for 24 h.
All glycans and EGTA suppressed BP-induced TNF- and IL-6
secretion significantly (EGTA and mannan: P	0.01; GalNAc:
P	0.05; Fig. 5). Notably, EGTA treatment reduced the cyto-
kine secretion ability, not only of BP-stimulated mast cells but
also of PBS-primed (control) mast cells (P	0.01; Fig. 5). The
effect of laminarin, a non-MR and -MGL ligand, on BP-in-
duced cytokine secretion was also tested on BMMCs. TNF-
(to 63.81.4%, P	0.01) and IL-6 (to 45.02.4%, P	2.4) se-
cretion was suppressed significantly when cells were pretreated
with laminarin, which also suggests a role for Dectin-1 in the
BP–mast cell interaction (data not shown).
Syk inhibition suppresses TNF- and enhances IL-6
secretion by BP-stimulated mast cells
Downstream CLR signaling was investigated by assessing the
involvement of Syk kinase [29] in cytokine secretion by BP-
stimulated mast cells. BMMCs were treated with Syk inhibitor
(piceatannol) before stimulation with BP for 24 h. TNF- se-
cretion was reverted to basal level by Syk inhibition (Fig. 6A),
whereas IL-6 secretion levels appeared enhanced dramatically
in BP-stimulated and control groups (Fig. 6B).
Blocking of MR and MGL suppresses BP-induced
NF-B activation but not ERK phosphorylation
To further understand the signaling pathways involved in CLR-
mediated BP stimulation of mast cells, the effect of anti-MR- and
anti-MGL-blocking antibodies on NF-B p65 and ERK phosphory-
lation was investigated. As reported previously, BP stimulation of
mast cells enhances ERK and NF-B p65 activation [30]. NF-B
p65 activation could be reversed by blocking MR or MGL (P	0.01;
Fig. 7A and C), whereas anti-MGL- or anti-MR-blocking antibody
Figure 5. Carbohydrate treatment impairs BP-induced cytokine secretion in
mast cells. BMMCs were treated with EGTA (10 mM), mannan (50 g/ml),
and GalNAc (50 mM), 30 min before stimulation with BP (100 bacteria/cell)
for 24 h. TNF- (A) and IL-6 (B) secretion was measured with commercial
ELISA. Data are presented as the mean  sd of three independent experi-
ments. *P 	 0.05 and **P 	 0.01 compared with control group; P 	 0.05
and P 	 0.01 compared with control BP-stimulated group.
Figure 4. Anti-MR- and anti-MGL-blocking antibodies do not suppress BP-induced up-regulation of ICAM1. PCMCs were treated with PBS (control;
A) or anti-MR (B)- or anti-MGL (C)-blocking antibody (1 g/ml), 30 min before stimulation with BP (100 bacteria/cell) for 24 h. Cell-surface
marker expression of ICAM1 was measured by flow cytometry. Data are presented as the mean  sd of three independent experiments (D). *P 	
0.05 and **P 	 0.01 compared with control group.
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treatment, before BP stimulation, had no statistical effect on ERK
phosphorylation (Fig. 7A and B).
Blocking of MR and MGL suppresses LOS-induced
cytokine secretion in mast cells
Whole-cell vaccine studies suggest that BP-derived LOS is cru-
cial to activate innate immune cells to generate proinflamma-
tory cytokines in Bordetella infections [42]. The role of B. per-
tussis LOS in CLR-mediated mast cell activation was investi-
gated. LOS from BP heat-inactivated cells was isolated by
digestion of the cell lysate with proteinase K, followed by high-
speed centrifugation (Fig. 8A). BMMCs were stimulated with
blocking anti-MR and anti-MGL antibodies, 30 min before
stimulation with this LOS preparation for 24 h. As a result of
the presence of traces of proteinase K in LOS preparation, the
effect of proteinase K on mast cell was also tested, resulting in
negligible cytokine secretion. The blocking of MR and MGL
on LOS-stimulated mast cells inhibited cytokine secretion (Fig.
8B and C), as observed previously in the case of BP-stimulated
cells (Fig. 1A and B).
DISCUSSION
Mast cells are a major component of protective immunity
against microbial infection. These cells are a potent source of
proinflammatory mediators, such as TNF- and IFN-, that can
promote Th1-driven host defense against bacteria and proto-
zoa [7, 43–46]. They play a crucial role in the clearance of
bacterial infection, such as B. pertussis and E. coli [4, 10]. Here,
we show for the first time that MR and MGL are expressed by
BMMCs and PCMCs. Furthermore, MR and MGL proved to be
functionally involved in the induction of cytokine secretion of
B. pertussis-challenged mast cells and reversed the ability of
these cells to prime naïve CD4 T cells to secrete cytokines.
MR and MGL have been reported to play a role in T cell acti-
vation by APCs, such as DCs and macrophages [47].
In the case of MR, our findings correlate with studies in
other immune cells, as MR was shown to be involved in the
activation of macrophages by M. tuberculosis in vitro [48]. In
contrast, MGL was associated previously with the suppression
rather than induction of cytokine secretion by pathogen-stimu-
lated immune cells. In DCs, a C. jejunum mutant lacking a
functional MGL ligand induced increased IL-6 production
compared with WT [21]. Similarly, modulation of MGL on
DCs by cestode antigens leads to inhibition of LPS-induced
proinflammatory cytokine secretion [49]. However, other stud-
ies have shown that activation of MGL leads to maturation of
DCs and IFN- secretion in CD8 T cell cocultures [50]. Our
results reveal a new stimulatory function of MGL in pathogen–
mast cell interaction. Furthermore, MR and MGL play a role
Figure 6. Inhibition of Syk
suppresses BP-induced TNF-
secretion and enhances IL-6
secretion in mast cells.
BMMCs were treated with
PBS (control) or Syk inhibi-
tor (10 M), 30 min before
stimulation with BP (100 bac-
teria/cell) for 24 h. TNF-
(A) and IL-6 (B) secretion
was measured with commer-
cial ELISA. Data are pre-
sented as the mean  sd of
three independent experi-
ments. **P 	 0.01 compared
with control (PBS) group.
Figure 7. Blocking of MR and MGL suppresses BP-induced activation of NF-B p65 but not ERK phosphorylation. BMMCs were treated with anti-
MR- and anti-MGL-blocking antibodies before stimulation with BP for 15 min. Protein samples were analyzed by Western blot for phosphorylated-
ERK (phospho-ERK), total ERK, phosphorylated-NF-B p65, and -actin expression. cont, Control (A). Values of phosphorylated-ERK (B) and
NF-B p65 (C) were normalized to total ERK and -actin and are expressed in arbitrary units as percent-fold increases over PBS control. Densi-
tometry data are presented as the mean  sd of three independent experiments. *P 	 0.05 and **P 	 0.01 compared with control (PBS) group;
P 	 0.01 compared with control BP-stimulated group.
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in the internalization of pathogens, as observed for M. tubercu-
losis [51, 52], and B. pertussis can adhere and be phagocytised
by mast cells [10]. It would be interesting in future studies to
investigate the role of MR and MGL in the binding and up-
take of BP antigens.
Similar to DCs and macrophages, mast cells express PRRs,
such as TLR2, TLR3, TLR4, TLR6, TLR7, and TLR9, that rec-
ognize invading pathogens [53, 54]. BP stimulation has been
reported to cause ERK phosphorylation on mast cells via acti-
vation of the TLR4 signaling pathway [55, 56] and activation
of MAPK and NF-B pathways inducing cytokine secretion and
cell-surface marker up-regulation in immune cells [30]. Block-
ing MR and MGL on mast cells suppressed NF-B p65 but not
ERK phosphorylation. A similar trend has also been observed
in LPS-stimulated macrophages, where blocking the CLR sig-
naling pathway resulted in the suppression of the phosphoryla-
tion of JNK but not p38 or ERK [57]. Furthermore, the re-
cently observed link between ERK phosphorylation and ICAM1
up-regulation [58] can be used to better understand the ab-
sence of any effect of CLR blocking on the expression level of
ICAM1. CLR modulation has been associated recently with
impairment of NF-B activation in LPS-stimulated DCs, sug-
gesting the involvement of alternative signaling pathways to
TLR4 in LPS challenge [59].
Syk is a ubiquitous nonreceptor tyrosine kinase with diverse
biological activities [60]. It is involved in the signaling from
BCRs and TCRs, FcRs, and CLRs, including Dectin-1 [29, 61].
Syk binds to the phosphorylated intracellular domain of the
CLR and mediates signaling that results in transcription factor
activation of cytokine secretion in DCs [62]. In macrophages,
blocking of Syk suppressed LPS-induced activation of the
MAPK pathway [57]. Interestingly, in our experiments, block-
ing of Syk had conflicting effects on TNF- and IL-6 secretion
by BP-stimulated mast cells. These results could be explained
with the diverse function of Syk in immune cells. Recently, it
was reported that Syk binds to TLR4 and plays a role in the
response to bacterial pathogens or LPS in DCs and macro-
phages [60, 63, 64], leading to proinflammatory cytokine se-
cretion. On the other side, Syk is also activated at different
stages of the CLR signaling pathway, resulting in activation or
inhibition of the TLR signaling pathway, and affects cellular
responses, such as migration, adhesion, differentiation, or in-
flammatory and regulatory mediator release. The interaction
of Syk with different receptors has yet to be identified [29].
To simplify our system focusing on the most probable li-
gands of CLRs and TLRs [65], LOS was isolated from heat-
inactivated BP and used in mast cell stimulation assays. LOS is
usually a potent inducer of TLR4-mediated signaling, resulting
in the release of proinflammatory cytokines [14, 42]. In our
study, the LOS-induced cytokine secretion by mast cells was
suppressed by blocking MR and MGL, thus supporting the hy-
pothesis of CLR involvement in LOS immune-cell stimulation.
Notably, LOS stimulation of mast cells resulted in lower cyto-
kine levels compared with the levels obtained with heat-inacti-
vated, whole-cell BP. This is in agreement with previously re-
ported in vitro stimulation of macrophages with BP LOS, re-
sulting in reduced levels of TNF- and IL-6 secretion [14]. All
of these data suggest the synergistic action of B. pertussis LOS
on TLRs and CLRs, together with other toxins during infec-
tion [65].
Human MGL has been reported to exhibit a narrow binding
specificity toward terminal GalNAc moieties, whereas in mice,
two distinct gene products, mMGL1 and mMGL2, show dis-
tinct carbohydrate-recognition profiles with affinity toward
Lewis X [Gal1–4(Fuc1–3)GlcNAc] and GalNAc, respectively
[66]. To date, mMGL-1 and -2 have been reported to be ex-
pressed by mouse macrophages [67] and DCs [52]; this study
represents the first report of MGL expression in PCMCs and
BMMCs. As a result of the high sequence homology (91.5%
amino acid identity) between mMGL-1 and -2, the ER-MP23
clone, used in this study, by binding to both lectins, does not
allow for the identification of the specific lectin involved in
the BP–mast cell interactions. However, the inhibitory effect
Figure 8. Blocking MR and MGL suppresses LOS-induced cytokine secretion in mast cells. LOS was isolated from BP antigen and analyzed by sil-
ver-stained SDS-PAGE (A). 1: Whole B. pertussis cell lysate (10 g); 2: proteinase K (prot-K; 5 g); 3: B. pertussis LOS crude preparation (10 l); 4:
B. pertussis LOS supernatant; 5: B. pertussis LOS pellet. Proteinase K (28.9 kDa) and LOS (10 kDa) are indicated by arrows. BMMCs were stimu-
lated with 1 u/ml (equivalent to 100 bacteria/cell) LOS for 24 h in the presence and absence of anti-MR- or anti-MGL-blocking antibodies. TNF-
(B) and IL-6 (C) secretion was measured by commercial ELISAs. Data are presented as the mean  sd of three independent experiments. *P 	
0.05 and **P 	 0.01 compared with the control LOS group.
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on cytokine secretion observed in the presence of GalNAc in-
dicates a mMGL-2-type glycan-binding specificity.
Notably, the reported LOS structure of BP Tohama I, used
in this study, does not feature any terminal GalNAc residues
[68], and it has to be speculated that mast cell-derived MGL
exhibits alternative glycan-binding specificities, or the LOS
used in this study contains additional saccharidic epitopes not
characterized previously. The latter hypothesis is supported by
studies conducted on Ng LOS. Ng exhibits different LOS phe-
notypes, each targeting a different set of receptors on DCs; in
particular, Ng LOS phenotype C carries a terminal GalNAc
epitope and was the first bacterial ligand ever described for
human MGL on DCs [67]. The identification of the potential
binding epitopes on BP-derived LOS for the MR is somewhat
less challenging as a result of the broad range of ligands re-
ported for this CLR. MR can recognize the terminal GlcNAc
on BP LOS through its eight tandemly arranged C-type lectin-
like domains, with reported affinity for mannose, fucose, and
GlcNAc [68].
Whole-cell vaccine studies suggest that BP-derived LOS plays
a crucial role in the development of polarized Th1 immune
responses, and signal trough TLR4 is critical in innate im-
mune cells in the generation of inflammatory cytokines in B.
pertussis infection [42, 69]. Our study suggests that other than
TLR4, CLRs are also involved in BP activation via the LOS an-
tigen, and in the development of new vaccines, carbohydrate
moieties could prove to be useful in the activation of innate
immune cells and the promotion of these inflammatory im-
mune responses. In summary, we showed that MR and MGL
are involved in the interaction of BP with mast cells, and the
LOS in the cell wall displays similar interactions. This sheds
further light on mast cell biology and the role of mast cells in
the defense system against bacterial infections. Bacterial-in-
duced TLR signaling is well-studied, although less is known
about CLRs and their crosstalk with other signaling pathways.
Further studies are required to examine CLR involvement in
bacteria recognition and its stimulatory/inhibitory effect on
TLR signaling.
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Fasciola hepatica tegumental antigens indirectly induce an M2
macrophage-like phenotype in vivo
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SUMMARY
The M2 subset of macrophages has a critical role to play in
host tissue repair, tissue fibrosis and modulation of adaptive
immunity during helminth infection. Infection with the hel-
minth, Fasciola hepatica, is associated with M2 macrophag-
es in its mammalian host, and this response is mimicked by
its excretory-secretory products (FhES). The tegumental
coat of F. hepatica (FhTeg) is another major source of
immune-modulatory molecules; we have previously shown
that FhTeg can modulate the activity of both dendritic cells
and mast cells inhibiting their ability to prime a Th1
immune response. Here, we report that FhTeg does not
induce Th2 immune responses but can induce M2-like phe-
notype in vivo that modulates cytokine production from
CD4+ cells in response to anti-CD3 stimulation. FhTeg
induces a RELMa expressing macrophage population
in vitro, while in vivo, the expression of Arg1 and Ym-1/2
but not RELMa in FhTeg-stimulated macrophages was
STAT6 dependent. To support this finding, FhTeg induces
RELMa expression in vivo prior to the induction of IL-13.
FhTeg can induce IL-13-producing peritoneal macrophages
following intraperitoneal injection This study highlights the
important role of FhTeg as an immune-modulatory source
during F. hepatica infection and sheds further light on
helminth–macrophage interactions.
Keywords dendritic cells, eosinophils, Fasciola hepatica,
IL-13, M2 macrophages, STAT6
INTRODUCTION
The liver fluke, Fasciola hepatica, causes fascioliasis, a
major global food-borne zoonosis infecting both humans
and animals (1). The helminth can survive within its hosts
for many years due to its ability to manipulate host immu-
nity (2), in particular the suppression of Th1 immune
responses as this is associated with immune protection in
the definitive host (3). Infection gives rise to a polarized
Th2 response that is characterized by the production of
IL-4, IL-5 and IL-13 with the absence of IFN-c (4, 5). Dur-
ing F. hepatica infection, the immediate effect on innate
immune cells ultimately results in the polarization of Th2
immune response in concert with inhibiting the ability of
these innate immune cells to promote Th1 immunity (5).
For example, F. hepatica infection inhibits the development
of classically activated macrophages (M1) which facilitates
the switch to alternative activation (M2). In addition, den-
dritic cells and mast cells are hyporesponsive to activation
by Th1 inducing microbial ligands (6, 7).
During F. hepatica infection, there are two major
sources of modulatory antigens; flukes shed their outer
tegumental coat (FhTeg) every 2–3 h and continuously
release excretory/secretory products (FhES). Both of these
antigenic mixes are in constant contact with cells of the
hosts immune system and elicit immune-modulatory
effects (5–7). We are particularly interested in examining
the modulatory properties of FhTeg and have shown that
FhTeg can inhibit LPS driven sepsis in mice by preventing
the release of the pro-inflammatory mediators, nitric
oxide, IL-6, TNF and IL-12 in vivo (5, 6). FhTeg impacts
upon dendritic cell (DC) and mast cell maturation and
function by inducing phenotypes that are hyporesponsive
to TLR and non-TLR ligands, with decreased production
of a panel of pro-inflammatory cytokines and reduced
expression of costimulatory markers (6, 7), thus impairing
both DCs and mast cells ability to prime T cells. FhTeg
induces SOCS3 expression, a negative regulator of the
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TLR signalling pathway, which explains the suppression
of NFjB and the MAPKs, ERK, p38 and JNK in these
cell populations (8). The interaction with mast cells occurs
in a STAT6 independent manner suggesting that a Th2
environment is not required for mast cell–FhTeg interac-
tions (9).
Like mast cells and DCs, macrophages are also an
important component of the innate immune response and
have the capacity to promote the differentiation of T cells.
During infection with F. hepatica or exposure to FhES,
peritoneal macrophages exhibit an M2-like phenotype as
measured by the gene expression of Ym-1/2, Arg1 and
RELMa while simultaneously demonstrating a lack of
M1-associated genetic markers (5, 10). The induction of
M2 macrophages is thought to be a necessary functional
switch from killing to repair, ultimately benefiting both
the parasite and host. Functionally, these macrophages are
unable to support the differentiation of type 1 cells from
naive CD4+ T cells and instead have been shown to pro-
mote the differentiation of Th2 and Treg cells (10, 11).
Considering the modulatory effect that FhTeg displayed
on mast cells and DCs, this paper examines whether
FhTeg also alters the phenotype and biological function
of macrophages.
MATERIALS AND METHODS
Animals and antigens
C57BL/6, BALB/c and STAT6/ mice 6–8 weeks old
were purchased from Charles River (Carrentrilla, Ireland).
Mice were kept under specific pathogen-free conditions at
the Bioresource Unit, Faculty of Health and Science, Dub-
lin City University, Ireland. All mice were maintained
according to the guidelines of the Irish Department of
Children and Health. Ethical approval for mice experi-
ments was obtained from DCU ethics committee and the
Irish Department of Children and Health.
BALB/c, C57BL/6 or STAT6/ mice were injected intra-
peritoneally (i.p.) three times per week for 1 or 3 weeks with
F. hepatica excretory-secretory products [FhES:20 lg per
mouse in PBS (200 lL)] or tegumental coat antigen [FhTeg;
20 lg per mouse in PBS (200 lL)] was prepared as previ-
ously published (6). Prior to administration, endotoxin lev-
els of antigens were determined using the Pyrogene
endotoxin detection system (Cambrex). Antigen concentra-
tions were determined by optimizations assays which are
performed for each new antigen batch and the following
concentrations were used for the in vitro experiments:
FhES (20 lg/mL) and FhTeg (10 lg/mL). FhES and
FhTeg gave endotoxin levels similar to background levels
and were less than the lower limit of detection in this
assay (<001 EU/mL). All protein concentrations were
determined using a BCA protein assay kit Thermo Scien-
tific, Rockford, IL, USA.
Purification of macrophages from peritoneal exudate
cells (PECs)
Peritoneal exudate cells (PECs) were obtained from each
mouse by injecting 10 mL of ice cold sterile PBS into the
peritoneal cavity. Cell numbers and viability were moni-
tored using Trypan blue staining. Macrophages were iso-
lated from PECs by culturing them in RPMI containing
10% FCS for 2 h. Adherent cells represented our macro-
phage population which were >95% positive for the
expression of F4/80+ as determined by flow cytometry.
Coculturing of macrophages with CD4+ cells
Following stimulation with antigens, peritoneal macro-
phages were incubated with na€ıve splenic CD4+ T cells at
a ratio of 1 : 4 on a plate precoated with 05 lg/well of
anti-CD3 (e-Bioscience, Hatfield, UK). CD4+ T cells were
isolated using MACS CD4+ T-Cell Isolation Kit (Milte-
nyiBiotec, Surrey, UK). Cocultures were maintained at
37°C and 5% CO2 for 72 h when supernatants were taken,
and IFN-c, IL-4, IL-13 and IL-5 were then measured by
commercial ELISA (BD Biosciences, Oxford, UK).
Determination of arginase activity
After lysis of 1 9 106 macrophages with Triton X-100 and
with L-arginine as a substrate, the arginase activity was
determined as previously described (5) (Donnelly 2008). One
unit of enzyme activity was defined as the amount of enzyme
that catalyses the formation of 1 lmol of urea per min.
RNA extraction and RT-PCR
Total RNA was extracted from cultured cells using TRI-
sure (MyBio, Kilkenny, Ireland) as recommended by the
manufacturers instructions. First strand cDNA was syn-
thesized with random primers from 1 lg total RNA using
GoScript Reverse Transcription System (Promega, Madi-
son, WI, USA.) and then used as a template for PCR
using primers specific for Arg 1, Ym-1/2, iNOS, RELMa,
IL-4, IL-13 and b-actin. Each amplification step was pre-
ceded by a denaturation phase at 95°C for 5 min and pre-
ceded by a final extension phase of 72°C for 5 min. PCR
products were electrophorized on 1% agarose gels with
SYBRSafe (Invitrogen, Paisley, UK) as our gel stain. The
primer sequences and amplification steps were as previ-
ously described (5, 10).
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Cytokine assays
Spleen cells were removed for restimulation in vitro with
PBS (negative control), FhTeg (10 lg/mL) or FhES
(20 lg/mL) or PMA (25 ng/mL)/anti-CD3 (1 lg/mL; posi-
tive control). After 72 h, supernatants were collected and
the levels of IFN-c, IL-4, IL-13 and IL-5 quantified by
ELISA (BD Biosciences). Supernatant was obtained from
FhTeg-stimulated macrophages for measurement of IL-4
and IL-13 by ELISA (BD Biosciences).
Flow cytometry
Monoclonal antibodies with fluorescent tags were used
which targeted the following cell surface markers: PE-
conjugated CD11b (BD Biosciences), FITC-conjugated
F4/80 (Biolegend, San Diego, CA, USA), efluor 660 con-
jugated IL-13 and PE-conjugated Siglec-f (e-Bioscience
Ltd). Cells were blocked for 15 min with anti-CD16/CD32
(Fcc III/II Receptor) prior to incubation with fluorescent
antibodies. Antibody incubations were performed in wash-
ing buffer (PBS containing 2% FCS, 5 mM EDTA and
005% NaN3). Isotype controls corresponding to the
above antibodies were used to rule out nonspecific bind-
ing. Acquisition was performed using a FACSAria cell
sorter (BD Immunocytometry Systems, Oxford, UK), and
data were analysed using FLOWJO software (Treestar, Ash-
land, OR, USA).
Statistics
All data were analysed for normality prior to statistical
testing by ORIGIN 6.1 software (OriginLab Corporation,
Northhampton, MA, USA). Where multiple group com-
parisons were made, data were analysed using one-way
ANOVA. For comparisons between two groups, the Students
t-test was used. In all tests, P < 005 was deemed signifi-
cant. Where data was not normal, we normalized the data
and measured significant differences based upon an analy-
sis of variance using a post hoc Duggans test.
RESULTS
FhTeg induces a phenotype of macrophages in vivo that
express M2 markers
Fasciola hepatica infection induces the expression of
genetic markers within peritoneal macrophages that are
characteristic of an M2 phenotype: Arg-1, RELMa and
Ym-1/2. Furthermore, exposure of mice to the secretory
products (FhES) of F. hepatica also results in enhanced
expression of the same M2-associated genes (5). Consider-
ing the likely interaction that occurs between FhTeg and
macrophages during infection, we asked whether, like
FhES, FhTeg also contained molecules capable of induc-
ing an M2 macrophage phenotype. Thus, BALB/c mice
(n = 4) were injected three times per week over a 3 weeks
period with either PBS, FhES (20 lg/mL), or FhTeg
(10 lg/mL) and Arg-1, RELMa and Ym-1/2 gene expres-
sion measured by RT-PCR in isolated peritoneal macro-
phages. In comparison with the PBS-treated mice,
macrophages isolated from both FhES- and FhTeg-treated
mice expressed Arg-1, RELMa and Ym-1/2 while neither
antigen induced iNOS expression, a marker of classically
activated macrophages (Figure 1).
FhTeg-activated macrophages suppress cytokine secretion
from CD4+ T cells
There have been many hypotheses to the role that hel-
minth-induced M2 macrophages might play during infec-
tion such as modulating of T-cell function (12). To define
a function for FhTeg-M2 macrophages, we assessed their
ability to modulate the activation of T cells in vitro. Perito-
neal macrophages were isolated from mice (n = 4) treated
with either PBS, FhES or FhTeg as described above and
then cocultured, in the presence of anti-CD3, with CD4+
spleen cells harvested from na€ıve mice. As expected, T cells
cultured in the presence of macrophages isolated from
PBS-treated mice secreted significant levels of IFN-c
(P ≤ 0001; Figure 2a), IL-13 (P ≤ 0001; Figure 2b), IL-4
(P ≤ 0001; Figure 2c) but not IL-5 (Figure 2d) in
response to stimulation with anti-CD3 when compared to
T cells stimulated with anti-CD3 only. In comparison with
the PBS-control samples, the addition of macrophages
isolated from both FhES- and FhTeg-treated mice caused
Figure 1 FhTeg induces a phenotype of macrophages in vivo that
express M2 markers: Mice were injected three times per week for
3 weeks with PBS, FhES (20 lg per mouse) or FhTeg (10 lg per
mouse). Total RNA was extracted from isolated peritoneal
macrophages and RT-PCR performed for the gene markers Arg 1,
RELM a, Ym-1/2 and iNOS. b-actin was measured as a reference
gene. Data are representative of one mouse of four mice per
group, and the experiment was repeated twice.
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significant decreases in the secretion of both IFN-c
(Figure 2a FhES P ≤ 001, FhTeg P ≤ 00001) and IL-4
(Figure 2b: (FhTegES P ≤ 0001, FhTeg P ≤ 00001). T
cells cocultured with macrophages isolated from FhES-
and FhTeg-treated mice induced a significant increase in
IL-5 (FhTegES P ≤ 001, FhTeg P ≤ 005), while no sig-
nificant changes were observed from the mean production
of IL-13 from T cells cocultured with macrophages from
FhES- and FhTeg-treated mice compared with macro-
phages from PBS-treated mice.
FhTeg does not induce antigen-specific Th2 immune
responses in vivo
Mice infected with F. hepatica metacercariae induce strong
Th2 immune responses as characterized by the presence of
IL-4, IL-5 and IL-13 with no antigen-specific IFNc
detected (O’Neill et al., 2000 (4)), and these responses can
be mimicked by mice treated with FhES (10). Using FhES as
a control, we injected BALB/c mice with PBS, FhES (20 lg)
or FhTeg (10 lg) three times per week for 3 weeks and
spleen cells were isolated for restimulation with PBS, FhTeg
(10 lg/mL) or FhES (20 lg/mL) and PMA (25 ng/mL)/anti-
CD3 (1 lg/mL). FhES injected mice produced signiﬁcant lev-
els of FhES-speciﬁc IL-4 (P ≤ 0001), IL-5 (P ≤ 001) and
IL-13 (P ≤ 0001) but not IFNc cytokines (Figure 3), while
spleen cells from FhTeg injected mice failed to produce IFN-
c, IL-4, IL-5 and IL-13 cytokines in response to FhTeg
(Figure 3). PBS-stimulated spleen cells did not produce
cytokines, while cells stimulated with PMA/anti-CD3 secreted
all cytokines tested.
FhTeg does not directly induce an M2-like macrophage
phenotype
We then addressed the possibility that like FhES, FhTeg
might directly interact with macrophages and induce the
expression of M2 genetic markers including the secretion
of IL-10 and PGE2. To investigate this, murine macro-
phages (RAW 264.7) were stimulated again with FhTeg
(10 lg) and a positive and negative control for measure-
ment of cytokine secretion and arginase activity. Here,
FhTeg did not directly induce the secretion of IL-10
(Figure 4a), PGE2 (Figure 4b), the expression of Arg-1
(Figure 4c) or the production of arginase (Figure 4d).
FhTeg-activated macrophages are partially STAT6
dependent
Most typically, previous studies into the activation of M2
macrophages during helminth infection have suggested
that they are primarily induced by the Th2-type cytokines
IL-4 and IL-13 (10, 13, 14) and given that FhTeg does not
induce Th2 cytokines we went on to determine a role for
IL-13 and IL-4 in this process by performing these studies
in STAT6/ mice. STAT6/ (or C57BL/6 background
control) mice were given our standard regime of 3 9 3
intraperitoneal injections of FhES, FhTeg or PBS as a
(a) (b)
(c) (d)
Figure 2 FhTeg-activated macrophages suppress cytokine secretion from CD4+ T cells. Mice were injected three times per week for 3 weeks
with PBS, FhES (20 lg per mouse) or FhTeg (10 lg per mouse). Isolated peritoneal macrophages were cocultured with na€ıve CD4+ T cells at
a ratio of 1 : 4 on plates precoated with anti-CD3 (05 lg/well). After 72 h, supernatants were taken and analysed by ELISA for IFN-c (a),
IL-4 (b), IL-5 (c) and IL-13 (d). Data are representative of four mice per group, and the experiment was repeated three times; +++ P ≤ 0001
compared with T cells stimulated with anti-CD3 only; * p ≤ 0.05 **, P ≤ 001; ***, P ≤ 0001, ****, P ≤ 00001 compared with PBS controls.
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control. Both IL-4 and IL-13 activate M2 macrophages
using STAT6 signalling pathways, and it has been shown
that T cells from STAT6/ mice lack the ability to pro-
duce either IL-4 or IL-13. Analysis of peritoneal macro-
phages harvested after the final treatment of parasite
antigens revealed that in the absence of STAT6, FhES
failed to induce the expression of any of the M2 markers
examined (Figure 5a). In contrast, macrophages isolated
from FhTeg-treated mice showed increased expression of
RELMa but not Arg-1 or Ym-1/2 (Figure 5a). In agree-
ment with this RT-PCR result, a decrease in arginase
activity was observed in STAT6/ mice for both FhES
(P ≤ 005; Figure 5b) and FhTeg (P ≤ 0001; Figure 5d).
These results indicate that each of the expression of M2
(a) (b)
(c) (d)
Figure 3 FhTeg does not induce antigen-specific Th2 immune responses in vivo: Balb/c mice were injected three times per week for 3 weeks
with PBS, FhES (20 lg per mouse) or FhTeg (10 lg per mouse). Spleens cells were removed and plated at 2 9 106/mL for restimulation in
vitro with PBS, FhES (20 lg/mL) or FhTeg (10 lg/mL) and PMA (25 ng/mL)/anti-CD3 (1 lg/mL). After 72 h, spleen cell supernatants
were analysed by ELISA (BD Biosciences) for IFN-c (a), IL-4 (b), IL-5 (c) and IL-13 (d). Data are the mean (SEM) of three individual
wells for four individual mice and are representative of two experiments, **, P ≤ 001; ***, P ≤ 0001 compared with controls.
(a)
(b)
(c)
(d)
Figure 4 FhTeg does not directly induce an M2-like macrophage phenotype. RAW 264.7 macrophages and BMDMs were stimulated with
PBS, FhES (20 lg/mL) or FhTeg (10 lg/mL). After 18 h, total RNA was extracted and Arg-1 and B-actin measured by RT-PCR and cells
lysed for measurement of arginase activity. Supernatant was removed for measurement of IL-10 by ELISA (BD Biosciences). Data are the
mean (SEM) of three individual wells and are representative of two experiments, **, P ≤ 001; ***, P ≤ 0001 compared with controls.
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genotypic markers may be induced by different mecha-
nisms, and at least, in the case of Arg-1 and Ym-1/2, the
induction of expression by FhTeg is undoubtedly depen-
dent upon STAT6 signalling mechanisms.
RELMa gene expression is observed prior to the
expression of IL-13, while FhTeg can induce RELMa
but not IL-13 directly from macrophages in vitro, in vivo
it is also associated with IL-13 producing macrophages
As RELMa gene expression was observed in a stat/6
dependent manner, we went on to examine the expression
of M2 markers and IL-4/IL-13 in the first 24 h following
FhTeg injection. Here, mice were injected with FhTeg
intraperitoneally and after 1, 6 and 24 h peritoneal exu-
date cells were collected for measurement of IL-4, IL-13,
Arg-1, Ym-1/2 and RELMa gene expression by RT-PCR.
Following FhTeg injection, RELMa was expressed at 1 h
post-injection, while IL-13 and Arg-1 were detected at 6 h.
FhES injection induced Arg1 expression at 1 h post-injec-
tion, while IL-13 and RELMa were expressed at 5 h.
There was no expression of Ym-1/2 and IL-4 detected at
any time point examined (Figure 6a).
As IL-13 is an early source of a Th2 cytokine following
FhTeg injection, we examined the expression of IL-13 in
peritoneal macrophages as these were previously shown to
be good innate source of this cytokine (12). Peritoneal cav-
ity cells were isolated following three i.p. injections of
FhTeg over 7 days. On day 8, the total number of macro-
phages in the peritoneal cavity of FhTeg-treated mice was
significantly increased (P ≤ 001; Figure 6a) compared
with mice receiving PBS. Furthermore, the number of
these cells expressing intracellular IL-13 was also signifi-
cantly enhanced (P ≤ 001; Figure 6b). We then went on
to demonstrate that RAW macrophages (264.7) stimulated
with FhTeg (10 lg/mL) induced RELMa gene expression,
while it did not directly stimulate the secretion of IL-13
from these cells.
DISCUSSION
The tegumental coat of F. hepatica (FhTeg) is shed from
the fluke every 2–3 h and is therefore a major interface
between the parasite and its environment. In the adult
fluke, the tegument is 15–20 lm thick and the surface is
increased by intuckings of the plasma membrane (apical
invagination). The apical membrane is covered by thick
(30 + 25 nm) glycocalix (15) which contains a rich source
of glycoproteins. The tegument has multiple functions like
absorption of exogenous nutrients, synthesis and secretion
of various substances, osmoregulation and protection
against enzymes, the bile and hosts immune responses
(15). An intact glycocalix and syncytium is essential to the
survival of the fluke in the host (15). We have previously
characterized FhTeg as a source of immune modulators.
FhTeg-stimulated DCs and mast cells are both hypore-
sponsive to TLR ligand activation (6, 7), and FhTeg-trea-
ted DCs and mast cells are unable to prime T cells (6, 7).
Consistently, this study demonstrates that FhTeg also
modulates the activity of macrophages, inducing an
M2-like phenotype that modulates cytokine secretion from
CD4+ cells.
Both FhTeg- and FhES- activated macrophages sup-
press IFNc from CD4+ cells which is one of the key mod-
ulatory properties displayed during F. hepatica infection.
The importance of Th1 suppression during infection is
critical to the parasites survival as these responses are
associated with host protection as demonstrated in studies
(a) (b)
Figure 5 FhTeg-activated macrophages are partially STAT6 dependent: C57BL/6 (background strain) and STAT6/ mice were injected
three times per week for 3 weeks with PBS, FhES (20 lg) or FhTeg (10 lg) and peritoneal macrophages isolated for measurement of Arg
1, Ym-1/2, RELMa, iNOS and b-actin gene expression by RT-PCR (a) or arginase activity (b). Data are representative of one of four mice
per group, and the experiment was repeated twice; **, P ≤ 001 compared with controls.
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with cattle and sheep (3, 16). Studies in experimental mod-
els support this observation as IL-4/ mice, which are
predisposed towards a Th1 immune response, are less sus-
ceptible to F. hepatica infection with reduced liver damage
compared with IFN-cR/ mice that elicited strong Th2
responses and are highly susceptible to infection (4). The
efficacy of F. hepatica vaccine is also associated with
enhanced lymphocyte proliferation and IFN-c expression
(3). A number of F. hepatica secretory enzymes have been
identified and recombinantly expressed, and these mole-
cules mimic the Th1 inhibitory properties observed during
F. hepatica infection (17, 18). The parasite through the
release of these molecules suppress Th1 immune responses
within hours post-infection, and this phenomenon can be
seen in both innate and adaptive effector cells (5–7). Like-
wise, during F. hepatica infection, M2-like macrophages
are observed and these cells are capable of suppressing
IFNc from CD4+ cells.
In conjunction with the suppression of Th1 immune
cells, F. hepatica infection is associated with the early
induction of Th2 immune responses. Here, we demonstrate
that FhTeg-activated macrophages promote the secretion
of IL-5 from CD4+ cells. In contrast to FhES, it fails to
induce antigen-specific Th2 immune responses. FhES is an
important antigen source in the promotion of a Th2 type
immune response during infection; we believe that FhTeg
shares this property by supporting FhES in promoting a
favourable environment for the promotion of Th2 immune
responses. In support of this hypothesis, FhTeg induces
the early expression of IL-13 and induces an IL-13
expressing macrophage population previously associated
with Th2 mediated diseases (12). IL-13 mediates localized
tissue effects such as chemokine secretion, goblet cell
hyperplasia, mucus production and smooth muscle altera-
tions (19, 20). IL-13 administered intranasally to mice pro-
motes eosinophil activation and survival through a direct
stimulation of eotaxin and RANTES production (21, 22).
IL-13 is also critical for the expulsion of intestinal worms
and for the induction of M2 macrophages that promote
granuloma formation and tissue fibrosis during helminth
infection. (23). It is possible that the early induction of
IL-13 induced by FhTeg works locally promoting the dif-
ferentiation of M2 macrophages which could contribute to
the liver fibrosis observed during F. hepatica infection.
Our data indicate that signalling through STAT6 is
required to induce the expression of Arg1 and Ym-1/2, as
these markers were not observed in STAT6/ mice trea-
ted with FhTeg. Signal transducers and activators of
transcription (STATs) are a family of transcription factors
that activate gene transcription of factors such as
cytokines and that IL-4/IL-13 both specifically activate
STAT6 through the IL-4R (24). STAT6/ T cells are
(a) (b) (c)
Figure 6 FhTeg induces RELMa gene expression prior to IL-13 expression and is associated with IL-13 producing macrophages, although
it can induce RELMa but not IL-13 directly from macrophages in vitro. (a) BALB/c mice were i.p. injected with either PBS, FhES (20 lg
per mouse) or FhTeg (10 lg per mouse) and peritoneal exudate cells (PECs) removed after 1, 6 and 24 h for RNA extraction. RT-PCR
was performed for Arg 1, Ym-1/2, RELMa, IL-4, IL-13 and b-actin as a reference gene. Data are representative of one of three mice per
group and the experiment repeated twice. (b) BALB/c mice were i.p. injected with either PBS, FhES (20 lg per mouse) or FhTeg (10 lg
per mouse). After 7 days, PECs were isolated and analysed by flow cytometry for intracellular IL-13 in macrophages. Data are
representative of four mice per group, and the experiment was repeated twice; *, P ≤ 005 compared with controls. (c) RAW 264.7
macrophages were stimulated with PBS, FhES (20 lg/mL) or FhTeg (10 lg/mL). After 18 h, total RNA was extracted and RELMa and
B-actin measured by RT-PCR. Supernatant was removed for measurement of IL-13 by ELISA (BD Biosciences). Data are the mean
(SEM) of three individual wells and are representative of two experiments, *P ≤ 0.05; compared with controls.
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unable to differentiate into IL-4 and IL-13 producing Th2
cells in vitro or in vivo and these cytokines are critical to
the development of M2 macrophages (25). Therefore,
while FhTeg can induce partial activation of M2 pheno-
type in the absence of IL-13/IL-4, like other helminths,
they cannot induce the full complement of M2 markers
(12). During Schistosoma mansoni infection, STAT6/
mice were unable to mount a Th2 immune response to sol-
uble egg antigen (SEA) (26) and STAT6/ mice also fail
to develop airway hyper-responsiveness after Th2-allergen
provocation (27). Similarly, we did not observe antigen-
specific Th2 immune responses in STAT6/ mice injected
with FhES (unpublished data).
STAT6/ mice treated with FhTeg expressed RELMa
gene, and FhTeg can also induce RELMa prior to IL-13
gene expression and directly from macrophages in vitro
which supports this finding. RELMa is a family member
of cysteine-rich secretory proteins that is highly expressed
during helminth infection and allergy (19). RELMa has
an important regulatory role during helminth infection
protecting mice against gastrointestinal infection (28) and
acting as a negative regulator of Th2 responses modulat-
ing granuloma formation, tissue fibrosis and exacerbated
Th2 cytokine secretion during S. mansoni infection (29,
30). In support of our findings, a recent study in IL-13
receptor 1 deficient mice concluded that IL-13 is not
required for gene expression of RELMa in the liver during
S. mansoni infection (31). In this study, the appearance of
RELMa in the absence of STAT6 and prior to IL-13
expression would support this finding, while the expres-
sion of RELMa within the peritoneal exudate cells could
be attributed to a number of cellular sources such as
eosinophils, B cells and macrophages. Our data clearly
demonstrate that FhTeg induces expression of RELMa
directly in macrophages and therefore represents an impor-
tant source of this molecule. Furthermore, it would be
interesting to examine FhTeg driven immune-moldulatory
properties in the absence of RELMa as it is known to
limit Th2 responses in the Schistosoma egg model of pul-
monary inflammation (29), particularly because FhTeg
does not drive antigen-specific Th2 immune responses.
In this study, while FhTeg and FhES both induce
M2-like macrophages in vivo, there are a number of differ-
ences observed between the two antigenic sources. FhES
can directly induce an Arg1+, IL-10+ and PGE2+ macro-
phage population, while FhTeg induces a RELMa+,
IL-10 and PGE2 macrophage population. The differ-
ences between the two antigen sources are not surprising
as FhES consists predominantly of enzymes released from
the parasite gut, whereas FhTeg is a rich source of glyco-
proteins from its glycocalyx coat (15). While FhTeg can
induce RELMa in the absence of STAT6, FhES can
induce Arg1 prior to the expression of Th2 cytokines.
There is now a range of molecules identified as capable
of directly inducing an M2 phenotype (32), some of
which have been identified within the secretions and
homogenates of helminth parasites (10). We have yet to
identify this molecule in FhTeg; however, FhES contains
a peroxiredoxin that can directly interact with macrophag-
es to induce an M2-like phenotype (5, 10).
M2 macrophages are central to the immune response
during helminth infection, and the findings in this study
provide us with insight into the interaction between
F. hepatica tegumental antigens and macrophages. While
F. hepatica tegumental coat shares many properties with
FhES, there are also differences in their interaction with
macrophages which points to the fact that these antigen
sources may utilize alternative pathways ensuring redun-
dancy in the process of macrophage activation during
infection. While this study sheds further light on the
importance of FhTeg interaction with innate immune cells
during F. hepatica infection, further work is needed to
fully understand the role of FhTeg-macrophage interac-
tions during F. hepatica infection.
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